

(19)



Eur päisches Patentamt
European Patent Office
Office européen des brev ts



(11) Publication number:

0 470 039 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **07.12.94** (51) Int. Cl.⁵: **C07D 209/08**, C07D 231/56,
C07D 401/12, C07D 401/14,
C07D 209/10, C07D 401/04,
C07D 405/04, C07D 405/14,
C07D 409/04, C07D 409/14,
A61K 31/40, A61K 31/415
- (21) Application number: **91610058.9**
- (22) Date of filing: **22.07.91**

The file contains technical information submitted
after the application was filed and not included in
this specification

(54) **Novel 3-arylindole and 3-arylindazole derivatives.**

- (30) Priority: **30.07.90 DK 1811/90**
- (43) Date of publication of application:
05.02.92 Bulletin 92/06
- (45) Publication of the grant of the patent:
07.12.94 Bulletin 94/49
- (64) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE
- (56) References cited:
EP-A- 0 135 781
EP-A- 0 200 322
DE-A- 2 811 031

CHEMICAL & PHARMACEUTICAL BULLETIN
vol. 33, no. 5, May 1985, JAPAN pages 1826 -
1835; **MAKOTO ADACHI ET AL.:**
'Aminohaloborane in Organic Synthesis
IX.Exclusive ortho Acylation Reaction of N-
Monoaminoalkylanilines'

**J.-M. Meunier, A. Shvaloff, Neurotransmit-
teurs, MASSON, p.227**

- (73) Proprietor: **H. LUNDBECK A/S**
Ottillavej 7-9
DK-2500 Kobenhavn-Valby (DK)
- (72) Inventor: **Perregaard, Jens Kristian**
22, Thyrasvej
DK-3630 Jaegerspris (DK)
Inventor: **Andersen, Kim**
100 Cl, Vesterbrogade
DK-1620 Copenhagen-V (DK)
- (74) Representative: **Petersen, John Meidahl**
c/o H. Lundbeck A/S
Patent Department
Ottillavej 7-9
DK-2500 Copenhagen-Valby (DK)


Not : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 470 039 B1


Description

The present invention relates to novel 3-arylindole or 3-arylindazole derivatives and their acid addition salts with selective and long lasting central serotonin S₂ (5-hydroxytryptamine-2 ; 5-HT₂) antagonistic activity, to methods for preparing such compounds, to medicaments comprising such compounds as an active ingredient and to the beneficial use of these derivatives in the treatment of CNS disorders such as anxiety, aggression, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, and Parkinson's disease with a low degree of undesired side effects.

The novel indole and indazole derivatives of the present invention are represented by the following formula :




wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, hydroxy, trifluoromethyl, and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; R¹-R⁴ are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphonyl, cyano, trifluoromethyl, or trifluoromethylthio; the dotted line emanating from X in the ring system designates an optional bond; when said dotted line indicates a bond, X is nitrogen or a group CR⁶ wherein R⁶ is hydrogen, halogen, trifluoromethyl or lower alkyl; when the dotted line indicates no bond, X is CH₂ ; the dotted line, emanating from the Y, indicates an optional bond; when it does not indicate a bond Y is N or CH; and when it indicates a bond Y is C; R⁵ is hydrogen, or lower alkyl, optionally substituted with one or two hydroxy groups, or R⁵ is a group taken from structures 1a and 1b:



1a.

or



1b.

wherein n is an integer from 2 - 6;
W is oxygen or sulphur;
U is nitrogen or CH ;
Z is -(CH₂)_m-, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH₂- or -CSCH₂-;
V is oxygen, CH₂, or NR⁷, wherein R⁷ is hydrogen or lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl optionally substituted with one or two hydroxy groups;
U¹ is a group NR⁸, wherein R⁸ is hydrogen or lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl optionally substituted with one or two hydroxy groups; and
V¹ is NR⁹R¹⁰, where each of R⁹ and R¹⁰ may be independently selected among the R⁸-substituents; provided that R⁵ may not be methyl when R¹-R⁴ each are hydrogen, X and Y are CH and Ar is phenyl.

Stereoisomers, prodrugs and pharmaceutically acceptable salts of the compounds of formula I are also embraced by the invention.

The term "lower alkyl" is intended to mean a straight or branched alkyl group having from one to four carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, etc. Lower alkoxy, lower alkylthio and lower alkylsulfonyl similarly designate such groups wherein the alkyl moiety is a lower alkyl group as defined above.

Lower alkenyl is intended to mean an alkenyl group containing from 2 to 4 carbon atoms, for example ethenyl, 1-propenyl, 2-butenyl, etc.

Cycloalkyl means cycloalkyl having from three to eight carbon atoms inclusive.

Halogen means fluoro, chloro, bromo or iodo.

The term "indicate an optional bond" is intended to mean that the dotted lines may or may not represent a bond, i.e. that the rings may or may not have a double bond in the positions of the dotted lines in Formula I.

The Z groups $-\text{COCH}_2-$ and $-\text{CSCH}_2-$ may be incorporated in the ring of the structure 1a in both directions.

The acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulphonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.

Prodrugs of the present invention may be conventional esters with available hydroxy groups, or in particular if the compound is a compound of the general formula I wherein R^5 is a group of the structure 1a wherein V is NH or the structure 1b where U^1 is NH and/or V^1 is NHR^{10} they may exist as prodrugs in which said nitrogen atom is acylated with a group



wherein A is O, S or NR^a with R^a being hydrogen, lower alkyl, or phenyl optionally substituted with one or more substituents selected from the group comprising halogen, trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio and cyano;

B is a group R^b which is alkyl or alkenyl containing from one to twentyfour carbon atoms inclusive, or cycloalkyl or cycloalkylalkyl, optionally substituted with one or two hydroxy groups, phenyl optionally substituted with one or more substituents selected from the group comprising halogen, trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio, or cyano; or

B is QR^b , wherein Q is O or S and R^b is one of the substituents defined for R^b above; or

B is NR^cR^d , wherein R^c and R^d independently are either hydrogen or one of the substituents defined for R^b above.

Although the latter prodrugs are not esters, they have been found to decompose properly in order to release the compound of the invention over a desired prolonged period of time when administered parenterally as a depote formulation in an appropriate oil, such as peanut oil, sesame oil, cotton seed oil, corn oil, soy bean oil, olive oil, coconut oil (e.g. viscoleo®), etc., or synthetic esters of fatty acids and glycerol or propylenglycol.

Only one 3-arylindole or 3-arylindazole derivative substituted in the 1-position with a piperidinyl, piperazinyl or tetrahydropyridyl group is known from the prior art.

1-(1-methyl-4-piperidinyl)-3-phenylindole is disclosed in Adachi et al, *Chem. Pharm. Bull.*, 33(5), 1826-1835, (1985), as an intermediate in the synthesis of 2-acyl-N-(1-methyl-4-piperidinyl)aniline. Nothing is disclosed or suggested as regards the pharmacological properties of said compound.

On the other hand indole or indazole derivatives having an aryl substituent in the 1-position and a tetrahydropyridyl, piperidinyl or piperziny group in the the 3 position have been disclosed in a number of patents.

DE Offenlegungsschrift No. 2811031 (Laboratories Sauba S.A.) relates to 1-(optionally subst. phenyl)-3-((4-alkyl or aryl)-piperazin-1-yl)-indole derivatives stated to have antiinflammatory activity.

EP-A2 224919 (Fujisawa Pharmaceutical Co., Ltd.) discloses 1-phenyl-3-(4-(thiazolylalkyl)piperazin-1-yl)-indole derivatives as antiallergy agents.

DE Offenlegungsschrift No. 1695604 (Pfizer Corporation) describes 1-phenyl-3-(optionally 1-benzyl or 1-methyl substituted 4-piperidiny)-2-indolones having anti-depressant effects.

EP-A 0 135 781 and US Patents Nos. 4,670,447, 4,758,668 and 4,853,470 all generically relate to a very broad class of 1-aryl-3-piperidylindazoles alleged to have analgesic and antipsychotic and in some of the patents also antidepressant effects. Antipsychotic effects are shown by the apomorphine climbing assay which is a test for classical neuroleptic activity, i.e. dopamine antagonism, and antidepressant effects are shown in the tetrabenazine ptosis test for a few compounds.

EP-A 0 281 309 and US Patents No. 4,831,031 disclose 3-[4-(heterocycleethyl (or -butyl))piperazin-1-yl]indazoles substituted in the 1-position with trifluoromethylphenyl and claimed to be useful as antipsychotics as shown in the apomorphine climbing test.

European Patent Publication No. 0 302 423 relates to 1-phenyl-3-(1-piperazinyl)-1H-indazoles claimed to be useful as analgesics, anticonvulsants and antidepressants, the antidepressant effects again shown in the tetrabenazine ptosis test in mice. Only results for a few compounds showing quite weak effects are given.

From our own US patent No 4,710,500 (corresponding to EP patent No 0200323) 1-aryl-3-(1,2,3,6-tetrahydropyridin-4-yl)-, 1-aryl-3-(4-piperidiny)- and 1-aryl-3-(1-piperazinyl)-indole derivatives are known. The compounds are claimed to be potent and long-lasting dopamine antagonists, and accordingly to be useful in the treatment of psychoses and additionally to be strong 5-HT₂ antagonists indicating effects in the treatment of depression, negative symptoms of schizophrenia and neuroleptic-induced extrapyramidal side effects and cardiovascular diseases. Some of the compounds are selective 5-HT₂ antagonists *in vivo*.

Previously evidence of various clinical effects of 5-HT₂ antagonists have been presented. For example reference may be made to the following:

The selective 5-HT₂ antagonist ritanserin has been shown to be an antidepressant and to improve depressive symptoms of schizophrenia (E. Klier, W. H. Strauss; Pharmacopsychiat. 21 (1988), pp. 391-393) and it has been demonstrated to exert effects in an animal test reminiscent of anxiolytic drug activity (F.C. Colpart et al; Psychopharmacology (1985) 86; 303-305). Furthermore ritanserin has been shown to improve the quality of sleep (P. A. J. Janssen; Pharmacopsychiat. 21 (1988), 33-37).

Furthermore it is generally believed that 5-HT is involved in migraine attacks. The links between 5-HT and migraine attacks are several and they suggest a number of mechanisms whereby 5-HT may be involved (Scrip Report; "Migraine - Current trends in research and treatment"; PJB Publications Ltd.; May 1991). Various 5-HT₂ antagonists are in clinical trials as anti-migraine agents, such as sergolexole (c.f. for example Pharma Projects, May 1991, 1359-1365).

Studies of the mixed serotonin and dopamine receptor antagonist setoperone indicate that blockade of 5-HT₂ receptors may be related to improvement of negative symptoms of schizophrenia (Ceulemans et al, Psychopharmacology (1985) 85, 329-332).


Finally, ritanserin has been found to relieve neuroleptic-induced parkinsonism (Bersani et al.; Clinical Neuropharmacology, 13, No. 6 (1990), 500-506).

Surprisingly, it has now been found that the novel indole or indazole derivatives of the present invention are selective 5-HT₂ antagonists with prolonged activity, and accordingly are useful in the treatment of anxiety, aggression, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, drug-induced Parkinsonism and Parkinson's disease substantially without causing neurological side effects.

The compounds of the present invention are selective, and most of them very selective, antagonists of the 5-HT₂ receptor, measured as the ratio between the dopamine D-2 receptor and the 5-HT₂ receptor antagonistic activities. Only a few compounds with such a selectivity profile are known from the prior art. Such compounds include ritanserin, seganserin, ICI 169369, ICI 170809, sergolexole and MDL 11939, which compounds are very different in chemical structure from the present compounds.

A preferred subgroup of compounds are those wherein X is a CR⁶ group; most preferably those wherein R² and/or R⁶ are other than hydrogen.

Preferably, Ar is phenyl optionally substituted with halogen, most preferably 4-fluorophenyl; R⁵ is a group



wherein R⁷, R⁸,

R⁹ and R¹⁰ independently are selected from hydrogen, lower alkyl or alkenyl; R² is selected from halogen, -CF₃, and -CH₃; R³ is selected from H, halogen, -CF₃, and -CH₃; and R¹ and R⁴ are H.

Particularly preferred compounds are:

- 5 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole,
 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-(3-propyl)imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole,
 2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 10 2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-4-piperidyl)-1*H*-indole, and 1-[1-[2-(1,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole.

In another aspect the present invention provides a pharmaceutical preparation comprising at least one compound of the Formula I as an active ingredient together with a pharmaceutically acceptable carrier or diluent.

- 15 The compounds of the Formula I and the pharmaceutically acceptable acid addition salts thereof may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection.


Suitable pharmaceutical preparations may be prepared by methods well known in the art. Conveniently, the compounds of the invention are administered in unit dosage form containing said compound in an amount of about 0.10 - 100 mg, preferably about 1 - 50 mg.

The total daily dose usually ranges from about 0.1 to 500 mg of the active compound of the invention. In a further aspect the present invention provides the use of a compound of the Formula I for the manufacturing of a pharmaceutical preparation for the treatment of CNS disorders.


- 25 The present invention also provides a method for treating CNS disorders comprising administration of a compound having the general Formula I or an acid addition salt thereof to a patient suffering from such a disease.

Finally, the present invention provides a method for the preparation of a derivative having the general Formula I, which method comprises:


- a) reacting a compound of the following formula:




- 45 wherein R¹, R², R³, R⁴, X, Y, Ar and the dotted lines are as defined above, with a lower alkyl halide, alkyl mesylate or tosylate, with an epoxide of the formula




wherein R' is hydrogen, methyl or ethyl or with a halide of the general formula



10 wherein n, W, U, V, Z, V' and U' are as defined above;
b) reacting a compound of following formula:




25 wherein R¹, R², R³, R⁴, R⁶, Ar and the dotted line are as defined above, with a compound of the general formula




in which R⁵ is as defined above and hal is halogen;

c) reducing the indole ring of a compound of the general formula




45 wherein R¹-R⁵, Ar, Y and the dotted line are as defined above, to a dihydroindole ring;

d) reducing the double bond in the tetrahydropyridyl ring in a compound of the formula:



wherein $R^1 - R^5$, X, Ar and the dotted line are as defined above;


e) reducing the pyridinium ring in a compound of following formula:



wherein $R^1 - R^5$, X, Ar and the dotted line are as defined above except that R^5 may not be hydrogen, and hal is halogen, to a tetrahydropyridine ring;


35 f) reducing the pyridinium ring in a compound of the above Formula VIII or the pyridyl ring of a compound of formula XIV (below) to a piperidine ring;

g) reducing the carbonyl group of a compound of the following formula:




55 wherein $R^1 - R^4$, X, Y, Ar and the dotted lines are as previously defined and R^{16} is hydrogen, lower alkyl or lower alkoxy;

h) acylating an aminoalkyl derivative of the following formula :



20 wherein $R^1 - R^4$, X, Y, Ar, R^8 , n and the dotted lines are as defined above, with an acylating agent such as a carboxylic acid halogenide, anhydride or mixed anhydride, or a carbamyl or thiocarbamyl chloride, an isocyanate, isothiocyanate, or a substituted chloroformate;

i) ringclosure reaction of an intermediate ethylene or propylene diamine derivative of the following formula :




45 wherein $R^1 - R^4$, R^8 , n, X, Y, Ar and the dotted lines are as defined above and m is 2 or 3, with phosgene, thiophosgene or carbondisulphide to form a substituent of the structure **1a** ; or

50

55

j) reducing a carboxylic acid or carboxylic acid derivative of the following formula :



wherein $R^1 - R^4$, X, Y, Ar and the dotted lines are as previously defined, R^{17} is hydrogen or lower alkyl and p is 1, 2 or 3;

and then, if desired:


acylating a compound prepared in one of the methods (a) to (j) having the formula I in which R^5 is a structure 1a or 1b wherein V is NH, or V^1 is NHR^{10} or U^1 is NH with an acylating agent, or esterifying an available hydroxy group in a compound of formula I in order to obtain a prodrug;

converting a compound prepared in one of methods (a) to (j) in a pharmaceutically acceptable acid addition salt thereof; or

resolving an optically active compound of formula I prepared in one of methods (a) to (j) in optically active isomers thereof.

In method (a) the reaction is conveniently performed at 20-120 °C in an aprotic solvent such as acetone or methyl isobutyl ketone in the presence of free base (e.g. K_2CO_3 or triethylamine) and the starting compounds of Formula II are prepared as described below.

3-aryl-1-(4-piperidyl)indoles and 3-aryl-1-(4-piperidyl)indazoles are prepared as shown in the following reaction scheme:



wherein $R^1 - R^4$, R^6 and Ar are as defined above.

An 3-arylindole or 3-arylindazole of the Formula XIII is arylated with 4-chloro- or 4-bromopyridine in NMP, DMF, HMPA or DMSO with potassium carbonate as base and catalyzed by copper, copper(I) iodide or copper(I) bromide at 150-210 °C. The 3-aryl-1-(4-pyridyl)indole or 3-aryl-1-(4-pyridyl)indazole of Formula XIV thus obtained is reduced to the 3-aryl-1-(4-piperidyl)indole or 3-aryl-1-(4-piperidyl)indazole of the Formula XV with hydrogen at low pressure (3 ato.) in the presence of platinum.

3-Arylindoles, which are unsubstituted in the 2-position, are prepared from the corresponding 2-cyano-3-arylindoles or 3-arylindole-2-carboxylic esters by alkaline or acidic hydrolysis followed by decarboxylation in NMP or quinoline with copper catalysis. The 2-cyano-3-arylindoles and 3-arylindole-2-carboxylic esters

used are prepared either from the corresponding anilines by Japp-Klingemann reaction followed by Fischer indole synthesis or from the corresponding 2-benzoylanilines according to modified literature procedures (Morooka et al, *Synthesis*, **1978**, 445, Hughes et al, *J. Proc. Roy. Soc. N. S. Wales*, **1939**, 72, 209 and C. D. Jones, *J. Org. Chem.*, **1972**, 37, 3624).

5 2-Substituted 3-arylindoles are prepared either from the corresponding 2-benzoyl-anilines or by Fischer indole synthesis from the corresponding substituted phenyl hydrazones (e.g. (4-fluorophenyl)acetone (4-methylphenyl)hydrazone) according to modified literature procedures (Greuter et al, *Helv. Chem. Acta*, **1974**, 57, 281 and Yamamoto et al, *Chem. Pharm. Bull.*, **1968**, 16, 2313).

3-Arylindazoles are prepared either from the corresponding 2-benzoylanilines or by heating the correspond-
10 ing 2-chloro - or bromobenzophenone hydrazone with base, according to modified literature procedures (Dziewonski et al., *Bull. Intern. Acad. Polonaise, Casse Sci. Math. Nat.*, **1935A**, 333 (*Chem. Abstr.*, **1936**, 30, 1972) and Gladstone et al, *J Chem. Soc.*, **1965**, 3048).

2-Halo-3-aryl-1-(4-piperidyl)indoles are prepared from the corresponding 3-aryl-1-(4-piperidyl)indoles, in which the piperidine nitrogen is protected by a suitable aminoprotective group (e.g. methyl or 2,2,2-trichloroethyl carbamate), by halogenation with an halogenation reagent such as *N*-bromosuccinimide, *N*-chlorosuccinimide or bromine in an inert solvent (e.g. CCl₄ or acetic acid) according to modified literature procedures (Hino et al., *Tetrahedron*, **1974**, 30, 2123), followed by deprotection of the piperidine nitrogen by standard methods which are obvious to the chemist skilled in the art.

In method (b) the reaction is performed by refluxing a compound of Formula IV with a compound of
20 Formula V and a strong base (e.g. sodium amide) in an inert solvent, e.g. toluene. The starting compounds of Formula IV are prepared by reacting the corresponding 3-arylindoles, prepared as described above, with hydroxylamine-O-sulphonic acid and strong base (e.g. potassium tert-butoxide) in a polar aprotic solvent (e.g. DMF).

In method (c) the reduction is conveniently performed with a complex hydride (e.g. sodium borohydride) in
25 acidic solution (e.g. trifluoroacetic acid).

In method (d) the reduction is suitably carried out at a low hydrogen pressure (3 ato.) in the presence of platinum or palladium or by refluxing a compound of formula VII with ammonium formate and palladium in a water miscible solvent (e.g. ethanol).

In method (e) the reduction is expediently carried out with a complex hydride (e.g. sodium borohydride in
30 methanol) whereas the reduction in method (f) preferably is performed by catalytic hydrogenation with platinum as a catalyst. The starting compounds of Formula VIII are prepared by quaternizing a 1-(4-pyridyl)-3-arylindole or 1-(4-pyridyl)-3-arylindazole, prepared as described above, with a lower alkyl halide or a halide of the general Formula IIIa or IIIb in MIBK or acetone. The reduction in method (g) is conveniently carried out with lithium aluminum hydride in tetrahydrofuran, or diethyl ether, or with diborane in
35 tetrahydrofuran. Aminoalkyl derivatives of the Formula X (method h) are prepared by alkylating a compound of the Formula II with a halo-nitrile of the following formula: $\text{hal}(\text{CH}_2)_n\text{CN}$ in the presence of a base (e.g. K₂CO₃ or triethylamine) in an inert solvent such as acetone, MIBK or toluene at elevated temperature (30-100 °C). The cyano group may be reduced according to standard procedures using e.g. AlH₃, LiAlH₄ or B₂H₆. The R⁹ substituent is introduced by direct alkylation or by an acylation/reduction procedure, which is
40 obvious to the chemist skilled in the art. Acylation of the thus obtained amino derivatives is accomplished by addition of an acylating agent at a low temperature (-20-30 °C) preferably in a chlorinated solvent (dichloromethane, chloroform, or 1,1,1-trichloroethane) and, if necessary, in the presence of a base to neutralize any acidic reaction product formed.

Ethylene or propylene diamines as intermediates for the ringclosure procedure in method (i) are prepared
45 by repeating with appropriate reagents the procedure described for the preparation of the aminoalkyl derivatives used as starting materials in method (h). Generally, heating (80-150 °C) is required to effect ringclosure with the appropriate carbonyl- or thiocarbonyl precursor compound (phosgene, thiophosgene, carbondisulphide, urea or thiourea).

In method (j) the reduction is conveniently carried out using a complex hydride (e.g. lithium aluminum
50 hydride) in an inert solvent (e.g. diethyl ether). The starting compounds of Formula XII are prepared by reacting a compound of Formula II with a halocarboxylic acid ester of formula $\text{hal}(\text{CH}_2)_p\text{CO}_2\text{R}^{17}$ in the presence of a base (e.g. K₂CO₃ or triethylamine) in an inert solvent such as acetone, MIBK or toluene at elevated temperature (30-100 °C).

The ω-haloalkyl-2-imidazolidinone alkylating reagents (substructure of structure IIIa) were prepared
55 according to modified literature procedures (see eg. Johnston, T.P.; McCaleb, G.S.; Montgomery, J.A. The Synthesis of Antineoplastic Agents. XXXII. N-Nitrosureas. *J. Med. Chem.* **1963**, 6, 669-681; Ebetino, F.F. *Belg. Patent* 653421, 1965; *Chem. Abstr.* **1966**, 64, 12684; Costeli, J.; Züst, A. *Ger. Offen* 2035370, 1971; *Chem. Abstr.* **1971**, 74, 87985z). Other sidechains of structure IIIa were prepared as stated in the literature.

The acid addition salts of the compounds of the invention are easily prepared by methods well known in the art. The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or with an excess of the acid in an aqueous immiscible solvent, such as diethyl ether or chloroform, with the desired salt separating directly. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts.

In the following the invention is further illustrated by way of examples, which in no way may be construed as limiting for the invention.

10 EXAMPLE 1

3-(4-Fluorophenyl)-1*H*-indole 1a.

Methyl 3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **22d** (59.6 g) was refluxed in a mixture of methanol (1.5 l) and 2 N aqueous NaOH (500 ml) for 3.5 h. The reaction mixture was cooled to room temperature, the solvents were evaporated *in vacuo* and water (500 ml) was added. The alkaline solution was acidified and the thus formed precipitate was filtered off and dissolved in ethyl acetate (750 ml). The ethyl acetate solution was washed with brine (500 ml) and dried (Na₂SO₄). Evaporation of the solvents afforded the crude 4-fluorophenyl-1*H*-indole-2-carboxylic acid which was used without further purification.

A mixture of the crude indole-2-carboxylic acid (55.0 g), Cu (2.0 g) and quinoline (1.0 l) was refluxed for 2.5 h, cooled and filtered. The filtrate was poured into water (800 ml) and extracted with diethyl ether (2 x 800 ml). The combined organic phases were successively washed with 1 N hydrochloric acid (4 x 1.0 l), washed with brine (1.0 l) and dried (Na₂SO₄). Evaporation of the solvent *in vacuo* gave the title compound which was precipitated from diethyl ether. Yield: 43.6 g, mp 98-100 °C.

In a corresponding manner the following indole derivatives were prepared:

5-Chloro-3-(4-fluorophenyl)-1*H*-indole **1b**, mp 81-83 °C.

3-(4-Fluorophenyl)-5-methyl-1*H*-indole **1c**, mp 123-126 °C.

6-Chloro-3-(4-fluorophenyl)-1*H*-indole **1d**, (oil).

5-Fluoro-3-(4-fluorophenyl)-1*H*-indole **1e**, (oil).

3-(4-Fluorophenyl)-5-trifluoromethyl-1*H*-indole **1f**, (oil).

5-Chloro-3-phenyl-1*H*-indole **1g**, mp 84-86 °C.

EXAMPLE 2

35 3-(4-Fluorophenyl)-1-(4-pyridyl)-1*H*-indole 2a.

3-(4-Fluorophenyl)-1*H*-indole **1a** (39.3 g), 4-chloropyridine hydrochloride (55.8 g), K₂CO₃ (102.8 g), CuBr (15 g) and N-methylpyrrolidinone (1.2 l) were refluxed under stirring for 18 h. The reaction mixture was cooled, poured into water (1.0 l) and extracted with diethyl ether (2 x 1 l). The combined organic phases were washed with brine (3 x 1.5 l), dried (Na₂SO₄) and treated with activated carbon. Evaporation of the solvent gave the title compound which was crystallized from diethyl ether. Yield: 42.0 g, mp 115-118 °C.

In a corresponding manner the following indole derivatives were prepared:

5-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole **2b**, mp 162-164 °C.

3-(4-Fluorophenyl)-5-methyl-1-(4-pyridyl)-1*H*-indole **2c**, mp 125-127 °C.

5-Fluoro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole **2d**, mp 129-134 °C.

6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole **2e**, mp 194-198 °C.

3-(4-Fluorophenyl)-1-(4-pyridyl)-5-trifluoromethyl-1*H*-indole **2f**, mp 163-165 °C.

5-Chloro-3-phenyl-1-(4-pyridyl)-1*H*-indole **2g**, mp 130-132 °C.

50 EXAMPLE 3

(intermediate for method a)

55 6-Chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole 3a.

6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole **2e** (1.8 g) was dissolved in acetic acid (100 ml) and PtO₂ (0.2 g) was added. After hydrogenation for 30 h at 3 atm the catalyst was filtered off, the acetic acid

was evaporated *in vacuo* and water (50 ml) was added. The acidic solution was made alkaline (pH >9) with concentrated sodium hydroxide and extracted with ethyl acetate (2 x 50 ml). The combined organic phases were successively washed with diluted sodium hydroxide (50 ml), washed with brine, and dried (Na₂SO₄). Evaporation of the solvent gave 1.5 g of the title compound as an oil.

5 In a corresponding manner the following indole and indazole derivatives were prepared:

- 3-(4-Fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3b**, (oil).
- 5-Chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3c**, (oil).
- 3-(4-Fluorophenyl)-5-methyl-1-(4-piperidyl)-1*H*-indole **3d**, (oil).
- 5-Fluoro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3e**, (oil).
- 10 3-(4-Fluorophenyl)-1-(4-piperidyl)-5-trifluoromethyl-1*H*-indole **3f**, (oil).
- 5-Chloro-3-phenyl-1-(4-piperidyl)-1*H*-indole **3g**, (oil).
- 6-Chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indazole **3h**, (oil).
- 3-(4-Fluorophenyl)-1-(4-piperidyl)-5-trifluoromethyl-1*H*-indazole **3i**, (oil).

15 EXAMPLE 4

(method a)

6-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole, maleate **4a**.

20

A mixture of 6-chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3a** (1.5 g), 1-(2-chloroethyl)-3-methyl-2-imidazolidinon (1.1 g), K₂CO₃ (1.0 g), KI (0.5 g) and methyl isobutyl ketone (100 ml) was refluxed for 18 h. The reaction mixture was cooled, poured into water (50 ml) and extracted with ethyl acetate (2 x 50 ml). The combined organic phases were dried (Na₂SO₄) and the solvents were evaporated *in vacuo*. The remaining oil was purified by column chromatography on silica gel (eluted with ethyl acetate/isopropanol 9:1 containing 4 % triethylamine). The title compound was precipitated as its maleate from ethyl acetate. Yield: 1.4 g, mp 110-112 °C.

25

In a corresponding manner the following indole and indazole derivatives were prepared:

- 6-Chloro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4b**, mp 192-194 °C.
- 30 6-Chloro-3-(4-fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, hydrochloride, hydrate **4c**, mp 255-258 °C.
- 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4d**, mp 171-174 °C.
- 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4e**, mp 161-164 °C.
- 35 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-piperidyl]-1*H*-indole **4f**, mp 128-133 °C.
- 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole **4g**, mp 185-187 °C.
- 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, oxalate **4h**, mp 175-177 °C.
- 40 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole, fumarate **4i**, mp 103-105 °C.
- 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-(2-pyrrolidinon-1-yl)ethyl]-4-piperidyl]-1*H*-indole, oxalate **4j**, mp 120-122 °C.
- 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4k**, mp 172-173 °C.
- 45 3-(4-Fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, hydrochloride, hydrate **4l**, mp 242-244 °C.
- 5-Fluoro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4m**, mp 153-156 °C.
- 5-Fluoro-3-(4-fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4n**, mp 143-145 °C.
- 50 5-Fluoro-3-(4-fluorophenyl)-1-[1-[2-(oxazolidin-2-on-3-yl)ethyl]-4-piperidyl]-1*H*-indole **4o**, mp 123-125 °C.
- 5-Chloro-3-phenyl-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4p**, mp 155-157 °C.
- 5-Chloro-3-phenyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4q**, mp 146-148 °C.
- 2,3-Dihydro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-fluoro-1*H*-indole **4r**, mp 182-186 °C.
- 55 3-(4-Fluorophenyl)-5-methyl-1-[1-(2-propyl)-4-piperidyl]-1*H*-indole, maleate **4s**, m p 162-163 °C.
- 6-Chloro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indazole **4t**, mp 195-197 °C.
- 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-trifluoromethyl-1*H*-indazole **4u**, mp

217-219 °C.

3-(4-Fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-5-trifluoromethyl-1*H*-indole 4v, mp 156-158 °C.

2-Bromo-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole 4x, mp 194-196 °C.

5

EXAMPLE 5

(intermediates for methods e and f)

10

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5a.

A mixture of 2,5-dimethyl-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 17a (5.0 g) and 1-(2-iodoethyl)-2-imidazolidinon (7.6 g) and methyl isobutyl ketone (50 ml) was refluxed for 6 h. After cooling to room temperature the precipitated product was filtered off and dried *in vacuo* at 70 °C overnight. This afforded

15

6.3 g of the title compound, mp 215-217 °C.

In a corresponding manner the following indole derivatives were prepared:

4-[3-(4-Fluorophenyl)-5-methyl-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5b, mp >250 °C.

20

4-[3-(4-Fluorophenyl)-5-trifluoromethyl-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5c, mp >250 °C.

EXAMPLE 6

(method e)

25

2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole 6a.

30

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5a - (6.3 g) was suspended in ethanol (100 ml) and sodium borohydride (2.1 g) was added in three portions during 3.5 h. Then the solvent was evaporated *in vacuo* and water (100 ml) was added. The mixture obtained was extracted with dichloromethane (2 x 50 ml). The combined organic phases were washed with brine (100 ml) and dried (MgSO₄). Evaporation of the solvent gave the title compound as an oil, which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 8:1 containing 4 % triethylamine). Yield: 2.5 g, mp 151-153 °C.

35

In a corresponding manner the following indole derivatives were prepared: 2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole 6b, mp 98-100 °C.

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-5-methyl-1*H*-indole 6c, mp 129-131 °C.

40

3-(4-Fluorophenyl)-5-methyl-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole, maleate 6d, mp 168-171 °C.

5-Chloro-2-methyl-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-phenyl-1*H*-indole, oxalate 6e, mp 165-168 °C.

45

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-5-trifluoromethyl-1*H*-indole 6f, mp 113-115 °C.

EXAMPLE 7

(method d)

50

2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole 7a.

55

Ammonium formate (12 g) was added in small portions during 18 h to a refluxing mixture of 2,5-dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole 6a (1.9 g), 5 % palladium on activated carbon (1 g) and ethanol (50 ml). The reaction mixture was cooled to room temperature and the solvents were evaporated *in vacuo*. After addition of water the mixture was made alkaline with concentrated NaOH and extracted with ethyl acetate (2 x 50 ml). The combined organic phases were dried (Na₂SO₄) and the solvents were evaporated *in vacuo*. This afforded the title compound which

crystallized from diethyl ether. Yield 0.2 g, mp 188-190 °C.

In a corresponding manner the following indole derivatives were prepared:

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-trifluoromethyl-1H-indole **7b**, mp 182-186 °C

5 1-[1-[2-(Imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-2-methyl-3-phenyl-1H-indole **7c**, mp 179-183 °C.

EXAMPLE 8

(intermediates for methods e and f)

10

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1H-indol-1-yl]-1-methylpyridinium, iodide **8a**.

2,5-Dimethyl-3-(4-fluorophenyl)-1-(4-pyridyl)-1H-indole **17a** (5.0 g), methyl iodide (5 ml) and acetone (100 ml) were heated at 40 °C for 18 h. After cooling to room temperature the precipitated product was filtered off and dried *in vacuo* at 70 °C overnight. yield: 6.3 g, mp 217-219 °C.

15

In a corresponding manner the following indole derivatives were prepared:

4-(5-Chloro-2-methyl-3-phenyl-1H-indol-1-yl)-1-methylpyridinium iodide **8b**, mp 225-227 °C.

4-[3-(4-Fluorophenyl)-5-methyl-1H-indol-1-yl]-1-methylpyridinium, iodide **8c**, mp > 250 °C.

20 EXAMPLE 9

(method f)

2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-4-piperidyl)-1H-indole **9a**.

25

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1H-indol-1-yl]-1-methylpyridinium, iodide **8a** (3.0 g) was dissolved in acetic acid (75 ml) and PtO₂ (0.4 g) was added. After hydrogenation for 2 weeks at 3 atmo the catalyst was filtered off, the acetic acid was evaporated *in vacuo* and water (50 ml) was added. The thus obtained acidic solution was made alkaline (pH > 9) with concentrated sodium hydroxide and extracted with ethyl acetate (2 x 50 ml). The organic phases were successively washed with diluted sodium hydroxide (50 ml), washed with brine and dried (Na₂SO₄). Evaporation of the solvent gave 1.3 g of the title compound as an oil, which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 8:1 containing 4 % triethylamine) and crystallized from heptane. Yield 0.4 g, mp 110-112 °C.

30

In a corresponding manner the following indole derivative was prepared: 5-Chloro-2-methyl-3-phenyl-1-(1-methyl-4-piperidyl)-1H-indole **9b**, mp 131-136 °C (decomp.).

35

EXAMPLE 10

(intermediates for method g)

40

Methyl 4-[3-(4-fluorophenyl)-5-methyl-1H-indol-1-yl]piperidine-1-carboxylate **10a**.

A mixture of 3-(4-fluorophenyl)-5-methyl-1-(4-piperidyl)-1H-indole **3d** (6.0 g), K₂CO₃ (3.0 g) and dichloromethane (50 ml) was cooled to 0-5 °C and a solution of methyl chloroformate (2.2 g) in dichloromethane (50 ml) was added during 0.5 h. After reaction for further 2 h at room temperature the reaction mixture was washed with water (2 x 100 ml) and dried (MgSO₄). Evaporation of the solvents *in vacuo* afforded the title compound, which was used without further purification. Yield: 6.7 g, (oil). in a corresponding manner the following indole derivative was prepared:

45

2,2,2-Trichloroethyl-4-[3-(4-fluorophenyl)-1H-indol-1-yl]piperidine-1-carboxylate **10b** (oil).

50

EXAMPLE 11

(method g)

55 3-(4-Fluorophenyl)-5-methyl-1-(1-methyl-4-piperidyl)-1H-indole, fumarate **11a**.

A solution of the crude methyl 4-[3-(4-fluorophenyl)-5-methyl-1H-indol-1-yl]piperidine-1-carboxylate **10a**, (6.7 g) in dry tetrahydrofuran (75 ml) was added to a suspension of lithium aluminum hydride (4 g) in dry

tetrahydrofuran (75 ml) during 0.5 h and the reaction mixture was refluxed for 1 h. After cooling on an ice bath water (5 ml), 6 N aqueous NaOH (5 ml) and water (10 ml) were added, successively. The precipitate was filtered off, the filtrate was dried (MgSO₄) and the solvents were evaporated *in vacuo*. This afforded the title compound, as an oil, which was precipitated as its fumarate from ethanol. Yield: 1.4 g, mp 170-172 °C.

5

EXAMPLE 12

(intermediate for method h)

10 1-[1-(2-Aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 12a.

A solution of 3-(4-fluorophenyl)-5-methyl-1-(4-piperidyl)-1*H*-indole 3d (20 g), chloroacetonitrile (5.4 g) and triethylamine (7.5 ml) in *N*-methylpyrrolidinone (125 ml) was heated at 60 °C for 2 h. The reaction mixture was poured into ice (200 g) and extracted with diethyl ether (2 x 200 ml). The combined organic phases were washed with brine (3 x 250 ml), dried (Na₂SO₄) and the solvents evaporated *in vacuo*. This afforded the 1-[1-(2-cyanomethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, as an oil, which was used without further purification. Yield: 22.2 g. To a suspension of aluminum chloride (5.0 g) in dry diethyl ether (200 ml) was added lithium aluminum hydride (5.0 g) at 10-15 °C. Then a solution of the crude cyanomethyl compound in dry tetrahydrofuran (300 ml) was added dropwise during 0.5 h at 10-15 °C. The reaction mixture was refluxed for 2 h, cooled on an ice bath and concentrated aqueous NaOH (25 ml) was added. The inorganic salts were filtered off and the solvent evaporated *in vacuo*. The remaining oil was dissolved in dichloromethane, dried (MgSO₄) and the solvent was evaporated. This afforded the title compound as an oil. Yield: 18.9 g.

25 **EXAMPLE 13**

(method h)

1-[1-[2-(3,3-Dimethyl-1-thioureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 13a.

30

A solution of 1-[1-(2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, 12a (5.0 g), *N,N*-dimethylthiocarbamoylchloride (2.1 g) and triethylamine (5 ml) in dichloromethane (150 ml) was refluxed for 18 h. After cooling to room temperature the reaction mixture was washed with water and dried (MgSO₄). Evaporation of the solvent afforded the title compound as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate containing 4 % triethylamine). The title compound precipitated from ethyl acetate and was recrystallized from diethyl ether. Yield: 0.8 g, mp 106-108 °C.

In a corresponding manner the following indole derivative was prepared:

1-[1-[2-(3,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 13b, mp 126-128 °C.

40

EXAMPLE 14

(intermediate for method h)

45 1-[1-(*N*-Methyl-2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 14a

A mixture of 1-[1-(2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 12a (8.9 g), K₂CO₃ (4.2 g) and dichloromethane (80 ml) was cooled to 0-5 °C and a solution of methyl chloroformate (2.9 g) in dichloromethane (50 ml) was added during 15 min. After reaction for further 2 h at room temperature the reaction mixture was washed with water (2 x 50 ml), dried (MgSO₄) and the solvents were evaporated *in vacuo*. This afforded the 1-[1-(*N*-methoxycarbonyl-2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, as an oil, which was used without further purification. Yield: 8.8 g.

A solution of the crude 1-[1-(*N*-methoxycarbonyl-2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole (8.8 g) in dry tetrahydrofuran (75 ml) was added to a suspension of lithium aluminum hydride (2 g) in dry tetrahydrofuran (75 ml) during 15 min and the reaction mixture was refluxed for 1.5 h. After cooling on an ice bath water (4 ml), 4 N aqueous NaOH (2.5 ml) and water (10 ml) were added, successively. The precipitate was filtered off, the solution was dried (Na₂SO₄) and the solvents were evaporated. This afforded the title compound, as an oil. Yield: 6.9 g.

EXAMPLE 15

(method h)

5 1-[1-[2-(1,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, hydrochloride **15a**.

A mixture of 1-(1-(*N*-methyl-2-aminoethyl)-4-piperidyl)-3-(4-fluorophenyl)-5-methyl-1*H*-indole **14a** (6.9), methyl isocyanate (2.1 g) and K₂CO₃ (4 g) in methyl isobutyl ketone (150 ml) was refluxed for 6 h. After cooling to room temperature water (100 ml) was added and the mixture was extracted with ethyl acetate (2 x 100 ml). The combined organic phases were washed with brine and dried (MgSO₄). Evaporation of the solvent afforded the title compound as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 4:1, containing 4 % triethylamine). The title compound was precipitated as its hydrochloride from diethyl ether. Yield: 0.9 g, mp 88-90 °C.

EXAMPLE 16

(method j)

3-(4-Fluorophenyl)-1-[1-(2-hydroxyethyl)-4-piperidyl]-5-methyl-1*H*-indole, oxalate **16a**.

A solution of ethyl bromoacetate in acetone was added during 15 min to a mixture of 3-(4-fluorophenyl)-5-methyl-1-(4-piperidyl)-1*H*-indole **3d** (5.0 g), K₂CO₃ (2.5 g) and acetone (100 ml) at room temperature. After another 2 h the solvents were evaporated, water was added and the mixture was extracted with ethyl acetate (2 x 100 ml). The combined organic phases were washed with brine and dried (Na₂SO₄). Evaporation of the solvent afforded the crude methyl 4-[3-(4-fluorophenyl)-5-methyl-1*H*-indol-1-yl]-1-piperidinacetate (6.0 g), which was used without further purification.

A solution of the crude methyl ester (6.0 g) in tetrahydrofuran (50 ml) was added to a suspension of lithium aluminum hydride (1.2 g) in dry tetrahydrofuran (50 ml) and the mixture was refluxed for 1 h. After cooling on ice bath, water (1.5 ml) and 4 N aqueous NaOH (1.5 ml) were added. The precipitate was filtered off and the filtrate was dried (Na₂SO₄). Evaporation of the solvents afforded the title compound (4.2 g) as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate containing 4 % triethylamine). The title compound precipitated as its oxalate from acetone. Yield: 0.09 g, mp 81-83 °C.

EXAMPLE 17

2,5-Dimethyl-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole **17a**.

2,5-Dimethyl-(4-fluorophenyl)-1*H*-indole **24a** (50 g), 4-bromopyridine, hydrochloride (80 g), K₂CO₃ (90 g), CuBr (10 g) and *N*-methylpyrrolidone (750 ml) were refluxed under stirring for 18 h. The reaction mixture was cooled, poured into water (1.0 l) and extracted with diethyl ether (2 x 750 ml). The combined organic phases were washed with brine (3 x 1 l), dried (Na₂SO₄) and treated with activated carbon. Evaporation of the diethyl ether afforded the title compound (29.8 g) which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 3:1). The title compound crystallized from diethyl ether. Yield: 20.5 g, mp 172-174 °C.

In a corresponding manner the following indole and indazole derivatives were prepared:

5-Chloro-2-methyl-3-phenyl-1-(4-pyridyl)-1*H*-indole **17b**, mp 158-160 °C.

6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indazole **17c**, (oil).

3-(4-Fluorophenyl)-1-(4-pyridyl)-5-trifluoromethyl-1*H*-indazole **17d**, (oil).

EXAMPLE 18

(method c)

2,3-Dihydro-5-fluoro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **18a**

To a solution of 5-fluoro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3e** (2 g) in trifluoroacetic acid (30 ml) was added sodium cyanoborohydride (1 g). After 2 h reaction at room temperature the solvent was evaporated *in vacuo* and ethyl acetate (50 ml) was added. The mixture was washed twice with aqueous 2 N

sodium hydroxide (50 ml) and dried (Na_2SO_4). Evaporation of the solvent *in vacuo* afforded the crude product which was used without further purification. Yield: 1.5 g (oil).

In a corresponding manner the following indole derivative was prepared:

2,3-Dihydro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole **18b**, mp 180-185 °C.

EXAMPLE 19

(intermediate for method b)

1-Amino-3-(4-fluorophenyl)-5-methyl-1*H*-indole **19a**.

Potassium *tert*-butoxid (7.5 g) was added to a solution of 3-(4-fluorophenyl)-5-methyl-1*H*-indole **1c** (15 g) in DMF during 15 min at 0-5 °C. Then a suspension of potassium hydroxylamine-O-sulphonate in DMF (prepared by addition of potassium *tert*-butoxid (7.5 g) to a suspension of hydroxylamine-O-sulphonic acid (7.6 g) in DMF (100 ml) during 0.5 h at 0-5 °C) was added slowly at 0-5 °C. After reaction at 0 °C for 1 h the mixture was poured into ice, and extracted with diethyl ether (2 x 250 ml). The combined organic phases were washed with brine (3 x 250 ml) and dried (Na_2SO_4). Evaporation of the solvents afforded the title compound which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:3) and crystallized from diethylether. Yield: 4.3 g, mp 116-120 °C.

EXAMPLE 20

(method b)

3-(4-Fluorophenyl)-5-methyl-1-(1-methylpiperazin-4-yl)-1*H*-indole **20a**.

To a mixture of 1-amino-3-(4-fluorophenyl)-5-methyl-1*H*-indole **19a** (1 g) and toluene (20 ml) was added a 50 % suspension of sodium amide in xylene (1.0 ml). After reaction for 15 min at room temperature a solution of *N,N*-bis(2-chloroethyl)methylamine (0.8 g) in toluene was added slowly and the mixture was refluxed for 3 h. After cooling to room temperature, the solvents were evaporated *in vacuo* and water (100 ml) was added. The mixture was extracted with ethyl acetate (2 x 50 ml) and the combined organic phases were dried (Na_2SO_4). Evaporation of the solvents *in vacuo* afforded the title compound, which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 4:1 containing 4 % triethylamine) and crystallized from heptane. Yield: 0.5 g, mp 105-107 °C.

EXAMPLE 21

1-[1-[2-(3-Acetylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, oxalate **21a** - (Prodrug).

To a mixture of 3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole **4g** (3 g), K_2CO_3 (1.3 g) and toluene (50 ml) was added a solution of acetyl chloride (0.6 ml) in toluene (5 ml) during 10 min at 0-5 °C. After reaction for further 18 h at room temperature the reaction mixture was filtered, the solvent was evaporated *in vacuo* and ethyl acetate (50 ml) was added. The thus formed solution was washed with brine (50 ml), dried (Na_2SO_4) and the solvent was evaporated *in vacuo*. This afforded the title compound as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate containing 4 % triethylamine). The title compound precipitated as its oxalate from acetone. Yield: 2.0 g, mp 233-235 °C.

In a corresponding manner the following indole derivative was prepared: 1-[1-[2-(3-Decanoylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, oxalate **21b**, mp 175-176 °C.

EXAMPLE 22

Methyl 3-(4-fluorophenyl)-5-methyl-1*H*-indole-2-carboxylate **22a**.

To a solution of *p*-toluidine (119.4 g) in conc. aqueous HCl (575 ml) was added a solution of NaNO_2 - (84.6 g) in water (500 ml) at 0-5 °C during 1.5 h. The reaction mixture was added in one portion to a

mixture of methyl 2-(4-fluorobenzyl)-3-oxo-butanoate (250 g), KOH (220 g), water (0.5 l), ethanol (1.25 l) and ice (2 kg) under stirring. After reaction for 2 h at room temperature the reaction mixture was extracted with diethyl ether (2 x 2 l). The combined organic phases were washed with water (3 l) and dried (Na₂SO₄). Evaporation of the solvents afforded the crude 4-tolylhydrazone of methyl 2-oxo-3-(4-fluorophenyl)-propanoate (330 g), which was used without further purification.

A mixture of the crude hydrazone, methanol (2.25 l) and aqueous H₂SO₄ (100 ml) was refluxed for 18 h. The reaction mixture was cooled to room temperature and a part of the solvents were evaporated *in vacuo*. The thus obtained solution was cooled to 0 °C and the precipitated compound was filtered off and dried overnight *in vacuo* at 60 °C. Yield: 180 g, mp 151-155 °C.

In a corresponding manner the following indole derivatives were prepared: Methyl 5-chloro-3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **22b**, mp 184-186 °C.

Methyl 5-fluoro-3-(4-fluorophenyl)-1*H*-indole-2-carboxylate, **22c**, (oil).

Methyl 3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **22d**, mp 148-150 °C.

Methyl 3-(4-fluorophenyl)-5-trifluoromethyl-1*H*-indole-2-carboxylate **22e**, mp 136-139 °C.

Methyl 5-chloro-3-phenyl-1*H*-indole-2-carboxylate **22f**, (oil).

EXAMPLE 23

Methyl 6-chloro-3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **23a**.

To a mixture of a 50 % sodium hydride suspension in mineral oil (52.5 g) (which was extracted with dry heptane) and dry tetrahydrofuran (250 ml) was added a solution of N-benzoyl 5-chloro-2-(4-fluorobenzoyl)-aniline (129 g) in dry tetrahydrofuran (500 ml) during 0.5 h at 20 °C (ice bath). After 1 h methyl 2-bromoacetate (101 ml) was added during 0.5 h at 20 °C (ice bath) and the mixture was stirred for another 1 hour. The solvents were evaporated *in vacuo*. The remaining oil was diluted with methanol (250 ml) and 5.4 M sodium methoxide in methanol (670 ml) was added carefully. After 1 h at room temperature the solvents were evaporated *in vacuo* and water (0.5 l) was added. The thus obtained mixture was extracted with ethyl acetate (2 x 0.75 l) and the combined organic phases were washed with brine and dried (Na₂SO₄). Evaporation of the solvents *in vacuo* afforded the title compound, which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:3) and crystallized from heptane. Yield: 33 g, mp 172-183 °C.

EXAMPLE 24

2,5-Dimethyl-3-(4-fluorophenyl)-1*H*-indole **24a**.

A solution of 4-fluorophenylacetone (60 g), 4-tolylhydrazine, HCl (68.8 g) and triethylamine (165 ml) in ethanol (600 ml) was refluxed for 18 h. The reaction mixture was cooled to room temperature, the solvents were evaporated *in vacuo* and water (500 ml) was added to the remaining oil. The thus obtained mixture was extracted with ethyl acetate (2 x 250 ml). The combined organic phases were washed with brine and dried (Na₂SO₄). Evaporation of the solvents afforded the crude 4-fluorophenylacetone tolylhydrazone (100 g) as an oil, which was used without further purification.

The crude hydrazone (100 g), ethanol (700 ml) and conc. aqueous H₂SO₄ (40 ml) were refluxed for 18 h. After cooling to room temperature water (0.5 l) was added. The thus obtained mixture was extracted with (2 x 700 ml) ethyl acetate and the combined organic phases were washed with brine, dried and the solvents were evaporated *in vacuo*. This afforded the title compound, which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:4) and crystallized from heptane. Yield: 75.5 g, mp:124-128 °C.

In a corresponding manner the following indole derivative was prepared: 5-Chloro-3-phenyl-2-methyl-1*H*-indole **24b**, (oil).

EXAMPLE 25

6-Chloro-3-(4-fluorophenyl)-1*H*-indazole **25a**.

To solution of 5-chloro-2-(4-fluorobenzoyl)aniline (5 g) in 6 M aqueous HCl (25 ml) was added a solution of NaNO₂ (2.5 g) in water (5 ml) at 0-5 °C under stirring during 15 min. After stirring for further 0.5 h at 0 °C a solution of SnCl₂ (20 g) in conc. aqueous HCl (25 ml) was added. The reaction mixture was allowed to

heat to room temperature and after 0.5 h the precipitate was filtered off and suspended in 2 N aqueous NaOH. The suspension was filtered and dichloromethane was added to the precipitate. The thus obtained solution was washed with brine and dried (MgSO₄). Evaporation of the solvents afforded the title compound (2.5 g) as an oil which was used without further purification.

- 5 In a corresponding manner the following indazole derivative was prepared: 3-(4-Fluorophenyl)-5-trifluoromethyl-1*H*-indazole **25b**, (oil)

EXAMPLE 26

- 10 2-Bromo-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **26a**.

A mixture of 2,2,2-trichloroethyl 4-[3-(4-fluorophenyl)-1*H*-indol-1-yl]piperidine-1-carboxylate **10b** (4.0 g), N-bromosuccinimide (1.5 g) and tetrachloromethane (60 ml) was refluxed for 2 h. The reaction mixture was cooled to room temperature and the precipitate was filtered off. Evaporation of the solvent afforded the crude 2,2,2-trichloroethyl 2-bromo-4-[3-(4-fluorophenyl)-1*H*-indol-1-yl]piperidine-1-carboxylate (4.4 g) as an oil which was used without further purification. A mixture of the crude 2-bromo-indole (4.4 g), zinc powder (4.4 g) and 90 % acetic acid in water (150 ml) was heated at 40 °C for 30 min. The reaction mixture was filtered and the solvent evaporated *in vacuo*. To the remaining oil was added ethyl acetate (50 ml) and the thus obtained solution was washed successively with water, 4 N aqueous NaOH and brine. Evaporation of the solvents afforded the title compound as an oil (2.9 g).

EXAMPLE 27

- 2-Chloro-3-(4-fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **27a**.

A mixture of 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4h** (3.0 g), dimethylsulphoxide (0.51 g) and conc. aqueous HCl (1 ml) was heated to 60 °C for 0.5 h under stirring. The reaction mixture was cooled to room temperature and water was added. The solution was extracted with ethyl acetate (2 x 50 ml). The combined organic phases were washed with 4 N aqueous NaOH and brine. Evaporation of the solvent gave an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:3). This afforded the title compound which crystallized from diethyl ether. Yield 0.4 g, mp 127-130 °C.

35 PHARMACOLOGICAL TESTS

The compounds of the invention were tested in well recognized and reliable methods. The tests were as follows and the results are given in the following Table 1. The well known 5HT₂ antagonists ritanserin and ICI 169369 were included in the tests for comparison purposes.

40 INHIBITION OF ³H-KETANSERIN BINDING TO SEROTONIN S₂

(5-HT₂) RECEPTORS IN RAT CORTEX *IN VITRO*

- 45 By this method the inhibition by drugs of the binding of ³H-Ketanserin (0,5 nM) to Serotonin S₂ (5-HT₂) receptors in membranes from rat is determined *in vitro*. Method in Hyttel, *Pharmacology & Toxicology*, **61**, 126-129, 1987.

Procedure

- 50 Male Wistar (Mol:Wist) rats (125-250 g) are sacrificed and cortical tissue is dissected and weighed. The tissue is homogenized (Ultra Turrax, 10 sec.) in 10 ml of ice-cold 50 mM tris buffer pH 7.7 (at 25 °C). The centrifuge glassware used in this step has been rinsed by sonication for 10 min. in ethanol. The homogenate is centrifuged twice at 20,000 g for 10 min. at 4 °C with rehomogenization of the pellet in 10 ml ice-cold buffer. The final pellet is homogenized in 500 vol (w/v) ice-cold buffer.

Incubation tubes kept on ice in triplicate receive 100 µl of drug solution in water (or water for total binding) and 2000 µl of tissue suspension (final tissue content corresponds to 4 mg original tissue). The binding experiment is initiated by addition of 100 µl of ³H-Ketanserin (final concentration 0.5 nM) and by

placing the tubes in a 37 °C water bath. After incubation for 30 min. the samples are filtered under vacuum (0-50 mBar) through Whatman GF/F filters (25 mm). The tubes are rinsed with 5 ml ice-cold buffer which are then poured on the filters. Thereafter, the filters are washed with 2 x 5 ml of buffer. The filters are placed in counting vials and 4 ml of appropriate scintillation fluid (e.g. Picofluor TM 15) are added. After shaking for 1 h and storage 2 hrs in the dark the content of radioactivity is determined by liquid scintillation counting. Specific binding is obtained by subtracting the nonspecific binding in the presence of 1 µM mianserin.

For determination of the inhibition of binding five concentrations of drugs covering 3 decades are used.

The measured cpm are plotted against drug concentration on semilogarithmic paper and the best fitting S-shaped curve is drawn. The IC₅₀ value is determined as the concentration at which the binding is 50% of the total binding in control samples minus the nonspecific binding in the presence of 1 µM mianserin.

³H-Ketanserin = [ethylene-³H]-ketanserin hydrochloride from New England Nuclear, specific activity 60-80 Ci/mmol).

15 INHIBITION OF ³H-SPIPERONE BINDING TO DOPAMINE D-2 RECEPTORS IN RAT CORPUS STRIATUM IN VITRO

By this method the inhibition by drugs of the binding of ³H-spiperone (= ³H-spiroperidol) (0.5 nM) to dopamine D-2 receptors in membranes from rat corpus striatum is determined *in vitro*. Method and results in Hyttel & Larsen, J. *Neurochem*, **44**, 1615-1622, 1985).

Procedure

Male Wistar (Mol:Wistar) rats (125-250 g) are sacrificed and striatal tissue is dissected and weighed. The tissue is homogenized (Ultra Turrax, 10 sec.) in 10 ml of ice-cold 50 mM K-phosphate buffer pH 7.4 (at 25 °C). The homogenate is centrifuged twice at 20,000 g for 10 min. at 4 °C with rehomogenization of the pellet in 10 ml ice-cold buffer. The final pellet is homogenized in 1300 vol (w/v) ice-cold buffer.

Incubation tubes kept on ice in triplicate receive 100 µl of drug solution in water (or water for total binding) and 4000 µl of tissue suspension (final tissue content corresponds to 3.08 mg original tissue). The binding experimental is initiated by addition of 100 µl of ³H-spiperone (final concentration 0.5 nM) and by placing the tubes in a 37 °C water bath. After incubation for 10 min. the samples are filtered under vacuum (0-50 mBar) through Whatman GF/F filters (25 mm). The tubes are rinsed with 5 ml ice-cold buffer which are then poured on the filters. Thereafter, the filters are washed with 2 x 5 ml of buffer. The filters are placed in counting vials and 4 ml of appropriate scintillation fluid (e.g. Picofluor TM 15) are added. After shaking for 1 h and storage 2 hrs in the dark the content of radioactivity is determined by liquid scintillation counting. Specific binding is obtained by subtracting the nonspecific binding in the presence of 10 µM of 6,7-ADTN.

For determination of the inhibition of binding five concentrations of drugs covering 3 decades are used.

The measured cpm are plotted against drug concentration on semilogarithmic paper and the best fitting S-shaped curve is drawn. The IC₅₀ value is determined as the concentration at which the binding is 50% of the total binding in control samples minus the nonspecific binding in the presence of 10 µM of 6,7-ADTN.

³H-Spiperone = [phenyl-4-³H]-spiperone from Amersham international plc. England, specific activity 15-25 Ci/mmol.

TABEL 1

| 5 | Compound | ³ H-Ketanserin Binding IC ₅₀ nM | ³ H-Spiroperidol Binding IC ₅₀ nM |
|----|----------|--|--|
| | 4a | 1.5 | 46 |
| 10 | 4b | 1.9 | 37 |
| | 4c | 3.7 | 42 |
| | 4d | 5.7 | 410 |
| | 4e | 5.4 | 570 |
| 15 | 4f | 1.4 | 550 |
| | 4g | 1.6 | 920 |
| | 4h | 2.7 | 1100 |
| 20 | 4i | 1.4 | 680 |
| | 4j | 4.5 | 1200 |
| | 4k | 3.1 | 120 |
| | 4l | 3.3 | 74 |
| 25 | 4m | 3.2 | 250 |
| | 4n | 3.1 | 190 |
| | 4o | 37 | 790 |
| 30 | 4p | 29 | 2800 |
| | 4q | 25 | 3000 |
| | 4r | 3.4 | 230 |
| | 4s | 12 | 330 |
| 35 | 4t | 38 | 1900 |
| | 4u | 220 | 42000 |
| | 4v | 11 | >1000 |
| 40 | 4x | 11 | 650 |
| | 6a | 2.8 | 6300 |
| | 6b | 3.8 | 710 |
| 45 | 6c | 1.4 | 320 |
| | 6d | 4.4 | 32 |
| | 6e | 9.4 | 1000 |
| | 6f | 3.6 | 440 |
| 50 | 7a | 3.4 | 6900 |

55

TABEL 1 (continued)

| Compound | ³ H-Ketanserin Binding IC ₅₀ nM | ³ H-Spiroperidol Binding IC ₅₀ nM |
|------------|--|--|
| 7b | 6.2 | >1000 |
| 7c | 7.8 | 5300 |
| 9a | 5.3 | 2600 |
| 9b | 17 | 2900 |
| 11a | 4.5 | 540 |
| 13a | 3.7 | 250 |
| 13b | 2.3 | 260 |
| 15a | 1.8 | >1000 |
| 16a | 22 | 1500 |
| 18b | 4.3 | 1100 |
| 20a | 13 | 3900 |
| 21a | 18 | 890 |
| 27a | 10 | 3200 |
| Ritanserin | 0.4 | 12 |
| ICI 169369 | 15.0 | 490 |

It is seen from the table that the derivatives of the present invention which have been tested are all selective 5-HT₂ ligands, the affinity for the 5-HT₂ receptor as shown in the ³H-ketanserin binding test being very high as compared to the affinity for the dopamine D-2 receptor as measured in the ³H-spiroperidol binding test. As compared to the known standard 5-HT₂ antagonists ritanserin and ICI 169369 the compounds of the invention are in general found to be more selective.

Additionally the compounds of the invention were tested in the following well known and reliable *in vivo* tests :

QUIPAZINE INHIBITION

Quipazine is a 5-HT₂ agonist, which induces head twitches in rats. The test is a test for 5-HT₂-antagonistic effect testing the ability to inhibit head twitches. The method and test results for some reference substances are published by Arnt et al. (*Drug Development Research*, 16, 59-70, 1989).

ANTAGONISM OF PERGOLIDE-INDUCED CIRCLING BEHAVIOUR IN RATS WITH UNILATERAL 6-OHDA LESIONS

Dopamine D-2 agonists induce contralateral circling behaviour in rats with 6-OHDA lesions. Pergolide-induced circling is antagonized by dopamine D-2 antagonists. (Arnt, J. and J. Hyttel, *Eur. J. Pharmacol.* 102, 349-354, 1984; Arnt, J. and J. Hyttel, *J. Neural. Transm.* 67, 225-240, 1986). The test is an extremely sensitive test for dopamine D-2 antagonism *in vivo*.

These *in vivo* tests showed that the compounds of the invention are strong and selective 5-HT₂ antagonists with long duration of action *in vivo* (Quipazine test) and that they are substantially without

dopamine D-2 antagonistic activity *in vivo* as shown in the test for antagonism of pergolide induced circling.

Accordingly, the compounds of the present invention are selective 5-HT₂ antagonist *in vivo* and *in vitro* thus being useful in the treatment of anxiety, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, and Parkinson's Disease without neurological side effects as known from the classical neuroleptics.

FORMULATION EXAMPLES

The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.

For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.

Typical examples of recipes for the formulation of the invention are as follows:

20

1) Tablets containing 5 milligrams of Compound 4c calculated as the free base:

25

| | |
|--------------------|--------|
| Comp. 4c | 5 mg |
| Lactose | 18 mg |
| Potato starch | 27 mg |
| Sucrose | 58 mg |
| Sorbitol | 3 mg |
| Talcum | 5 mg |
| Gelatine | 2 mg |
| Povidone | 1 mg |
| Magnesium stearate | 0.5 mg |

30

35

2) Tablets containing 50 milligrams of Compound 4b calculated as the free base:

40

| | |
|--------------------|--------|
| Comp. 4b | 50 mg |
| Lactose | 16 mg |
| Potato starch | 45 mg |
| Sucrose | 106 mg |
| Sorbitol | 6 mg |
| Talcum | 9 mg |
| Gelatine | 4 mg |
| Povidone | 3 mg |
| Magnesium stearate | 0.6 mg |

45

50

55

3) Syrup containing per milliliter:

5

10

| | |
|----------------|----------|
| Comp. 4h | 10 mg |
| Sorbitol | 500 mg |
| Tragacanth | 7 mg |
| Glycerol | 50 mg |
| Methyl-paraben | 1 mg |
| Propyl-paraben | 0.1 mg |
| Ethanol | 0.005 ml |
| Water | ad 1 ml |

15 4) Solution for injection containing per milliliter:

20

| | |
|---------------|---------|
| Comp. 4c | 50 mg |
| Acetic acid | 17.9 mg |
| Sterile water | ad 1 ml |

25

5) Solution for injection containing per milliliter:

30

| | |
|------------------|---------|
| Comp. 4h | 10 mg |
| Sorbitol | 42.9 mg |
| Acetic acid | 0.63 mg |
| Sodium hydroxide | 22 mg |
| Sterile water | ad 1 ml |

35 **Claims**


Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. An 3-arylindole or 3-arylindazole derivative having formula :

40

45

50



55

wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, hydroxy, trifluoromethyl, and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R¹-R⁴ are independently selected from hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulphonyl, cyano, trifluoromethyl, or trifluoromethylthio;


the dotted line emanating from X in the ring system designates an optional bond; when said dotted line indicates a bond, X is nitrogen or a group CR⁶ wherein R⁶ is hydrogen, halogen, trifluoromethyl or C₁-C₄ alkyl;

when the dotted line indicates no bond, X is CH₂ ;

5 the dotted line, emanating from the Y, indicates an optional bond;


when it does not indicate a bond Y is N or CH; and when it indicates a bond Y is C; R⁵ is hydrogen or C₁-C₄ alkyl, optionally substituted with one or two hydroxy groups, or R⁵ is a group taken from structures 1a and 1b :

10



1a.

or



1b.

15

wherein n is an integer from 2 - 6;

20

W is oxygen, or sulphur;

U is nitrogen or CH;

Z is -(CH₂)_m-, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH₂- or -CSCCH₂-;

25

V is oxygen, CH₂, or NR⁷, wherein R⁷ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups;

U¹ is a group NR⁸, wherein R⁸ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups; and

V¹ is NR⁹R¹⁰, where each of R⁹ and R¹⁰ may be independently selected among the R⁸-substituents; provided that R⁵ may not be methyl when R¹-R⁴ each are hydrogen, X and Y are CH, and Ar is phenyl;

30


and pharmaceutically acceptable acid addition salts and prodrugs thereof.

2. A derivative according to claim 1, **characterized in** that Ar is phenyl optionally substituted with halogen, preferably 4-fluorophenyl.


35

3. A derivative according to any of claims 1 or 2 **characterized in** that R⁵ is a group of the formula

40



or



45

where R⁷, R⁸, R⁹ and R¹⁰ independently are selected from hydrogen, C₁-C₄ alkyl and C₂-C₄ alkenyl.

4. A derivative according to any of the previous claims, **characterized in** that X is CR⁶.

50

5. A derivative according to claim 4, **characterized in** that R² and/or R⁶ are other than hydrogen.

6. A derivative according to any of the previous claims, **characterized in** that R² is selected from halogen, -CH₃, and -CF₃ and/or R³ is selected from hydrogen, halogen, -CH₃, and -CF₃.

55

7. A derivative according to claim 1, **characterized in** that it is: 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole, 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole, 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole,

2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole,


2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,

2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-4-piperidyl)-1*H*-indole, or 1-[1-[2-(1,3-Dimethyl-1-ureido)-ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole.


8. A pharmaceutical preparation **characterized in** that it comprises a compound of any of the claims 1 - 7 or a pharmaceutically acceptable salt or a prodrug thereof as an active ingredient together with a pharmaceutically acceptable carrier or diluent.

9. Use of a derivative of any of claims 1 - 7 or a pharmaceutically acceptable salt or a prodrug thereof for the manufacture of a medicament for the therapeutical treatment of anxiety, aggression, negative symptoms of schizophrenia, depression, migraine, sleep disturbances, drug-induced Parkinsonism or Parkinsons disease.


10. A method for the preparation of a derivative of claim 1 comprising
a) reacting a compound of the following formula:




wherein R¹, R², R³, R⁴, X, Y, Ar and the dotted lines are as defined above, with a C₁-C₄ alkyl halide, alkyl mesylate or tosylate, with an epoxide of the formula



wherein R' is hydrogen, methyl or ethyl or with a halide of the general formula




or




wherein n, W, U, V, Z, V' and U' are as defined above;

b) reacting a compound of following formula:




wherein R¹, R², R³, R⁴, R⁶, Ar and the dotted line are as defined above, with a compound of the general formula




in which R⁵ is as defined above and hal is halogen;

c) reducing the indole ring of a compound of the general formula




wherein R¹-R⁵, Ar, Y and the dotted line are as defined above, to a dihydroindole ring;

d) reducing the double bond in the tetrahydropyridyl ring in a compound of the formula:



wherein R¹ - R⁵, X, Ar and the dotted line are as defined above;


e) reducing the pyridinium ring in a compound of following formula:



wherein $R^1 - R^5$, X, Ar and the dotted line are as defined above except that R^5 may not be hydrogen, and hal is halogen, to a tetrahydropyridine ring;


f) reducing the pyridinium ring in a compound of the above Formula VIII or the pyridyl ring of a compound of formula XIV to a piperidine ring;

g) reducing the carbonyl group of a compound of the following formula :




wherein $R^1 - R^4$, X, Y, Ar and the dotted lines are as previously defined and R^{16} is hydrogen, C_1-C_4 alkyl or C_1-C_4 alkoxy;

h) acylating an aminoalkyl derivative of the following formula :




wherein $R^1 - R^4$, X, Y, Ar, R^8 , n and the dotted lines are as defined above, with an acylating agent such as a carboxylic acid halogenide, anhydride or mixed anhydride, or a carbamyl or thiocarbamyl chloride, an isocyanate, isothiocyanate, or a substituted chloroformate;

i) ringclosure reaction of an intermediate ethylene or propylene diamine derivative of the following formula :



wherein $R^1 - R^4$, R^8 , n, X, Y, Ar and the dotted lines are as defined above and m is 2 or 3, with phosgene, thiophosgene or carbondisulphide to form a substituent of the structure **1a** ; or
j) reducing a carboxylic acid or carboxylic acid derivative of the following formula :



wherein $R^1 - R^4$, X, Y, Ar and the dotted lines are as previously defined, R^{17} is hydrogen or lower alkyl and p is 1, 2 or 3 ;

and then, if desired:


acylating a compound prepared in one of the methods (a) to (j) having the formula I in which R^5 is a structure **1a** or **1b** wherein V is NH, or V^1 is NHR^{10} or U^1 is NH with an acylating agent, or esterifying an available hydroxy group in a compound of formula I in order to obtain a prodrug;

converting a compound prepared in one of methods (a) to (j) in a pharmaceutically acceptable acid addition salt thereof; or

resolving an optically active compound of formula I prepared in one of methods (a) to (j) in optically active isomers thereof.

Claim for the following Contracting States : ES, GR

1. A method for the preparation of an 3-arylindole or 3-arylindazole derivative having formula :



wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, hydroxy, trifluoromethyl, and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;


R¹-R⁴ are independently selected from hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulphonyl, cyano, trifluoromethyl, or trifluoromethylthio;

the dotted line emanating from X in the ring system designates an optional bond; when said dotted line indicates a bond, X is nitrogen or a group CR⁶ wherein R⁶ is hydrogen, halogen, trifluoromethyl or C₁-C₄ alkyl;

when the dotted line indicates no bond, X is CH₂ ;


the dotted line, emanating from the Y, indicates an optional bond;

when it does not indicate a bond Y is N or CH; and when it indicates a bond Y is C; R⁵ is hydrogen or C₁-C₄ alkyl, optionally substituted with one or two hydroxy groups, or R⁵ is a group taken from structures 1a and 1b :



1a.

or



1b.

wherein n is an integer from 2 - 6;

W is oxygen, or sulphur;

U is nitrogen or CH ;


Z is -(CH₂)_m-, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH₂- or -CSCH₂-;

V is oxygen, CH₂, or NR⁷, wherein R⁷ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups;


U¹ is a group NR⁸, wherein R⁸ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups; and

V¹ is NR⁹R¹⁰, where each of R⁹ and R¹⁰ may be independently selected among the R⁸-substituents; provided that R⁵ may not be methyl when R¹-R⁴ each are hydrogen, X and Y are CH, and Ar is phenyl; or a pharmaceutically acceptable acid addition salt or prodrug thereof comprising


a) reacting a compound of the following formula:




wherein R¹, R², R³, R⁴, X, Y, Ar and the dotted lines are as defined above, with a C₁-C₄ alkyl halide, alkyl mesylate or tosylate, with an epoxide of the formula



wherein R' is hydrogen, methyl or ethyl or with a halide of the general formula




or




wherein n, W, U, V, Z, V¹ and U¹ are as defined above;

b) reacting a compound of following formula:




wherein R¹, R², R³, R⁴, R⁶, Ar and the dotted line are as defined above, with a compound of the general formula




in which R⁵ is as defined above and hal is halogen;


c) reducing the indole ring of a compound of the general formula



wherein R¹-R⁵, Ar, Y and the dotted line are as defined above, to a dihydroindole ring;
d) reducing the double bond in the tetrahydropyridyl ring in a compound of the formula:




wherein R¹ - R⁵, X, Ar and the dotted line are as defined above;
e) reducing the pyridinium ring in a compound of following formula:



wherein R¹ - R⁵, X, Ar and the dotted line are as defined above except that R⁵ may not be hydrogen, and hal is halogen, to a tetrahydropyridine ring;


f) reducing the pyridinium ring in a compound of the above Formula **VIII** or the pyridyl ring of a compound of formula **XIV** to a piperidine ring;

g) reducing the carbonyl group of a compound of the following formula :




20 wherein R¹ - R⁴, X, Y, Ar and the dotted lines are as previously defined and R¹⁶ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkoxy;

h) acylating an aminoalkyl derivative of the following formula :




40 wherein R¹ - R⁴, X, Y, Ar, R⁸, n and the dotted lines are as defined above, with an acylating agent such as a carboxylic acid halogenide, anhydride or mixed anhydride, or a carbamyl or thiocarbamyl chloride, an isocyanate, isothiocyanate, or a substituted chloroformate;

i) ringclosure reaction of an intermediate ethylene or propylene diamine derivative of the following formula :



wherein $R^1 - R^4$, R^8 , n , X , Y , Ar and the dotted lines are as defined above and m is 2 or 3, with phosgene, thiophosgene or carbondisulphide to form a substituent of the structure **1a**; or
j) reducing a carboxylic acid or carboxylic acid derivative of the following formula :



wherein $R^1 - R^4$, X , Y , Ar and the dotted lines are as previously defined, R^{17} is hydrogen or C_1-C_4 alkyl and p is 1, 2 or 3 ;

and then, if desired:

40 acylating a compound prepared in one of the methods (a) to (j) having the formula I in which R^5 is a structure **1a** or **1b** wherein V is NH , or V^1 is NHR^{10} or U^1 is NH with an acylating agent, or esterifying an available hydroxy group in a compound of formula I in order to obtain a prodrug;
converting a compound prepared in one of methods (a) to (j) in a pharmaceutically acceptable acid addition salt thereof; or
45 resolving an optically active compound of formula I prepared in one of methods (a) to (j) in optically active isomers thereof.


50

55

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Ein Arylindol oder 3-Arylindazolderivat mit folgender Formel:




worin Ar eine Phenylgruppe ist, gegebenenfalls substituiert mit einem oder mehreren Substituenten ausgewählt aus Halogen, Hydroxy, Trifluormethyl und Cyan, oder Ar ist 2-Thienyl, 3-Thienyl, 2-Furyl, 3-Furyl, 2-Pyridyl, 3-Pyridyl, oder 4-Pyridyl.

R¹-R⁴ sind unabhängig ausgewählt aus Wasserstoff, Halogen, C₁-C₄ Alkyl, C₁-C₄ Alkoxy, C₁-C₄ Alkylthio, C₁-C₄ Alkylsulphonyl, Cyan, Trifluormethyl, oder Trifluormethylthio;


die von X ausgehende gestrichelte Linie im Ringsystem deutet gegebenenfalls eine Bindung an; wenn die besagte gestrichelte Linie eine Bindung bezeichnet, dann ist X Stickstoff oder eine Gruppe CR⁶, worin R⁶ Wasserstoff, Halogen, Trifluormethyl oder C₁-C₄ Alkyl ist; wenn die gestrichelte Linie keine Bindung ist, dann ist X gleich CH₂;

die von Y ausgehende gestrichelte Linie, bedeutet gegebenenfalls eine Bindung; wenn sie keine Bindung anzeigt ist Y gleich N oder CH; wenn sie eine Bindung anzeigt, ist Y gleich C;

R⁵ ist Wasserstoff oder C₁-C₄ Alkyl, gegebenenfalls substituiert mit einer oder zwei Hydroxygruppen, oder R⁵ wird aus den Strukturen 1a und 1b genommen.



oder



1a.

1b.

worin n eine ganze Zahl von 2-6 ist;

W ist Sauerstoff, oder Schwefel;

U ist Stickstoff oder CH;

Z ist -(CH₂)_m-, wobei m 2 oder 3 ist, oder Z ist ein 1,2-Phenylen wahlweise substituiert mit Halogen oder Trifluormethyl, oder Z ist -CH=CH-, -COCH₂- oder -CSCH₂-;

V ist Sauerstoff, CH₂, oder NR⁷, worin R⁷ Wasserstoff ist oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert;


U¹ ist eine Gruppe NR⁸, worin R⁸ ein Wasserstoff ist, oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert; und

V¹ ist NR⁹R¹⁰, wo jede der R⁹ und R¹⁰ Gruppen unabhängig voneinander aus den R⁸-Substituenten ausgewählt werden können;

vorrausgesetzt daß, wenn R¹-R⁴ jeweils Wasserstoff sind, X und Y gleich CH sind, und Ar eine

Phenylgruppe ist, R⁵ nicht Methyl sein kann;
und pharmazeutisch annehmbare Säureadditionssalze und Medikamentenvorstufen derselben.

2. Derivat gemäß Anspruch 1, dadurch gekennzeichnet, daß Ar Phenyl ist, gegebenenfalls mit Halogen substituiert, vorzugsweise 4-Fluorphenyl.
3. Derivat gemäß irgendeiner der Ansprüche 1 oder 2 dadurch gekennzeichnet, daß R⁵ eine Gruppe der folgenden Formel ist



worin R⁷, R⁸, R⁹ und R¹⁰ unabhängig aus Wasserstoff, C₁-C₄ Alkyl oder C₂-C₄ Alkenyl ausgewählt sind.

4. Derivat gemäß irgendeinem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß X gleich CR⁶ ist.

5. Derivat gemäß Anspruch 4, dadurch gekennzeichnet, daß R² und/oder R⁶ etwas anderes als Wasserstoff sind.

6. Derivat gemäß einem beliebigen der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß R² aus Halogen, -CH₃, und -CF₃ ausgewählt ist und/oder R³ ist ausgewählt aus Halogen, -CH₃, und -CF₃.


7. Derivat gemäß Anspruch 1, dadurch gekennzeichnet, daß dieses ist:
5-Chlor-3-(4-fluorphenyl)-1-[1-[2-(3-methyl-imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1H-indol,
3-(4-Fluorphenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1H-indol,
3-(4-Fluorphenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1H-indol,
2,5-Dimethyl-3-(4-fluorphenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4yl]-1H-indol,
2,5-Dimethyl-3-(4-fluorphenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1H-indol,
2,5-Dimethyl-3-(4-fluorphenyl)-1-(1-methyl-4-piperidyl)-1H-indol, oder
1[1-[2-(1,3-Dimethyl-1-ureid)ethyl]-4-piperidyl]-3-(4-fluorphenyl)-5-methyl-1H-indol.

8. Pharmazeutische Zubereitung dadurch gekennzeichnet, daß sie eine Verbindung gemäß irgendeiner der Ansprüche 1-7, oder ein pharmazeutisch annehmbares Salz oder eine Medikamentenvorstufe derselben als aktiver Bestandteil umfasst, zusammen mit einem pharmazeutisch annehmbaren Träger oder Verdünnungsmittel.


9. Verwendung eines Derivates gemäß irgendeinem der Ansprüche 1-7 oder eines pharmazeutisch annehmbaren Salzes oder eine Medikamentenvorstufe derselben, zur Herstellung eines Medikaments für die therapeutische Behandlung von Angstzuständen, Aggressivität, negativen Symptomen von Schizophrenie, Depression, Migräne, Schlafstörungen, Pharmainduzierter Parkinsonismus oder Parkinsonscher Krankheit.

10. Verfahren zur Herstellung eines Derivates gemäß Anspruch 1, umfassend


a) zur Reaktion bringen einer Verbindung folgender Formel:




20 worin R¹, R², R³, R⁴, X, Y, Ar und die gestrichelten Linien wie oben definiert sind, mit einem C₁-C₄ Alkylhalogenid, Alkylmesylat oder Tosylat, mit einem Epoxid der Formel




30 worin R' Wasserstoff, Methyl oder Ethyl oder ein Halogenid der allgemeinen Formel



40 ist, worin n, W, U, V, Z, V¹, und U¹ wie oben definiert sind;
b) zur Reaktion bringen einer Verbindung folgender Formel:




55 worin R¹, R², R³, R⁴, R⁶, Ar und die gestrichelten Linien wie oben definiert sind, mit einer Verbindung der allgemeinen Formel




in der R⁵ wie oben definiert ist und hal ist Halogen;

c) Reduzieren des Indolrings einer Verbindung der allgemeinen Formel




worin R¹-R⁵, Ar, Y und die gestrichelten Linien wie oben definiert sind, zu einem Dihydroindolring;

d) Reduzieren der Doppelbindung im Tetrahydropyridylring in einer Verbindung der Formel:



worin R¹-R⁵, X, Ar und die gestrichelten Linien wie oben definiert sind,


e) Reduzieren des Pyridiniumrings in einer Verbindung der folgenden Formel:




worin R¹-R⁵, X, Ar und die gestrichelten Linien wie oben definiert sind, mit Ausnahme daß R⁵ nicht Wasserstoff sein kann, und hal ist Halogen, zum Tetrahydropyridinring;

f) Reduzieren des Pyridiniumrings in einer Verbindung der obigen Formel VIII oder der Pyridylring einer Verbindung der Formel XIV zu einem Piperidinring;

g) Reduzieren der Carbonylgruppe einer Verbindung der folgenden Formel:



20 worin R^1 - R^4 , X, Y, Ar und die gestrichelten Linien wie vorher definiert sind und R^{16} ist Wasserstoff, C_1 - C_4 Alkyl oder C_1 - C_4 Alkoxy;
h) Acylieren eines Aminoalkylderivates der folgenden Formel:




40 worin R^1 - R^4 , X, Y, Ar, R^8 , n und die gestrichelten Linien wie oben definiert sind, mit einem Acylierungsreagenz wie einem Carbonsäurehalogenid, Anhydrid oder einen gemischten Anhydrid, oder einem Harnstoff- oder Thioharnstoffchlorid, einem Isocyanat, Isothiocyanat, oder einem substituierten Chlorkohlensäureester.

45 i) Ringschlußreaktion eines intermediären Ethylen- oder Propylendiaminderivates der folgenden Formel:


50

55



20 worin R^1 - R^4 , R^8 , n , X , Y , Ar und die gestrichelten Linien wie oben definiert sind und m 2 oder 3 ist, mit Phosgen, Thiophosgen oder Kohlenstoffdisulfid zur Bildung eines Substituenten der Struktur **1a**; oder

j) Reduzieren einer Carbonsäure oder eines Carbonsäurederivates der folgenden Formel:



40 worin R^1 - R^4 , X , Y , Ar und die gestrichelten Linien wie oben definiert sind, R^{17} ist Wasserstoff oder ein niedriger Alkylrest und p ist 1, 2, oder 3;

und dann, wenn gewünscht:


45 Acylieren einer gemäß einem der Verfahren (a) bis (j) hergestellten Verbindung der Formel I, in der R^5 einer Struktur **1a** oder **1b** entspricht, worin V gleich NH , oder V^1 gleich NHR^{10} ist, oder U^1 gleich NH ist, mit einem Acylierungsreagenz, oder Veresterung einer verfügbaren Hydroxygruppe in einer Verbindung der Formel I um eine Medikamentenvorstufe zu erhalten;

Umwandlung einer, nach Methoden (a) bis (j) hergestellten Verbindung, in ein pharmazeutisch annehmbares Säureadditionssalze derselben; oder

50 Auflösung einer optisch aktiven Verbindung der Formel I, hergestellt nach einer der Verfahren (a) bis (j) in optisch aktive Isomere derselben.

Patentanspruch für folgende Vertragsstaaten : ES, GR

1. Ein Verfahren zur Herstellung eines Arylindol- oder 3-Arylindazolderivates mit folgender Formel:




worin Ar eine Phenylgruppe ist, gegebenenfalls substituiert mit einem oder mehreren Substituenten ausgewählt aus Halogen, Hydroxy, Trifluormethyl und Cyan, oder Ar ist 2-Thienyl, 3-Thienyl, 2-Furyl, 3-Furyl, 2-Pyridyl, 3-Pyridyl, oder 4-Pyridyl.

R¹-R⁴ sind unabhängig ausgewählt aus Wasserstoff, Halogen, C₁-C₄ Alkyl, C₁-C₄ Alkoxy, C₁-C₄ Alkylthio, C₁-C₄ Alkylsulphonyl, Cyan, Trifluormethyl, oder Trifluormethylthio;


die von X ausgehende gestrichelte Linie im Ringsystem deutet gegebenenfalls eine Bindung an; wenn die besagte gestrichelte Linie eine Bindung bezeichnet, dann ist X Stickstoff oder eine Gruppe CR⁶, worin R⁶ Wasserstoff, Halogen, Trifluormethyl oder C₁-C₄ Alkyl ist; wenn die gestrichelte Linie keine Bindung ist, dann ist X gleich CH₂;

die von Y ausgehende gestrichelte Linie, bedeutet gegebenenfalls eine Bindung; wenn sie keine Bindung anzeigt ist Y gleich N oder CH; wenn sie eine Bindung anzeigt, ist Y gleich C;

R⁵ ist Wasserstoff oder C₁-C₄ Alkyl, gegebenenfalls substituiert mit einer oder zwei Hydroxygruppen, oder R⁵ wird aus den Strukturen 1a und 1b genommen.



1a.



1b.

worin n eine ganze Zahl von 2-6 ist;

W ist Sauerstoff, oder Schwefel;

U ist Stickstoff oder CH;

Z ist -(CH₂)_m-, wobei m 2 oder 3 ist, oder Z ist ein 1,2-Phenylen wahlweise substituiert mit Halogen oder Trifluormethyl, oder Z ist -CH=CH-, -COCH₂- oder -CSCH₂-;

V ist Sauerstoff, CH₂, oder NR⁷, worin R⁷ Wasserstoff ist oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert;

U¹ ist eine Gruppe NR⁸, worin R⁸ ein Wasserstoff ist, oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert; und


V¹ ist NR⁹R¹⁰, wo jede der R⁹ und R¹⁰ Gruppen unabhängig voneinander aus den R⁸-Substituenten ausgewählt werden können;

vorausgesetzt daß, wenn R¹-R⁴ jeweils Wasserstoff sind, X und Y gleich CH sind, und Ar eine Phenylgruppe ist, R⁵ nicht Methyl sein kann;

oder ein pharmazeutisch annehmbares Säureadditionssalz oder Medikamentenvorstufe derselben,


umfassend:

a) zur Reaktion bringen einer Verbindung folgender Formel:





20

worin R¹, R², R³, R⁴, X, Y, Ar und die gestrichelten Linien wie oben definiert sind, mit einem C₁-C₄ Alkylhalogenid, Alkylmesylat oder Tosylat, mit einem Epoxid der Formel




worin R' Wasserstoff, Methyl oder Ethyl oder ein Halogenid der allgemeinen Formel




40

ist, worin n, W, U, V, Z, V¹, und U¹ wie oben definiert sind;
b) zur Reaktion bringen einer Verbindung folgender Formel:




worin R¹, R², R³, R⁴, R⁶, Ar und die gestrichelten Linien wie oben definiert sind, mit einer Verbindung der allgemeinen Formel




in der R⁵ wie oben definiert ist und hal ist Halogen;

c) Reduzieren des Indolrings einer Verbindung der allgemeinen Formel




worin R^1 - R^5 , Ar, Y und die gestrichelten Linien wie oben definiert sind, zu einem Dihydroindolring;

d) Reduzieren der Doppelbindung im Tetrahydropyridylring in einer Verbindung der Formel:



worin R^1 - R^5 , X, Ar und die gestrichelten Linien wie oben definiert sind;


e) Reduzieren des Pyridiniumrings in einer Verbindung der folgenden Formel:



worin R^1 - R^5 , X, Ar und die gestrichelten Linien wie oben definiert sind, mit Ausnahme daß R^5 nicht Wasserstoff sein kann, und hal ist Halogen, zum Tetrahydropyridinring;


f) Reduzieren des Pyridiniumrings in einer Verbindung der obigen Formel VIII oder der Pyridylring einer Verbindung der Formel XIV zu einem Piperidinring;

g) Reduzieren der Carbonylgruppe einer Verbindung der folgenden Formel:




worin R^1 - R^4 , X, Y, Ar und die gestrichelten Linien wie vorher definiert sind und R^{16} ist Wasserstoff, C_1 - C_4 Alkyl oder C_1 - C_4 Alkoxy;

h) Acylieren eines Aminoalkylderivates der folgenden Formel:




worin R^1 - R^4 , X, Y, Ar, R^8 , n und die gestrichelten Linien wie oben definiert sind, mit einem Acylierungsreagenz wie einem Carbonsäurehalogenid, Anhydrid oder einem gemischten Anhydrid, oder einem Harnstoff- oder Thioharnstoffchlorid, einem Isocyanat, Isothiocyanat, oder einem substituierten Chlorkohlensäureester.

i) Ringschlußreaktion eines intermediären Ethylen- oder Propylendiaminderivates der folgenden Formel:



worin R¹-R⁴, R⁵, n, X, Y, Ar und die gestrichelten Linien wie oben definiert sind und m 2 oder 3 ist, mit Phosgen, Thiophosgen oder Kohlenstoffdisulfid zur Bildung eines Substituenten der Struktur 1a; oder

j) Reduzieren einer Carbonsäure oder eines Carbonsäurederivates der folgenden Formel:



worin R¹-R⁴, X, Y, Ar und die gestrichelten Linien wie oben definiert sind, R¹⁷ ist Wasserstoff oder ein niedriger Alkylrest und p ist 1, 2, oder 3;

und dann, wenn gewünscht:

Acylieren einer gemäß, einem der Verfahren (a) bis (j) hergestellten Verbindung der Formel I, in der R⁵ einer Struktur 1a oder 1b entspricht, worin V gleich NH, oder V' gleich NHR¹⁰ ist, oder U' gleich NH ist, mit einem Acylierungsreagenz, oder Veresterung einer verfügbaren Hydroxygruppe in einer Verbindung der Formel I um eine Medikamentenvorstufe zu erhalten;


Umwandlung einer, nach Methoden (a) bis (j) hergestellten Verbindung, in ein pharmazeutisch annehmbares Säureadditionssalze derselben; oder

Auflösung einer optisch aktiven Verbindung der Formel I, hergestellt nach einer der Verfahren (a) bis (j) in optisch aktive Isomere derselben.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Un dérivé de 3-arylindole ou de 3-arylindazole de formule :



dans laquelle Ar est un phényle facultativement substitué avec un ou plusieurs substituants choisis parmi un halogène, un hydroxy, un trifluorométhyle et un cyano, ou Ar est un 2-thiényle, un 3-thiényle, un 2-furyle, un 3-furyle, un 2-pyridyle, un 3-pyridyle ou un 4-pyridyle ;

R¹ à R⁴ sont indépendamment choisis parmi un hydrogène, un halogène, un alkyle en C₁-C₄, un alcoxy en C₁-C₄, un alkylthio en C₁-C₄, un alkylsulfonyl en C₁-C₄, un cyano, un trifluorométhyle ou un trifluorométhylthio ;


le pointillé partant de X dans le système cyclique indique une liaison facultative ; lorsque ledit pointillé indique une liaison, X est un azote ou un groupe CR⁵ dans lequel R⁵ est un hydrogène, un halogène, un trifluorométhyle ou un alkyle en C₁-C₄ ;

lorsque le pointillé n'indique pas de liaison, X est CH₂ ;


le pointillé partant de Y indique une liaison facultative ;

lorsqu'il n'indique pas une liaison, Y est N ou CH ; et lorsqu'il indique une liaison, Y est C ;

R⁵ est un hydrogène ou un alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ou R⁵ est un groupe choisi parmi les structures 1a et 1b :



1a.



1b.

où n est un entier de 2 à 6 ;

W est un oxygène ou un soufre ;

U est un azote ou CH ;

Z est -(CH₂)_m, m étant 2 ou 3, ou Z est un 1,2-phénylène facultativement substitué avec un halogène ou un trifluorométhyle, ou Z est -CH=CH-, -COCH₂- ou -CSCH₂- ;

V est un oxygène, CH₂ ou NR⁷, où R⁷ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ;

U¹ est un groupe NR⁸ dans lequel R⁸ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ; et

V¹ est NR⁹R¹⁰ où chacun de R⁹ et de R¹⁰ peut être indépendamment choisi parmi les substituants R⁸ ; sous réserve que R⁵ ne puisse pas être un méthyle lorsque R¹ à R⁴ sont chacun un hydrogène, X et Y sont CH et Ar est un phényle ;

et les sels d'addition d'acides pharmaceutiquement acceptables et les précurseurs de médicament

correspondants.

2. Un dérivé selon la revendication 1, caractérisé en ce que Ar est un phényle facultativement substitué avec un halogène, de préférence un 4-fluorophényle.

3. Un dérivé selon l'une quelconque des revendications 1 ou 2, caractérisé en ce que R⁵ est un groupe de formule :



où R⁷, R⁸, R⁹ et R¹⁰ sont choisis indépendamment parmi un hydrogène, un alkyle en C₁-C₄ et un alcényle en C₂-C₄.

4. Un dérivé selon l'une quelconque des revendications précédentes, caractérisé en ce que X est CR⁶.

5. Un dérivé selon la revendication 4, caractérisé en ce que R² et/ou R⁶ sont autres qu'un hydrogène.

6. Un dérivé selon l'une quelconque des revendications précédentes, caractérisé en ce que R² est choisi parmi un halogène, -CH₃ et -CF₃ et/ou R³ est choisi parmi un hydrogène, un halogène, -CH₃ et -CF₃.

7. Un dérivé selon la revendication 1, caractérisé en ce qu'il est :

le 5-chloro-3-(4-fluorophényl)-1-[1-[2-(3-méthylimidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-1H-indole,

le 3-(4-fluorophényl)-1-[1-[2-(imidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-5-méthyl-1H-indole,

le 3-(4-fluorophényl)-5-méthyl-1-[1-[2-[3-(2-propyl)imidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-1H-indole,

le 2,5-diméthyl-3-(4-fluorophényl)-1-[1-[2-(imidazolidine-2-one-1-yl)éthyl]-1,2,3,6-tétrahydropyridine-4-yl]-1H-indole,

le 2,5-diméthyl-3-(4-fluorophényl)-1-[1-[2-(imidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-1H-indole,

le 2,5-diméthyl-3-(4-fluorophényl)-1-(1-méthyl-4-pipéridyl)-1H-indole ou


le 1-[1-[2-(1,3-diméthyl-1-uréido)éthyl]-4-pipéridyl]-3-(4-fluorophényl)-5-méthyl-1H-indole.

8. Une préparation pharmaceutique, caractérisée en ce qu'elle comprend un composé de l'une quelconque des revendications 1 à 7 ou un sel pharmaceutiquement acceptable ou un précurseur de médicament correspondants, en tant qu'ingrédient actif avec un véhicule ou diluant pharmaceutiquement acceptables.


9. Utilisation d'un dérivé de l'une quelconque des revendications 1 à 7 ou d'un sel pharmaceutiquement acceptable ou d'un précurseur de médicament correspondants pour la préparation d'un médicament pour le traitement thérapeutique de l'anxiété, de l'agression, des symptômes négatifs de la schizophrénie, de la dépression, de la migraine, des troubles du sommeil, du syndrome parkinsonien médicamenteux ou de la maladie de Parkinson.

10. Un procédé pour la préparation d'un dérivé de la revendication 1 comprenant :


a) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, X, Y, Ar et les pointillés sont tels que définis ci-dessus, avec un halogénure d'alkyle en C₁-C₄, un mésylate d'alkyle ou un tosylate, avec un époxyde de formule




dans laquelle R' est un hydrogène, un méthyle ou un éthyle, ou avec un halogénure de formule générale



où n, W, U, V, Z, V¹ et U¹ sont tels que définis ci-dessus ;
 b) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, R⁶, Ar et le pointillé sont tels que définis ci-dessus, avec un composé de formule générale




dans laquelle R⁵ est tel que défini ci-dessus et hal est un halogène ;

c) la réduction du cycle indole d'un composé de formule générale




dans laquelle R¹ à R⁵, Ar, Y et le pointillé sont tels que définis ci-dessus, en un cycle dihydro-indole ;

d) la réduction de la double liaison du cycle tétrahydropyridyle d'un composé de formule :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus ;


e) la réduction du cycle pyridinium d'un composé de formule suivante :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus, si ce n'est que R⁵ ne peut pas être un hydrogène, et hal est un halogène, en cycle tétrahydropyridine ;


f) la réduction du cycl pyridinium d'un composé de formule VIII ci-dessus ou du cycl pyridyle d'un composé de formule XIV en un cycle pipéridine ;

g) la réduction du groupe carbonyle d'un composé de formule suivante :




20 dans laquelle R^1 à R^4 , X, Y, Ar et les pointillés sont tels que précédemment définis et R^{16} est un hydrogène, un alkyle en C_1 - C_4 ou un alcoxy en C_1 - C_4 ;

h) l'acylation d'un dérivé d'aminoalkyle de formule suivante :




45 dans laquelle R^1 à R^4 , X, Y, Ar, R^8 , n et les pointillés sont tels que définis ci-dessus, avec un agent d'acylation tel qu'un halogénure, un anhydride ou un anhydride mixte d'acide carboxylique, ou un chlorure de carbamyle ou de thiocarbamyle, un isocyanate, un isothiocyanate ou un chloroformiate substitué ;

i) la réaction de cyclisation d'un dérivé intermédiaire d'éthylène-ou de propylène-diamine de formule suivante :



dans laquelle R^1 à R^4 , R^8 , n , X , Y , Ar et les pointillés sont tels que définis ci-dessus et m est 2 ou 3, avec le phosgène, le thiophosgène ou le disulfure de carbone, pour former un substituant de structure 1a ; ou

j) la réduction d'un acide carboxylique ou d'un dérivé d'acide carboxylique de formule suivante :




dans laquelle R^1 à R^4 , X , Y , Ar et les pointillés sont tels que précédemment définis, R^{17} est un hydrogène ou un alkyle inférieur et p est 1, 2 ou 3 ;

puis, si on le désire :

l'acylation d'un composé préparé dans l'un des procédés (a) à (j) répondant à la formule I dans laquelle R^5 est une structure 1a ou 1b lorsque V est NH , ou V' est NHR^{10} , ou U' est NH , avec un agent d'acylation, ou l'estérification d'un groupe hydroxy disponible dans un composé de formule I pour obtenir un précurseur de médicament ; la conversion d'un composé préparé selon l'un des procédés (a) à (j) en un sel d'addition d'acide pharmaceutiquement acceptable correspondant ; ou le dédoublement d'un composé optiquement actif de formule I, préparé selon l'un des procédés (a) à (j), en ses isomères optiquement actifs.

Revendication pour les Etats contractants suivants : ES, GR

1. Un procédé pour la préparation d'un dérivé de 3-arylindole ou de 3-arylindazole de formule :



dans laquelle Ar est un phényle facultativement substitué avec un ou plusieurs substituants choisis parmi un halogène, un hydroxy, un trifluorométhyle et un cyano, ou Ar est un 2-thiényle, un 3-thiényle, un 2-furyle, un 3-furyle, un 2-pyridyle, un 3-pyridyle ou un 4-pyridyle ;
R¹ à R⁴ sont indépendamment choisis parmi un hydrogène, un halogène, un alkyle en C₁-C₄, un alcoxy en C₁-C₄, un alkylthio en C₁-C₄, un alkylsulfonyle en C₁-C₄, un cyano, un trifluorométhyle ou un trifluorométhylthio ;


le pointillé partant de X dans le système cyclique indique une liaison facultative ; lorsque ledit pointillé indique une liaison, X est un azote ou un groupe CR⁶ dans lequel R⁶ est un hydrogène, un halogène, un trifluorométhyle ou un alkyle en C₁-C₄ ;

lorsque le pointillé n'indique pas de liaison, X est CH₂ ;

le pointillé partant de Y indique une liaison facultative ;


lorsqu'il n'indique pas une liaison, Y est N ou CH ; et lorsqu'il indique une liaison, Y est C ;

R⁵ est un hydrogène ou un alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ou R⁵ est un groupe choisi parmi les structures 1a et 1b :



1a.

ou



1b.

où n est un entier de 2 à 6 ;

W est un oxygène ou un soufre ;

U est un azote ou CH ;

Z est -(CH₂)_m-, m étant 2 ou 3, ou Z est un 1,2-phénylène

facultativement substitué avec un halogène ou un trifluorométhyle, ou Z est -CH=CH-, -COCH₂- ou -CSCH₂- ;


V est un oxygène, CH₂ ou NR⁷, où R⁷ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ;

U¹ est un groupe NR⁸ dans lequel R⁸ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ; et


V¹ est NR⁹R¹⁰ où chacun de R⁹ et de R¹⁰ peut être indépendamment choisi parmi les substituants R⁸ ; sous réserve que R⁵ ne puisse pas être un méthyle lorsque R¹ à R⁴ sont chacun un hydrogène, X et Y sont CH et Ar est un phényle ;

ou d'un sel d'addition d'acide pharmaceutiquement acceptable ou d'un précurseur de médicament correspondants, comprenant

a) la réaction d'un composé de formule suivante :



dans laquelle R¹, R², R³, R⁴, X, Y, Ar et les pointillés sont tels que définis ci-dessus, avec un halogénure d'alkyle en C₁-C₄, un mésylate d'alkyle ou un tosylate, avec un époxyde de formule




dans laquelle R' est un hydrogène, un méthyle ou un éthyle, ou avec un halogénure de formule générale




où n, W, U, V, Z, V' et U' sont tels que définis ci-dessus ;

b) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, R⁶, Ar et le pointillé sont tels que définis ci-dessus, avec un composé de formule générale




dans laquelle R⁵ est tel que défini ci-dessus et hal est un halogène ;

c) la réduction du cycle indole d'un composé de formule générale




dans laquelle R¹ à R⁵, Ar, Y et le pointillé sont tels que définis ci-dessus, en un cycle dihydro-indole ;

d) la réduction de la double liaison du cycle tétrahydropyridyle d'un composé de formule :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus ;


e) la réduction du cycle pyridinium d'un composé de formule suivante :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus, si ce n'est que R⁵ ne peut pas être un hydrogène, et hal est un halogène, en cycle tétrahydropyridine ;


f) la réduction du cycle pyridinium d'un composé de formule VIII ci-dessus ou du cycle pyridyle d'un composé de formule XIV en un cycle pipéridine ;

g) la réduction du groupe carbonyle d'un composé de formule suivante :




20 dans laquelle R^1 à R^4 , X, Y, Ar et les pointillés sont tels que précédemment définis et R^{16} est un hydrogène, un alkyle en C_1 - C_4 ou un alcoxy en C_1 - C_4 ;

h) l'acylation d'un dérivé d'aminoalkyle de formule suivante :




40 dans laquelle R^1 à R^4 , X, Y, Ar, R^8 , n et les pointillés sont tels que définis ci-dessus, avec un agent d'acylation tel qu'un halogénure, un anhydride ou un anhydride mixte d'acide carboxylique, ou un chlorure de carbamyle ou de thiocarbamyle, un isocyanate, un isothiocyanate ou un chloroformiate substitué ;

45 i) la réaction de cyclisation d'un dérivé intermédiaire d'éthylène-ou de propylène-diamine de formule suivante :



15 dans laquelle R^1 à R^4 , R^8 , n , X , Y , Ar et les pointillés sont tels que définis ci-dessus et m est 2 ou 3, avec le phosgène, le thiophosgène ou le disulfure de carbone, pour former un substituant de structure 1a ; ou

20 j) la réduction d'un acide carboxylique ou d'un dérivé d'acide carboxylique de formule suivante :



35 dans laquelle R^1 à R^4 , X , Y , Ar et les pointillés sont tels que précédemment définis, R^{17} est un hydrogène ou un alkyle en C_1-C_4 et p est 1, 2 ou 3 ;

puis, si on le désire :

40 l'acylation d'un composé préparé dans l'un des procédés (a) à (j) répondant à la formule I dans laquelle R^5 est une structure 1a ou 1b lorsque V est NH , ou V^1 est NHR^{10} , ou U^1 est NH , avec un agent d'acylation, ou l'estérification d'un groupe hydroxy disponible dans un composé de formule I pour obtenir un précurseur de médicament ; la conversion d'un composé préparé selon l'un des procédés (a) à (j) en un sel d'addition d'acide pharmaceutiquement acceptable correspondant ; ou

45 le dédoublement d'un composé optiquement actif de formule I, préparé selon l'un des procédés (a) à (j), en ses isomères optiquement actifs.

50

55

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 470 039 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **07.12.94** (51) Int. Cl.⁵: **C07D 209/08**, C07D 231/56,
C07D 401/12, C07D 401/14,
(21) Application number: **91610058.9** C07D 209/10, C07D 401/04,
C07D 405/04, C07D 405/14,
(22) Date of filing: **22.07.91** C07D 409/04, C07D 409/14,
A61K 31/40, A61K 31/415

The file contains technical information submitted
after the application was filed and not included in
this specification

(54) **Novel 3-arylindole and 3-arylindazole derivatives.**

- (30) Priority: **30.07.90 DK 1811/90**
(43) Date of publication of application:
05.02.92 Bulletin 92/06
(45) Publication of the grant of the patent:
07.12.94 Bulletin 94/49
(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE
(56) References cited:
EP-A- 0 135 781
EP-A- 0 200 322
DE-A- 2 811 031

CHEMICAL & PHARMACEUTICAL BULLETIN
vol. 33, no. 5, May 1985, JAPAN pages 1826 -
1835; **MAKOTO ADACHI ET AL.:**
'Aminohaloborane in Organic Synthesis
IX.Exclusive ortho Acylation Reaction of N-
Monoaminoalkylanilines'

J.-M. Meunier, A. Shvaloff, Neurotransmit-
teurs, MASSON, p.227

- (73) Proprietor: **H. LUNDBECK A/S**
Ottillavej 7-9
DK-2500 Kobenhavn-Valby (DK)
(72) Inventor: **Perregaard, Jens Kristian**
22, Thyrasvej
DK-3630 Jaegerspris (DK)
Inventor: **Andersen, Kim**
100 CI, Vesterbrogade
DK-1620 Copenhagen-V (DK)
(74) Representative: **Petersen, John Meidahl**
c/o H. Lundbeck A/S
Patent Department
Ottillavej 7-9
DK-2500 Copenhagen-Valby (DK)


EP 0 470 039 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).


Description

The present invention relates to novel 3-arylindole or 3-arylindazole derivatives and their acid addition salts with selective and long lasting central serotonin S₂ (5-hydroxytryptamine-2 ; 5-HT₂) antagonistic activity, to methods for preparing such compounds, to medicaments comprising such compounds as an active ingredient and to the beneficial use of these derivatives in the treatment of CNS disorders such as anxiety, aggression, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, and Parkinson's disease with a low degree of undesired side effects.

The novel indole and indazole derivatives of the present invention are represented by the following formula :



wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, hydroxy, trifluoromethyl, and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; R¹-R⁴ are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphonyl, cyano, trifluoromethyl, or trifluoromethylthio; the dotted line emanating from X in the ring system designates an optional bond; when said dotted line indicates a bond, X is nitrogen or a group CR⁶ wherein R⁶ is hydrogen, halogen, trifluoromethyl or lower alkyl; when the dotted line indicates no bond, X is CH₂ ; the dotted line, emanating from the Y, indicates an optional bond; when it does not indicate a bond Y is N or CH; and when it indicates a bond Y is C; R⁵ is hydrogen, or lower alkyl, optionally substituted with one or two hydroxy groups, or R⁵ is a group taken from structures **1a** and **1b**:



wherein n is an integer from 2 - 6;
W is oxygen or sulphur;
U is nitrogen or CH ;
Z is -(CH₂)_m-, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH₂- or -CSCH₂-;
V is oxygen, CH₂, or NR⁷, wherein R⁷ is hydrogen or lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl optionally substituted with one or two hydroxy groups;
U¹ is a group NR⁸, wherein R⁸ is hydrogen or lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl optionally substituted with one or two hydroxy groups; and
V¹ is NR⁹R¹⁰, where each of R⁹ and R¹⁰ may be independently selected among the R⁸-substituents; provided that R⁵ may not be methyl when R¹-R⁴ each are hydrogen, X and Y are CH and Ar is phenyl.

Stereoisomers, prodrugs and pharmaceutically acceptable salts of the compounds of formula I are also embraced by the invention.

The term "lower alkyl" is intended to mean a straight or branched alkyl group having from one to four carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, etc. Lower alkoxy, lower alkylthio and lower alkylsulfonyl similarly designate such groups wherein the alkyl moiety is a lower alkyl group as defined above.

Lower alkenyl is intended to mean an alkenyl group containing from 2 to 4 carbon atoms, for example ethenyl, 1-propenyl, 2-butenyl, etc.

Cycloalkyl means cycloalkyl having from three to eight carbon atoms inclusive.


Halogen means fluoro, chloro, bromo or iodo.

The term "indicate an optional bond" is intended to mean that the dotted lines may or may not represent a bond, i.e. that the rings may or may not have a double bond in the positions of the dotted lines in Formula I.

The Z groups -COCH₂- and -CSCH₂- may be incorporated in the ring of the structure 1a in both directions.

The acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulphonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.

Prodrugs of the present invention may be conventional esters with available hydroxy groups, or in particular if the compound is a compound of the general formula I wherein R⁵ is a group of the structure 1a wherein V is NH or the structure 1b where U¹ is NH and/or V¹ is NHR¹⁰ they may exist as prodrugs in which said nitrogen atom is acylated with a group



wherein A is O, S or NR^a with R^a being hydrogen, lower alkyl, or phenyl optionally substituted with one or more substituents selected from the group comprising halogen, trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio and cyano;

B is a group R^b which is alkyl or alkenyl containing from one to twentyfour carbon atoms inclusive, or cycloalkyl or cycloalkylalkyl, optionally substituted with one or two hydroxy groups, phenyl optionally substituted with one or more substituents selected from the group comprising halogen, trifluoromethyl, lower alkyl, lower alkoxy, lower alkylthio, or cyano; or

B is QR^b, wherein Q is O or S and R^b is one of the substituents defined for R^b above; or

B is NR^cR^d, wherein R^c and R^d independently are either hydrogen or one of the substituents defined for R^b above.

Although the latter prodrugs are not esters, they have been found to decompose properly in order to release the compound of the invention over a desired prolonged period of time when administered parenterally as a depote formulation in an appropriate oil, such as peanut oil, sesame oil, cotton seed oil, corn oil, soy bean oil, olive oil, coconut oil (e.g. viscoleo®), etc., or synthetic esters of fatty acids and glycerol or propylenglycol.

Only one 3-arylindole or 3-arylindazole derivative substituted in the 1-position with a piperidinyl, piperazinyl or tetrahydropyridyl group is known from the prior art.

1-(1-methyl-4-piperidinyl)-3-phenylindole is disclosed in Adachi et al, *Chem. Pharm. Bull.*, **33(5)**, 1826-1835, (1985), as an intermediate in the synthesis of 2-acyl-N-(1-methyl-4-piperidinyl)aniline. Nothing is disclosed or suggested as regards the pharmacological properties of said compound.

On the other hand indole or indazole derivatives having an aryl substituent in the 1-position and a tetrahydropyridyl, piperidinyl or piperazinyl group in the 3 position have been disclosed in a number of patents.

DE Offenlegungsschrift No. 2811031 (Laboratories Sauba S.A.) relates to 1-(optionally subst. phenyl)-3-((4-alkyl or aryl)-piperazin-1-yl)-indole derivatives stated to have antiinflammatory activity.

EP-A2 224919 (Fujisawa Pharmaceutical Co., Ltd.) discloses 1-phenyl-3-(4-(thiazolylalkyl)piperazin-1-yl)-indole derivatives as anti-allergy agents.

DE Offenlegungsschrift No. 1695604 (Pfizer Corporation) describes 1-phenyl-3-(optionally 1-benzyl or 1-methyl substituted 4-piperidiny)-2-indolones having anti-depressant effects.

EP-A 0 135 781 and US Patents Nos. 4,670,447 , 4,758,668 and 4,853,470 all generically relate to a very broad class of 1-aryl-3-pipendylindazoles alleged to have analgesic and antipsychotic and in some of the patents also antidepressant effects. Antipsychotic effects are shown by the apomorphine climbing assay which is a test for classical neuroleptic activity, i.e. dopamine antagonism, and antidepressant effects are shown in the tetrabenazine ptosis test for a few compounds.

EP-A 0 281 309 and US Patents No. 4,831,031 disclose 3-[4-(heterocycleethyl (or -butyl))piperazin-1-yl]indazoles substituted in the 1-position with trifluoromethylphenyl and claimed to be useful as antipsychotics as shown in the apomorphine climbing test.

European Patent Publication No. 0 302 423 relates to 1-phenyl-3-(1-piperazinyl)-1*H*-indazoles claimed to be useful as analgesics, anticonvulsants and antidepressants, the antidepressant effects again shown in the tetrabenazine ptosis test in mice. Only results for a few compounds showing quite weak effects are given.

From our own US patent No 4,710,500 (corresponding to EP patent No 0200323) 1-aryl-3-(1,2,3,6-tetrahydropyridin-4-yl)-, 1-aryl-3-(4-piperidiny)- and 1-aryl-3-(1-piperazinyl)-indole derivatives are known. The compounds are claimed to be potent and long-lasting dopamine antagonists, and accordingly to be useful in the treatment of psychoses and additionally to be strong 5-HT₂ antagonists indicating effects in the treatment of depression, negative symptoms of schizophrenia and neuroleptic-induced extrapyramidal side effects and cardiovascular diseases. Some of the compounds are selective 5-HT₂ antagonists *in vivo*.

Previously evidence of various clinical effects of 5-HT₂ antagonists have been presented. For example reference may be made to the following:

The selective 5-HT₂ antagonist ritanserin has been shown to be an antidepressant and to improve depressive symptoms of schizophrenia (E. Klier, W. H. Strauss; Pharmacopsychiat. 21 (1988), pp. 391-393) and it has been demonstrated to exert effects in an animal test reminiscent of anxiolytic drug activity (F.C. Colpart et al; Psychopharmacology (1985) 86; 303-305). Furthermore ritanserin has been shown to improve the quality of sleep (P. A. J. Janssen; Pharmacopsychiat. 21 (1988), 33-37).

Furthermore it is generally believed that 5-HT is involved in migraine attacks. The links between 5-HT and migraine attacks are several and they suggest a number of mechanisms whereby 5-HT may be involved (Scrip Report; "Migraine - Current trends in research and treatment"; PJB Publications Ltd.; May 1991). Various 5-HT₂ antagonists are in clinical trials as anti-migraine agents, such as sergolexole (c.f. for example Pharma Projects , May 1991, 1359-1365).

Studies of the mixed serotonin and dopamine receptor antagonist setoperone indicate that blockade of 5-HT₂ receptors may be related to improvement of negative symptoms of schizophrenia (Ceulemans et al, Psychopharmacology (1985) 85, 329-332).


Finally, ritanserin has been found to relieve neuroleptic-induced parkinsonism (Bersani et al.; Clinical Neuropharmacology, 13, No. 6 (1990), 500-506).

Surprisingly, it has now been found that the novel indole or indazole derivatives of the present invention are selective 5-HT₂ antagonists with prolonged activity, and accordingly are useful in the treatment of anxiety, aggression, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, drug-induced Parkinsonism and Parkinson's disease substantially without causing neurological side effects.

The compounds of the present invention are selective, and most of them very selective, antagonists of the 5-HT₂ receptor, measured as the ratio between the dopamine D-2 receptor and the 5-HT₂ receptor antagonistic activities. Only a few compounds with such a selectivity profile are known from the prior art. Such compounds include ritanserin, seganserin, ICI 169369, ICI 170809, sergolexole and MDL 11939, which compounds are very different in chemical structure from the present compounds.

A preferred subgroup of compounds are those wherein X is a CR⁶ group; most preferably those wherein R² and/or R⁶ are other than hydrogen.

Preferably, Ar is phenyl optionally substituted with halogen; most preferably 4-fluorophenyl;
R⁵ is a group



wherein R⁷, R⁸,

R⁹ and R¹⁰ independently are selected from hydrogen, lower alkyl or alkenyl; R² is selected from halogen, -CF₃, and -CH₃; R³ is selected from H, halogen, -CF₃, and -CH₃; and R¹ and R⁴ are H.

Particularly preferred compounds are:

- 5 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole,
 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole,
 2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 10 2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-4-piperidyl)-1*H*-indole, and 1-[1-[2-(1,3-Dimethyl-1-ureido)ethyl]-
 4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole.

In another aspect the present invention provides a pharmaceutical preparation comprising at least one compound of the Formula I as an active ingredient together with a pharmaceutically acceptable carrier or diluent.

- 15 The compounds of the Formula I and the pharmaceutically acceptable acid addition salts thereof may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection.


Suitable pharmaceutical preparations may be prepared by methods well known in the art. Conveniently, the compounds of the invention are administered in unit dosage form containing said compound in an amount of about 0.10 - 100 mg, preferably about 1 - 50 mg.

The total daily dose usually ranges from about 0.1 to 500 mg of the active compound of the invention. In a further aspect the present invention provides the use of a compound of the Formula I for the manufacturing of a pharmaceutical preparation for the treatment of CNS disorders.


- 25 The present invention also provides a method for treating CNS disorders comprising administration of a compound having the general Formula I or an acid addition salt thereof to a patient suffering from such a disease.

Finally, the present invention provides a method for the preparation of a derivative having the general Formula I, which method comprises:


- a) reacting a compound of the following formula:




- 45 wherein R¹, R², R³, R⁴, X, Y, Ar and the dotted lines are as defined above, with a lower alkyl halide, alkyl mesylate or tosylate, with an epoxide of the formula




wherein R' is hydrogen, methyl or ethyl or with a halide of the general formula




wherein n, W, U, V, Z, V¹ and U¹ are as defined above;
b) reacting a compound of following formula:



wherein R¹, R², R³, R⁴, R⁶, Ar and the dotted line are as defined above, with a compound of the general formula




in which R⁵ is as defined above and hal is halogen;
c) reducing the indole ring of a compound of the general formula




wherein R¹-R⁵, Ar, Y and the dotted line are as defined above, to a dihydroindole ring;

d) reducing the double bond in the tetrahydropyridyl ring in a compound of the formula:



wherein R¹ - R⁵, X, Ar and the dotted line are as defined above;


e) reducing the pyridinium ring in a compound of following formula:



wherein R¹ - R⁵, X, Ar and the dotted line are as defined above except that R⁵ may not be hydrogen, and hal is halogen, to a tetrahydropyridine ring;


35 f) reducing the pyridinium ring in a compound of the above Formula VIII or the pyridyl ring of a compound of formula XIV (below) to a piperidine ring;

g) reducing the carbonyl group of a compound of the following formula:




55 wherein R¹ - R⁴, X, Y, Ar and the dotted lines are as previously defined and R¹⁶ is hydrogen, lower alkyl or lower alkoxy;

h) acylating an aminoalkyl derivative of the following formula :




wherein $R^1 - R^4$, X , Y , Ar , R^8 , n and the dotted lines are as defined above, with an acylating agent such as a carboxylic acid halogenide, anhydride or mixed anhydride, or a carbamyl or thiocarbamyl chloride, an isocyanate, isothiocyanate, or a substituted chloroformate;

i) ringclosure reaction of an intermediate ethylene or propylene diamine derivative of the following formula :



wherein $R^1 - R^4$, R^8 , n , X , Y , Ar and the dotted lines are as defined above and m is 2 or 3, with phosgene, thiophosgene or carbondisulphide to form a substituent of the structure **1a** ; or

j) reducing a carboxylic acid or carboxylic acid derivative of the following formula :



wherein $R^1 - R^4$, X, Y, Ar and the dotted lines are as previously defined, R^{17} is hydrogen or lower alkyl and p is 1, 2 or 3;

and then, if desired:


acylating a compound prepared in one of the methods (a) to (j) having the formula I in which R^5 is a structure 1a or 1b wherein V is NH, or V^1 is NHR^{10} or U^1 is NH with an acylating agent, or esterifying an available hydroxy group in a compound of formula I in order to obtain a prodrug;

converting a compound prepared in one of methods (a) to (j) in a pharmaceutically acceptable acid addition salt thereof; or

resolving an optically active compound of formula I prepared in one of methods (a) to (j) in optically active isomers thereof.

In method (a) the reaction is conveniently performed at 20-120 °C in an aprotic solvent such as acetone or methyl isobutyl ketone in the presence of free base (e.g. K_2CO_3 or triethylamine) and the starting compounds of Formula II are prepared as described below.

3-aryl-1-(4-piperidyl)indoles and 3-aryl-1-(4-piperidyl)indazoles are prepared as shown in the following reaction scheme:



wherein R^1-R^4 , R^6 and Ar are as defined above.

An 3-arylindole or 3-arylindazole of the Formula XIII is arylated with 4-chloro- or 4-bromopyridine in NMP, DMF, HMPA or DMSO with potassium carbonate as base and catalyzed by copper, copper(I) iodide or copper(I) bromide at 150-210 °C. The 3-aryl-1-(4-pyridyl)indole or 3-aryl-1-(4-pyridyl)indazole of Formula XIV thus obtained is reduced to the 3-aryl-1-(4-piperidyl)indole or 3-aryl-1-(4-piperidyl)indazole of the Formula XV with hydrogen at low pressure (3 atm.) in the presence of platinum.

3-Arylindoles, which are unsubstituted in the 2-position, are prepared from the corresponding 2-cyano-3-arylindoles or 3-arylindole-2-carboxylic esters by alkaline or acidic hydrolysis followed by decarboxylation in NMP or quinoline with copper catalysis. The 2-cyano-3-arylindoles and 3-arylindole-2-carboxylic esters

used are prepared either from the corresponding anilines by Japp-Klingemann reaction followed by Fischer indole synthesis or from the corresponding 2-benzoylanilines according to modified literature procedures (Morooka et al, *Synthesis*, 1978, 445, Hughes et al, *J. Proc. Roy. Soc. N. S. Wales*, 1939, 72, 209 and C. D. Jones, *J. Org. Chem.*, 1972, 37, 3624).

- 5 2-Substituted 3-arylindoles are prepared either from the corresponding 2-benzoyl-anilines or by Fischer indole synthesis from the corresponding substituted phenyl hydrazones (e.g. (4-fluorophenyl)acetone (4-methylphenyl)hydrazone) according to modified literature procedures (Greuter et al, *Helv. Chem. Acta*, 1974, 57, 281 and Yamamoto et al, *Chem. Pharm. Bull.*, 1968, 16, 2313).

- 3-Arylindazoles are prepared either from the corresponding 2-benzoylanilines or by heating the correspond-
10 ing 2-chloro - or bromobenzophenone hydrazone with base, according to modified literature procedures (Dziewonski et al., *Bull. Intern. Acad. Polonaise, Casse Sci. Math. Nat.*, 1935A, 333 (*Chem. Abstr.*, 1936, 30, 1972) and Gladstone et al, *J Chem. Soc.*, 1965, 3048).

- 2-Halo-3-aryl-1-(4-piperidyl)indoles are prepared from the corresponding 3-aryl-1-(4-piperidyl)indoles, in
15 which the piperidine nitrogen is protected by a suitable aminoprotective group (e.g. methyl or 2,2,2-trichloroethyl carbamate), by halogenation with an halogenation reagent such as *N*-bromosuccinimide, *N*-chlorosuccinimide or bromine in an inert solvent (e.g. CCl₄ or acetic acid) according to modified literature procedures (Hino et al., *Tetrahedron*, 1974, 30, 2123), followed by deprotection of the piperidine nitrogen by standard methods which are obvious to the chemist skilled in the art.

- In method (b) the reaction is performed by refluxing a compound of Formula IV with a compound of
20 Formula V and a strong base (e.g. sodium amide) in an inert solvent, e.g. toluene. The starting compounds of Formula IV are prepared by reacting the corresponding 3-arylindoles, prepared as described above, with hydroxylamine-O-sulphonic acid and strong base (e.g. potassium tert-butoxide) in a polar aprotic solvent (e.g. DMF).

- In method (c) the reduction is conveniently performed with a complex hydride (e.g. sodium borohydride) in
25 acidic solution (e.g. trifluoroacetic acid).

- In method (d) the reduction is suitably carried out at a low hydrogen pressure (3 ato.) in the presence of platinum or palladium or by refluxing a compound of formula VII with ammonium formate and palladium in a water miscible solvent (e.g. ethanol).

- In method (e) the reduction is expediently carried out with a complex hydride (e.g. sodium borohydride in
30 methanol) whereas the reduction in method (f) preferably is performed by catalytic hydrogenation with platinum as a catalyst. The starting compounds of Formula VIII are prepared by quaternizing a 1-(4-pyridyl)-3-arylindole or 1-(4-pyridyl)-3-arylindazole, prepared as described above, with a lower alkyl halide or a

- halide of the general Formula IIIa or IIIb in MIBK or acetone. The reduction in method (g) is conveniently
35 carried out with lithium aluminum hydride in tetrahydrofuran, or diethyl ether, or with diborane in tetrahydrofuran. Aminoalkyl derivatives of the Formula X (method h) are prepared by alkylating a compound of the Formula II with a halo-nitrile of the following formula: $\text{hal}(\text{CH}_2)_n\text{CN}$ in the presence of a base (e.g.

- K₂CO₃ or triethylamine) in an inert solvent such as acetone, MIBK or toluene at elevated temperature (30-
100 °C). The cyano group may be reduced according to standard procedures using e.g. AlH₃, LiAlH₄ or B₂H₆. The R⁹ substituent is introduced by direct alkylation or by an acylation/reduction procedure, which is
40 obvious to the chemist skilled in the art. Acylation of the thus obtained amino derivatives is accomplished by addition of an acylating agent at a low temperature (-20-30 °C) preferably in a chlorinated solvent (dichloromethane, chloroform, or 1,1,1-trichloroethane) and, if necessary, in the presence of a base to neutralize any acidic reaction product formed.

- Ethylene or propylene diamines as intermediates for the ringclosure procedure in method (i) are prepared
45 by repeating with appropriate reagents the procedure described for the preparation of the aminoalkyl derivatives used as starting materials in method (h). Generally, heating (80-150 °C) is required to effect ringclosure with the appropriate carbonyl- or thiocarbonyl precursor compound (phosgene, thiophosgene, carbondisulphide, urea or thiourea).

- In method (j) the reduction is conveniently carried out using a complex hydride (e.g. lithium aluminum
50 hydride) in an inert solvent (e.g. diethyl ether). The starting compounds of Formula XII are prepared by reacting a compound of Formula II with a halocarboxylic acid ester of formula $\text{hal}-(\text{CH}_2)_p\text{CO}_2\text{R}^{17}$ in the presence of a base (e.g. K₂CO₃ or triethylamine) in an inert solvent such as acetone, MIBK or toluene at elevated temperature (30-100 °C).

- The ω-haloalkyl-2-imidazolidinone alkylating reagents (substructure of structure IIIa) were prepared
55 according to modified literature procedures (see eg. Johnston, T.P.; McCaleb, G.S.; Montgomery, J.A. The Synthesis of Antineoplastic Agents. XXXII. N-Nitrosureas. *J. Med. Chem.* 1963, 6, 669-681; Ebetino, F.F. *Belg. Patent* 653421, 1965; *Chem. Abstr.* 1966, 64, 12684; Costelli, J.; Züst, A. *Ger. Offen* 2035370, 1971; *Chem. Abstr.* 1971, 74, 87985z). Other sidechains of structure IIIa were prepared as stated in the literature.

The acid addition salts of the compounds of the invention are easily prepared by methods well known in the art. The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or with an excess of the acid in an aqueous immiscible solvent, such as diethyl ether or chloroform, with the desired salt separating directly. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts.

In the following the invention is further illustrated by way of examples, which in no way may be construed as limiting for the invention.

10 EXAMPLE 1

3-(4-Fluorophenyl)-1*H*-indole 1a.

Methyl 3-(4-fluorophenyl)-1*H*-indole-2-carboxylate 22d (59.6 g) was refluxed in a mixture of methanol (1.5 l) and 2 N aqueous NaOH (500 ml) for 3.5 h. The reaction mixture was cooled to room temperature, the solvents were evaporated *in vacuo* and water (500 ml) was added. The alkaline solution was acidified and the thus formed precipitate was filtered off and dissolved in ethyl acetate (750 ml). The ethyl acetate solution was washed with brine (500 ml) and dried (Na₂SO₄). Evaporation of the solvents afforded the crude 4-fluorophenyl-1*H*-indole-2-carboxylic acid which was used without further purification.

A mixture of the crude indole-2-carboxylic acid (55.0 g), Cu (2.0 g) and quinoline (1.0 l) was refluxed for 2.5 h, cooled and filtered. The filtrate was poured into water (800 ml) and extracted with diethyl ether (2 x 800 ml). The combined organic phases were successively washed with 1 N hydrochloric acid (4 x 1.0 l), washed with brine (1.0 l) and dried (Na₂SO₄). Evaporation of the solvent *in vacuo* gave the title compound which was precipitated from diethyl ether. Yield: 43.6 g, mp 98-100 °C.

In a corresponding manner the following indole derivatives were prepared:

- 5-Chloro-3-(4-fluorophenyl)-1*H*-indole 1b, mp 81-83 °C.
- 3-(4-Fluorophenyl)-5-methyl-1*H*-indole 1c, mp 123-126 °C.
- 6-Chloro-3-(4-fluorophenyl)-1*H*-indole 1d, (oil).
- 5-Fluoro-3-(4-fluorophenyl)-1*H*-indole 1e, (oil).
- 3-(4-Fluorophenyl)-5-trifluoromethyl-1*H*-indole 1f, (oil).
- 5-Chloro-3-phenyl-1*H*-indole 1g, mp 84-86 °C.

EXAMPLE 2

3-(4-Fluorophenyl)-1-(4-pyridyl)-1*H*-indole 2a.

3-(4-Fluorophenyl)-1*H*-indole 1a (39.3 g), 4-chloropyridine hydrochloride (55.8 g), K₂CO₃ (102.8 g), CuBr (15 g) and N-methylpyrrolidinone (1.2 l) were refluxed under stirring for 18 h. The reaction mixture was cooled, poured into water (1.0 l) and extracted with diethyl ether (2 x 1 l). The combined organic phases were washed with brine (3 x 1.5 l), dried (Na₂SO₄) and treated with activated carbon. Evaporation of the solvent gave the title compound which was crystallized from diethyl ether. Yield: 42.0 g, mp 115-118 °C.

In a corresponding manner the following indole derivatives were prepared:

- 5-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 2b, mp 162-164 °C.
- 3-(4-Fluorophenyl)-5-methyl-1-(4-pyridyl)-1*H*-indole 2c, mp 125-127 °C.
- 5-Fluoro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 2d, mp 129-134 °C.
- 6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 2e, mp 194-198 °C.
- 3-(4-Fluorophenyl)-1-(4-pyridyl)-5-trifluoromethyl-1*H*-indole 2f, mp 163-165 °C.
- 5-Chloro-3-phenyl-1-(4-pyridyl)-1*H*-indole 2g, mp 130-132 °C.

EXAMPLE 3

(intermediates for method a)

6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 3a.

6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 2e (1.8 g) was dissolved in acetic acid (100 ml) and PtO₂ (0.2 g) was added. After hydrogenation for 30 h at 3 atm the catalyst was filtered off, the acetic acid

was evaporated *in vacuo* and water (50 ml) was added. The acidic solution was made alkaline (pH >9) with concentrated sodium hydroxide and extracted with ethyl acetate (2 x 50 ml). The combined organic phases were successively washed with diluted sodium hydroxide (50 ml), washed with brine, and dried (Na₂SO₄). Evaporation of the solvent gave 1.5 g of the title compound as an oil.

5 In a corresponding manner the following indole and indazole derivatives were prepared:

- 3-(4-Fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3b**, (oil).
- 5-Chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3c**, (oil).
- 3-(4-Fluorophenyl)-5-methyl-1-(4-piperidyl)-1*H*-indole **3d**, (oil).
- 5-Fluoro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3e**, (oil).
- 10 3-(4-Fluorophenyl)-1-(4-piperidyl)-5-trifluoromethyl-1*H*-indole **3f**, (oil).
- 5-Chloro-3-phenyl-1-(4-piperidyl)-1*H*-indole **3g**, (oil).
- 6-Chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indazole **3h**, (oil).
- 3-(4-Fluorophenyl)-1-(4-piperidyl)-5-trifluoromethyl-1*H*-indazole **3i**, (oil).

15 EXAMPLE 4

(method a)

6-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole, maleate **4a**.

20

A mixture of 6-chloro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3a** (1.5 g), 1-(2-chloroethyl)-3-methyl-2-imidazolidinon (1.1 g), K₂CO₃ (1.0 g), KI (0.5 g) and methyl isobutyl ketone (100 ml) was refluxed for 18 h. The reaction mixture was cooled, poured into water (50 ml) and extracted with ethyl acetate (2 x 50 ml). The combined organic phases were dried (Na₂SO₄) and the solvents were evaporated *in vacuo*. The remaining oil was purified by column chromatography on silica gel (eluted with ethyl acetate/isopropanol 9:1 containing 4 % triethylamine). The title compound was precipitated as its maleate from ethyl acetate. Yield: 1.4 g, mp 110-112 °C.

25

In a corresponding manner the following indole and indazole derivatives were prepared:

- 6-Chloro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4b**, mp 192-194 °C.
- 30 6-Chloro-3-(4-fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, hydrochloride, hydrate **4c**, mp 255-258 °C.
- 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4d**, mp 171-174 °C.
- 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4e**, mp 161-164 °C.
- 35 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-piperidyl]-1*H*-indole **4f**, mp 128-133 °C.
- 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole **4g**, mp 185-187 °C.
- 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, oxalate **4h**, mp 175-177 °C.
- 40 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole, fumarate **4i**, mp 103-105 °C.
- 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-(2-pyrrolidinon-1-yl)ethyl]-4-piperidyl]-1*H*-indole, oxalate **4j**, mp 120-122 °C.
- 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4k**, mp 172-173 °C.
- 45 3-(4-Fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, hydrochloride, hydrate **4l**, mp 242-244 °C.
- 5-Fluoro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4m**, mp 153-156 °C.
- 5-Fluoro-3-(4-fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4n**, mp 143-145 °C.
- 50 5-Fluoro-3-(4-fluorophenyl)-1-[1-[2-(oxazolidin-2-on-3-yl)ethyl]-4-piperidyl]-1*H*-indole **4o**, mp 123-125 °C.
- 5-Chloro-3-phenyl-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole **4p**, mp 155-157 °C.
- 5-Chloro-3-phenyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4q**, mp 146-148 °C.
- 2,3-Dihydro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-fluoro-1*H*-indole **4r**, mp 182-186 °C.
- 55 3-(4-Fluorophenyl)-5-methyl-1-[1-(2-propyl)-4-piperidyl]-1*H*-indole, maleate **4s**, mp 162-163 °C.
- 6-Chloro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indazole **4t**, mp 195-197 °C.
- 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-trifluoromethyl-1*H*-indazole **4u**, mp

217-219 °C.

3-(4-Fluorophenyl)-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-5-trifluoromethyl-1*H*-indole 4v, mp 156-158 °C.

2-Bromo-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole 4x, mp 194-196 °C.

5

EXAMPLE 5

(intermediates for methods e and f)

10 4-[2,5-Dimethyl-3-(4-fluorophenyl)-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5a.

A mixture of 2,5-dimethyl-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole 17a (5.0 g) and 1-(2-iodoethyl)-2-imidazolidinon (7.6 g) and methyl isobutyl ketone (50 ml) was refluxed for 6 h. After cooling to room temperature the precipitated product was filtered off and dried *in vacuo* at 70 °C overnight. This afforded

15 6.3 g of the title compound, mp 215-217 °C.

In a corresponding manner the following indole derivatives were prepared:

4-[3-(4-Fluorophenyl)-5-methyl-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5b, mp >250 °C.

20 4-[3-(4-Fluorophenyl)-5-trifluoromethyl-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5c, mp >250 °C.

EXAMPLE 6

(method e)

25

2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole 6a.

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1*H*-indol-1-yl]-1-[2-(imidazolidin-2-on-1-yl)ethyl]pyridinium iodide 5a -
30 (6.3 g) was suspended in ethanol (100 ml) and sodium borohydride (2.1 g) was added in three portions during 3.5 h. Then the solvent was evaporated *in vacuo* and water (100 ml) was added. The mixture obtained was extracted with dichloromethane (2 x 50 ml). The combined organic phases were washed with brine (100 ml) and dried (MgSO₄). Evaporation of the solvent gave the title compound as an oil, which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 8:1 containing 4 % triethylamine). Yield: 2.5 g, mp 151-153 °C.

In a corresponding manner the following indole derivatives were prepared: 2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole 6b, mp 98-100 °C.

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-5-methyl-1*H*-indole 6c, mp 129-131 °C.

40 3-(4-Fluorophenyl)-5-methyl-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole, maleate 6d, mp 168-171 °C.

5-Chloro-2-methyl-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-phenyl-1*H*-indole, oxalate 6e, mp 165-168 °C.

45 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-5-trifluoromethyl-1*H*-indole 6f, mp 113-115 °C.

EXAMPLE 7

(method d)

50

2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole 7a.

Ammonium formate (12 g) was added in small portions during 18 h to a refluxing mixture of 2,5-dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole 6a
55 (1.9 g), 5 % palladium on activated carbon (1 g) and ethanol (50 ml). The reaction mixture was cooled to room temperature and the solvents were evaporated *in vacuo*. After addition of water the mixture was made alkaline with conc ntrated NaOH and extracted with ethyl ac tate (2 x 50 ml).The combined organic phases were dried (Na₂SO₄) and the solvents were evaporated *in vacuo*. This afforded the title compound which

crystallized from diethyl ether. Yield 0.2 g, mp 188-190 °C.

In a corresponding manner the following indole derivatives were prepared:

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-trifluoromethyl-1H-indole **7b**, mp 182-186 °C

5 1-[1-[2-(Imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-2-methyl-3-phenyl-1H-indole **7c**, mp 179-183 °C.

EXAMPLE 8

(intermediates for methods e and f)

10

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1H-indol-1-yl]-1-methylpyridinium, iodide **8a**.

2,5-Dimethyl-3-(4-fluorophenyl)-1-(4-pyridyl)-1H-indole **17a** (5.0 g), methyl iodide (5 ml) and acetone (100 ml) were heated at 40 °C for 18 h. After cooling to room temperature the precipitated product was

15 filtered off and dried *in vacuo* at 70 °C overnight. yield: 6.3 g, mp 217-219 °C.

In a corresponding manner the following indole derivatives were prepared:

4-(5-Chloro-2-methyl-3-phenyl-1H-indol-1-yl)-1-methylpyridinium iodide **8b**, mp 225-227 °C.

4-[3-(4-Fluorophenyl)-5-methyl-1H-indol-1-yl]-1-methylpyridinium, iodide **8c**, mp > 250 °C.

20 EXAMPLE 9

(method f)

2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-4-piperidyl)-1H-indole **9a**.

25

4-[2,5-Dimethyl-3-(4-fluorophenyl)-1H-indol-1-yl]-1-methylpyridinium, iodide **8a** (3.0 g) was dissolved in acetic acid (75 ml) and PtO₂ (0.4 g) was added. After hydrogenation for 2 weeks at 3 atmo the catalyst was filtered off, the acetic acid was evaporated *in vacuo* and water (50 ml) was added. The thus obtained acidic solution was made alkaline (pH >9) with concentrated sodium hydroxide and extracted with ethyl acetate (2 x 50 ml). The organic phases were successively washed with diluted sodium hydroxide (50 ml), washed with brine and dried (Na₂SO₄). Evaporation of the solvent gave 1.3 g of the title compound as an oil, which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 8:1 containing 4 % triethylamine) and crystallized from heptane. Yield 0.4 g, mp 110-112 °C.

30 In a corresponding manner the following indole derivative was prepared: 5-Chloro-2-methyl-3-phenyl-1-(1-methyl-4-piperidyl)-1H-indole **9b**, mp 131-136 °C (decomp.).

35

EXAMPLE 10

(intermediates for method g)

40

Methyl 4-[3-(4-fluorophenyl)-5-methyl-1H-indol-1-yl]piperidine-1-carboxylate **10a**.

A mixture of 3-(4-fluorophenyl)-5-methyl-1-(4-piperidyl)-1H-indole **3d** (6.0 g), K₂CO₃ (3.0 g) and dichloromethane (50 ml) was cooled to 0-5 °C and a solution of methyl chloroformate (2.2 g) in dichloromethane (50 ml) was added during 0.5 h. After reaction for further 2 h at room temperature the reaction mixture was washed with water (2 x 100 ml) and dried (MgSO₄). Evaporation of the solvents *in vacuo* afforded the title compound, which was used without further purification. Yield: 6.7 g, (oil). in a corresponding manner the following indole derivative was prepared:

45 2,2,2-Trichloroethyl-4-[3-(4-fluorophenyl)-1H-indol-1-yl]piperidine-1-carboxylate **10b** (oil).

50

EXAMPLE 11

(method g)

55 3-(4-Fluorophenyl)-5-methyl-1-(1-methyl-4-piperidyl)-1H-indole, fumarate **11a**.

A solution of the crude methyl 4-[3-(4-fluorophenyl)-5-methyl-1H-indol-1-yl]piperidine-1-carboxylate **10a**, (6.7 g) in dry tetrahydrofuran (75 ml) was added to a suspension of lithium aluminum hydride (4 g) in dry

tetrahydrofuran (75 ml) during 0.5 h and the reaction mixture was refluxed for 1 h. After cooling on an ice bath water (5 ml), 6 N aqueous NaOH (5 ml) and water (10 ml) were added, successively. The precipitate was filtered off, the filtrate was dried (MgSO₄) and the solvents were evaporated *in vacuo*. This afforded the title compound, as an oil, which was precipitated as its fumarate from ethanol. Yield: 1.4 g, mp 170-172 °C.

5

EXAMPLE 12

(intermediate for method h)

10 1-[1-(2-Aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 12a.

A solution of 3-(4-fluorophenyl)-5-methyl-1-(4-piperidyl)-1*H*-indole 3d (20 g), chloroacetonitrile (5.4 g) and triethylamine (7.5 ml) in *N*-methylpyrrolidinone (125 ml) was heated at 60 °C for 2 h. The reaction mixture was poured into ice (200 g) and extracted with diethyl ether (2 x 200 ml). The combined organic phases were washed with brine (3 x 250 ml), dried (Na₂SO₄) and the solvents evaporated *in vacuo*. This afforded the 1-[1-(2-cyanomethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, as an oil, which was used without further purification. Yield: 22.2 g. To a suspension of aluminum chloride (5.0 g) in dry diethyl ether (200 ml) was added lithium aluminum hydride (5.0 g) at 10-15 °C. Then a solution of the crude cyanomethyl compound in dry tetrahydrofuran (300 ml) was added dropwise during 0.5 h at 10-15 °C. The reaction mixture was refluxed for 2 h, cooled on an ice bath and concentrated aqueous NaOH (25 ml) was added. The inorganic salts were filtered off and the solvent evaporated *in vacuo*. The remaining oil was dissolved in dichloromethane, dried (MgSO₄) and the solvent was evaporated. This afforded the title compound as an oil. Yield: 18.9 g.

25 **EXAMPLE 13**

(method h)

1-[1-[2-(3,3-Dimethyl-1-thioureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 13a.

30

A solution of 1-[1-(2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, 12a (5.0 g), *N,N*-dimethylthiocarbamoylchloride (2.1 g) and triethylamine (5 ml) in dichloromethane (150 ml) was refluxed for 18 h. After cooling to room temperature the reaction mixture was washed with water and dried (MgSO₄). Evaporation of the solvent afforded the title compound as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate containing 4 % triethylamine). The title compound precipitated from ethyl acetate and was recrystallized from diethyl ether. Yield: 0.8 g, mp 106-108 °C.

In a corresponding manner the following indole derivative was prepared:

1-[1-[2-(3,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 13b, mp 126-128 °C.

40

EXAMPLE 14

(intermediate for method h)

45 1-[1-(*N*-Methyl-2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 14a

A mixture of 1-[1-(2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole 12a (8.9 g), K₂CO₃ (4.2 g) and dichloromethane (80 ml) was cooled to 0-5 °C and a solution of methyl chloroformate (2.9 g) in dichloromethane (50 ml) was added during 15 min. After reaction for further 2 h at room temperature the reaction mixture was washed with water (2 x 50 ml), dried (MgSO₄) and the solvents were evaporated *in vacuo*. This afforded the 1-[1-(*N*-methoxycarbonyl-2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, as an oil, which was used without further purification. Yield: 8.8 g.

A solution of the crude 1-[1-(*N*-methoxycarbonyl-2-aminoethyl)-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole (8.8 g) in dry tetrahydrofuran (75 ml) was added to a suspension of lithium aluminum hydride (2 g) in dry tetrahydrofuran (75 ml) during 15 min and the reaction mixture was refluxed for 1.5 h. After cooling on an ice bath water (4 ml), 4 N aqueous NaOH (2.5 ml) and water (10 ml) were added, successively. The precipitate was filtered off, the solution was dried (Na₂SO₄) and the solvents were evaporated. This afforded the title compound, as an oil. Yield: 6.9 g.

EXAMPLE 15

(method h)

- 5 1-[1-[2-(1,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, hydrochloride **15a**.

A mixture of 1-(1-(*N*-methyl-2-aminoethyl)-4-piperidyl)-3-(4-fluorophenyl)-5-methyl-1*H*-indole **14a** (6.9), methyl isocyanate (2.1 g) and K₂CO₃ (4 g) in methyl isobutyl ketone (150 ml) was refluxed for 6 h. After cooling to room temperature water (100 ml) was added and the mixture was extracted with ethyl acetate (2 x 100 ml). The combined organic phases were washed with brine and dried (MgSO₄). Evaporation of the solvent afforded the title compound as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 4:1, containing 4 % triethylamine). The title compound was precipitated as its hydrochloride from diethyl ether. Yield: 0.9 g, mp 88-90 °C.

EXAMPLE 16

(method j)

3-(4-Fluorophenyl)-1-[1-(2-hydroxyethyl)-4-piperidyl]-5-methyl-1*H*-indole, oxalate **16a**.

20 A solution of ethyl bromoacetate in acetone was added during 15 min to a mixture of 3-(4-fluorophenyl)-5-methyl-1-(4-piperidyl)-1*H*-indole **3d** (5.0 g), K₂CO₃ (2.5 g) and acetone (100 ml) at room temperature. After another 2 h the solvents were evaporated, water was added and the mixture was extracted with ethyl acetate (2 x 100 ml). The combined organic phases were washed with brine and dried (Na₂SO₄). Evaporation of the solvent afforded the crude methyl 4-[3-(4-fluorophenyl)-5-methyl-1*H*-indol-1-yl]-1-piperidinacetate (6.0 g), which was used without further purification.

25 A solution of the crude methyl ester (6.0 g) in tetrahydrofuran (50 ml) was added to a suspension of lithium aluminum hydride (1.2 g) in dry tetrahydrofuran (50 ml) and the mixture was refluxed for 1 h. After cooling on ice bath, water (1.5 ml) and 4 N aqueous NaOH (1.5 ml) were added. The precipitate was filtered off and the filtrate was dried (Na₂SO₄). Evaporation of the solvents afforded the title compound (4.2 g) as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate containing 4 % triethylamine). The title compound precipitated as its oxalate from acetone. Yield: 0.09 g, mp 81-83 °C.

EXAMPLE 17

- 35 2,5-Dimethyl-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indole **17a**.

2,5-Dimethyl-(4-fluorophenyl)-1*H*-indole **24a** (50 g), 4-bromopyridine, hydrochloride (80 g), K₂CO₃ (90 g), CuBr (10 g) and *N*-methylpyrrolidone (750 ml) were refluxed under stirring for 18 h. The reaction mixture was cooled, poured into water (1.0 l) and extracted with diethyl ether (2 x 750 ml). The combined organic phases were washed with brine (3 x 1 l), dried (Na₂SO₄) and treated with activated carbon. Evaporation of the diethyl ether afforded the title compound (29.8 g) which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 3:1). The title compound crystallized from diethyl ether. Yield: 20.5 g, mp 172-174 °C.

45 In a corresponding manner the following indole and indazole derivatives were prepared:

5-Chloro-2-methyl-3-phenyl-1-(4-pyridyl)-1*H*-indole **17b**, mp 158-160 °C.

6-Chloro-3-(4-fluorophenyl)-1-(4-pyridyl)-1*H*-indazole **17c**, (oil).

3-(4-Fluorophenyl)-1-(4-pyridyl)-5-trifluoromethyl-1*H*-indazole **17d**, (oil).

EXAMPLE 18

(method c)

2,3-Dihydro-5-fluoro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **18a**

55 To a solution of 5-fluoro-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **3e** (2 g) in trifluoroacetic acid (30 ml) was added sodium cyanoborohydride (1 g). After 2 h reaction at room temperature the solvent was evaporated *in vacuo* and ethyl acetate (50 ml) was added. The mixture was washed twice with aqueous 2 N

sodium hydroxide (50 ml) and dried (Na_2SO_4). Evaporation of the solvent *in vacuo* afforded the crude product which was used without further purification. Yield: 1.5 g (oil).

In a corresponding manner the following indole derivative was prepared:

2,3-Dihydro-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole **18b**, mp 180-185 °C.

EXAMPLE 19

(intermediate for method b)

10

1-Amino-3-(4-fluorophenyl)-5-methyl-1*H*-indole **19a**.

Potassium *tert*-butoxid (7.5 g) was added to a solution of 3-(4-fluorophenyl)-5-methyl-1*H*-indole **1c** (15 g) in DMF during 15 min at 0-5 °C. Then a suspension of potassium hydroxylamine-O-sulphonate in DMF (prepared by addition of potassium *tert*-butoxid (7.5 g) to a suspension of hydroxylamine-O-sulphonic acid (7.6 g) in DMF (100 ml) during 0.5 h at 0-5 °C) was added slowly at 0-5 °C. After reaction at 0 °C for 1 h the mixture was poured into ice, and extracted with diethyl ether (2 x 250 ml). The combined organic phases were washed with brine (3 x 250 ml) and dried (Na_2SO_4). Evaporation of the solvents afforded the title compound which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:3) and crystallized from diethylether. Yield: 4.3 g, mp 116-120 °C.

EXAMPLE 20

(method b)

25

3-(4-Fluorophenyl)-5-methyl-1-(1-methylpiperazin-4-yl)-1*H*-indole **20a**.

To a mixture of 1-amino-3-(4-fluorophenyl)-5-methyl-1*H*-indole **19a** (1 g) and toluene (20 ml) was added a 50 % suspension of sodium amide in xylene (1.0 ml). After reaction for 15 min at room temperature a solution of *N,N*-bis(2-chloroethyl)methylamine (0.8 g) in toluene was added slowly and the mixture was refluxed for 3 h. After cooling to room temperature, the solvents were evaporated *in vacuo* and water (100 ml) was added. The mixture was extracted with ethyl acetate (2 x 50 ml) and the combined organic phases were dried (Na_2SO_4). Evaporation of the solvents *in vacuo* afforded the title compound, which was purified by column chromatography on silica gel (eluted with ethyl acetate/ethanol 4:1 containing 4 % triethylamine) and crystallized from heptane. Yield: 0.5 g, mp 105-107 °C.

EXAMPLE 21

1-[1-[2-(3-Acetylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, oxalate **21a** - (Prodrug).

To a mixture of 3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole **4g** (3 g), K_2CO_3 (1.3 g) and toluene (50 ml) was added a solution of acetyl chloride (0.6 ml) in toluene (5 ml) during 10 min at 0-5 °C. After reaction for further 18 h at room temperature the reaction mixture was filtered, the solvent was evaporated *in vacuo* and ethyl acetate (50 ml) was added. The thus formed solution was washed with brine (50 ml), dried (Na_2SO_4) and the solvent was evaporated *in vacuo*. This afforded the title compound as an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate containing 4 % triethylamine). The title compound precipitated as its oxalate from acetone. Yield: 2.0 g, mp 233-235 °C.

In a corresponding manner the following indole derivative was prepared: 1-[1-[2-(3-Decanoylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole, oxalate **21b**, mp 175-176 °C.

EXAMPLE 22

Methyl 3-(4-fluorophenyl)-5-methyl-1*H*-indole-2-carboxylat **22a**.

To a solution of *p*-toluidine (119.4 g) in conc. aqueous HCl (575 ml) was added a solution of NaNO_2 - (84.6 g) in water (500 ml) at 0-5 °C during 1.5 h. The reaction mixture was added in one portion to a

- mixture of methyl 2-(4-fluorobenzyl)-3-oxo-butanoate (250 g), KOH (220 g), water (0.5 l), ethanol (1.25 l) and ice (2 kg) under stirring. After reaction for 2 h at room temperature the reaction mixture was extracted with diethyl ether (2 x 2 l). The combined organic phases were washed with water (3 l) and dried (Na₂SO₄). Evaporation of the solvents afforded the crude 4-tolylhydrazone of methyl 2-oxo-3-(4-fluorophenyl)-propanoate (330 g), which was used without further purification.
- 5 A mixture of the crude hydrazone, methanol (2.25 l) and aqueous H₂SO₄ (100 ml) was refluxed for 18 h. The reaction mixture was cooled to room temperature and a part of the solvents were evaporated *in vacuo*. The thus obtained solution was cooled to 0 °C and the precipitated compound was filtered off and dried overnight *in vacuo* at 60 °C. Yield: 180 g, mp 151-155 °C.
- 10 In a corresponding manner the following indole derivatives were prepared: Methyl 5-chloro-3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **22b**, mp 184-186 °C.
Methyl 5-fluoro-3-(4-fluorophenyl)-1*H*-indole-2-carboxylate, **22c**, (oil).
Methyl 3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **22d**, mp 148-150 °C.
Methyl 3-(4-fluorophenyl)-5-trifluoromethyl-1*H*-indole-2-carboxylate **22e**, mp 136-139 °C.
- 15 Methyl 5-chloro-3-phenyl-1*H*-indole-2-carboxylate **22f**, (oil).

EXAMPLE 23

Methyl 6-chloro-3-(4-fluorophenyl)-1*H*-indole-2-carboxylate **23a**.

- 20 To a mixture of a 50 % sodium hydride suspension in mineral oil (52.5 g) (which was extracted with dry heptane) and dry tetrahydrofuran (250 ml) was added a solution of N-benzoyl 5-chloro-2-(4-fluorobenzoyl)-aniline (129 g) in dry tetrahydrofuran (500 ml) during 0.5 h at 20 °C (ice bath). After 1 h methyl 2-bromoacetate (101 ml) was added during 0.5 h at 20 °C (ice bath) and the mixture was stirred for another 1
- 25 hour. The solvents were evaporated *in vacuo*. The remaining oil was diluted with methanol (250 ml) and 5.4 M sodium methoxide in methanol (670 ml) was added carefully. After 1 h at room temperature the solvents were evaporated *in vacuo* and water (0.5 l) was added. The thus obtained mixture was extracted with ethyl acetate (2 x 0.75 l) and the combined organic phases were washed with brine and dried (Na₂SO₄). Evaporation of the solvents *in vacuo* afforded the title compound, which was purified by column chromatog-
- 30 raphy on silica gel (eluted with ethyl acetate/heptane 1:3) and crystallized from heptane. Yield: 33 g, mp 172-183 °C.

EXAMPLE 24

35 2,5-Dimethyl-3-(4-fluorophenyl)-1*H*-indole **24a**.

- A solution of 4-fluorophenylacetone (60 g), 4-tolylhydrazine, HCl (68.8 g) and triethylamine (165 ml) in ethanol (600 ml) was refluxed for 18 h. The reaction mixture was cooled to room temperature, the solvents were evaporated *in vacuo* and water (500 ml) was added to the remaining oil. The thus obtained mixture
- 40 was extracted with ethyl acetate (2 x 250 ml). The combined organic phases were washed with brine and dried (Na₂SO₄). Evaporation of the solvents afforded the crude 4-fluorophenylacetone tolylhydrazone (100 g) as an oil, which was used without further purification.

- The crude hydrazone (100 g), ethanol (700 ml) and conc. aqueous H₂SO₄ (40 ml) were refluxed for 18 h. After cooling to room temperature water (0.5 l) was added. The thus obtained mixture was extracted with
- 45 (2 x 700 ml) ethyl acetate and the combined organic phases were washed with brine, dried and the solvents were evaporated *in vacuo*. This afforded the title compound, which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:4) and crystallized from heptane. Yield: 75.5 g, mp:124-128 °C.

- In a corresponding manner the following indole derivative was prepared: 5-Chloro-3-phenyl-2-methyl-1*H*-
- 50 indole **24b**, (oil).

EXAMPLE 25

6-Chloro-3-(4-fluorophenyl)-1*H*-indazole **25a**.

- 55 To solution of 5-chloro-2-(4-fluorobenzoyl)aniline (5 g) in 6 M aqueous HCl (25 ml) was added a solution of NaNO₂ (2.5 g) in water (5 ml) at 0-5 °C under stirring during 15 min. After stirring for further 0.5 h at 0 °C a solution of SnCl₂ (20 g) in conc. aqueous HCl (25 ml) was added. The reaction mixture was allowed to

heat to room temperature and after 0.5 h the precipitate was filtered off and suspended in 2 N aqueous NaOH. The suspension was filtered and dichloromethane was added to the precipitate. The thus obtained solution was washed with brine and dried (MgSO₄). Evaporation of the solvents afforded the title compound (2.5 g) as an oil which was used without further purification.

- 5 In a corresponding manner the following indazole derivative was prepared: 3-(4-Fluorophenyl)-5-trifluoromethyl-1*H*-indazole **25b**, (oil)

EXAMPLE 26

- 10 2-Bromo-3-(4-fluorophenyl)-1-(4-piperidyl)-1*H*-indole **26a**.

A mixture of 2,2,2-trichloroethyl 4-[3-(4-fluorophenyl)-1*H*-indol-1-yl]piperidine-1-carboxylate **10b** (4.0 g), N-bromosuccinimide (1.5 g) and tetrachloromethane (60 ml) was refluxed for 2 h. The reaction mixture was cooled to room temperature and the precipitate was filtered off. Evaporation of the solvent afforded the crude 2,2,2-trichloroethyl 2-bromo-4-[3-(4-fluorophenyl)-1*H*-indol-1-yl]piperidine-1-carboxylate (4.4 g) as an oil which was used without further purification. A mixture of the crude 2-bromo-indole (4.4 g), zinc powder (4.4 g) and 90 % acetic acid in water (150 ml) was heated at 40 °C for 30 min. The reaction mixture was filtered and the solvent evaporated *in vacuo*. To the remaining oil was added ethyl acetate (50 ml) and the thus obtained solution was washed successively with water, 4 N aqueous NaOH and brine. Evaporation of the solvents afforded the title compound as an oil (2.9 g).

EXAMPLE 27

- 2-Chloro-3-(4-fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **27a**.

A mixture of 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole **4h** (3.0 g), dimethylsulphoxide (0.51 g) and conc. aqueous HCl (1 ml) was heated to 60 °C for 0.5 h under stirring. The reaction mixture was cooled to room temperature and water was added. The solution was extracted with ethyl acetate (2 x 50 ml). The combined organic phases were washed with 4 N aqueous NaOH and brine. Evaporation of the solvent gave an oil which was purified by column chromatography on silica gel (eluted with ethyl acetate/heptane 1:3). This afforded the title compound which crystallized from diethyl ether. Yield 0.4 g, mp 127-130 °C.

35 PHARMACOLOGICAL TESTS

The compounds of the invention were tested in well recognized and reliable methods. The tests were as follows and the results are given in the following Table 1. The well known 5HT₂ antagonists ritanserin and ICI 169369 were included in the tests for comparison purposes.

40 INHIBITION OF ³H-KETANSERIN BINDING TO SEROTONIN S₂

(5-HT₂) RECEPTORS IN RAT CORTEX *IN VITRO*

- 45 By this method the inhibition by drugs of the binding of ³H-Ketanserin (0,5 nM) to Serotonin S₂ (5-HT₂) receptors in membranes from rat is determined *in vitro*. Method in Hyttel, *Pharmacology & Toxicology*, **61**, 126-129, 1987.

Procedure

- 50 Male Wistar (Mol:Wist) rats (125-250 g) are sacrificed and cortical tissue is dissected and weighed. The tissue is homogenized (Ultra Turrax, 10 sec.) in 10 ml of ice-cold 50 mM tris buffer pH 7.7 (at 25 °C). The centrifuge glassware used in this step has been rinsed by sonication for 10 min. in thanol. The homogenate is centrifuged twice at 20,000 g for 10 min. at 4 °C with rehomogenization of the pellet in 10 ml ice-cold buffer. The final pellet is homogenized in 500 vol (w/v) ice-cold buffer.

Incubation tubes kept on ice in triplicate receive 100 µl of drug solution in water (or water for total binding) and 2000 µl of tissue suspension (final tissue content corresponds to 4 mg original tissue). The binding experiment is initiated by addition of 100 µl of ³H-Ketanserin (final concentration 0.5 nM) and by

placing the tubes in a 37 °C water bath. After incubation for 30 min. the samples are filtered under vacuum (0-50 mBar) through Whatman GF/F filters (25 mm). The tubes are rinsed with 5 ml ice-cold buffer which are then poured on the filters. Thereafter, the filters are washed with 2 x 5 ml of buffer. The filters are placed in counting vials and 4 ml of appropriate scintillation fluid (e.g. Picofluor TM 15) are added. After shaking for 1 h and storage 2 hrs in the dark the content of radioactivity is determined by liquid scintillation counting. Specific binding is obtained by subtracting the nonspecific binding in the presence of 1 μM mianserin.

For determination of the inhibition of binding five concentrations of drugs covering 3 decades are used.

The measured cpm are plotted against drug concentration on semilogarithmic paper and the best fitting S-shaped curve is drawn. The IC₅₀ value is determined as the concentration at which the binding is 50% of the total binding in control samples minus the nonspecific binding in the presence of 1 μM mianserin.

³H-Ketanserin = [ethylene-³H]-ketanserin hydrochloride from New England Nuclear, specific activity 60-80 Ci/mmol).

15 INHIBITION OF ³H-SPIPERONE BINDING TO DOPAMINE D-2 RECEPTORS IN RAT CORPUS STRIATUM *IN VITRO*

By this method the inhibition by drugs of the binding of ³H-spiroperone (= ³H-spiroperidol) (0.5 nM) to dopamine D-2 receptors in membranes from rat corpus striatum is determined *in vitro*. Method and results in Hyttel & Larsen, J. *Neurochem*, **44**, 1615-1622, 1985).

Procedure

Male Wistar (Mol:Wistar) rats (125-250 g) are sacrificed and striatal tissue is dissected and weighed. The tissue is homogenized (Ultra Turrax, 10 sec.) in 10 ml of ice-cold 50 mM K-phosphate buffer pH 7.4 (at 25 °C). The homogenate is centrifuged twice at 20,000 g for 10 min. at 4 °C with rehomogenization of the pellet in 10 ml ice-cold buffer. The final pellet is homogenized in 1300 vol (w/v) ice-cold buffer.

Incubation tubes kept on ice in triplicate receive 100 μl of drug solution in water (or water for total binding) and 4000 μl of tissue suspension (final tissue content corresponds to 3.08 mg original tissue). The binding experimental is initiated by addition of 100 μl of ³H-spiroperone (final concentration 0.5 nM) and by placing the tubes in a 37 °C water bath. After incubation for 10 min. the samples are filtered under vacuum (0-50 mBar) through Whatman GF/F filters (25 mm). The tubes are rinsed with 5 ml ice-cold buffer which are then poured on the filters. Thereafter, the filters are washed with 2 x 5 ml of buffer. The filters are placed in counting vials and 4 ml of appropriate scintillation fluid (e.g. Picofluor TM 15) are added. After shaking for 1 h and storage 2 hrs in the dark the content of radioactivity is determined by liquid scintillation counting. Specific binding is obtained by subtracting the nonspecific binding in the presence of 10 μM of 6,7-ADTN.

For determination of the inhibition of binding five concentrations of drugs covering 3 decades are used.

The measured cpm are plotted against drug concentration on semilogarithmic paper and the best fitting S-shaped curve is drawn. The IC₅₀ value is determined as the concentration at which the binding is 50% of the total binding in control samples minus the nonspecific binding in the presence of 10 μM of 6,7-ADTN. ³H-Spiroperone = [phenyl-4-³H]-spiroperone from Amersham international plc. England, specific activity 15-25 Ci/mmol.

TABEL 1

| Compound | ³ H-Ketanserin Binding IC ₅₀ nM | ³ H-Spiroperidol Binding IC ₅₀ nM |
|----------|--|--|
| 4a | 1.5 | 46 |
| 4b | 1.9 | 37 |
| 4c | 3.7 | 42 |
| 4d | 5.7 | 410 |
| 4e | 5.4 | 570 |
| 4f | 1.4 | 550 |
| 4g | 1.6 | 920 |
| 4h | 2.7 | 1100 |
| 4i | 1.4 | 680 |
| 4j | 4.5 | 1200 |
| 4k | 3.1 | 120 |
| 4l | 3.3 | 74 |
| 4m | 3.2 | 250 |
| 4n | 3.1 | 190 |
| 4o | 37 | 790 |
| 4p | 29 | 2800 |
| 4q | 25 | 3000 |
| 4r | 3.4 | 230 |
| 4s | 12 | 330 |
| 4t | 38 | 1900 |
| 4u | 220 | 42000 |
| 4v | 11 | >1000 |
| 4x | 11 | 650 |
| 6a | 2.8 | 6300 |
| 6b | 3.8 | 710 |
| 6c | 1.4 | 320 |
| 6d | 4.4 | 32 |
| 6e | 9.4 | 1000 |
| 6f | 3.6 | 440 |
| 7a | 3.4 | 6900 |

TABEL 1 (continued)

| Compound | ³ H-Ketanserin Binding IC ₅₀ nM | ³ H-Spiroperidol Binding IC ₅₀ nM |
|------------|--|--|
| 7b | 6.2 | >1000 |
| 7c | 7.8 | 5300 |
| 9a | 5.3 | 2600 |
| 9b | 17 | 2900 |
| 11a | 4.5 | 540 |
| 13a | 3.7 | 250 |
| 13b | 2.3 | 260 |
| 15a | 1.8 | >1000 |
| 16a | 22 | 1500 |
| 18b | 4.3 | 1100 |
| 20a | 13 | 3900 |
| 21a | 18 | 890 |
| 27a | 10 | 3200 |
| Ritanserin | 0.4 | 12 |
| ICI 169369 | 15.0 | 490 |

It is seen from the table that the derivatives of the present invention which have been tested are all selective 5-HT₂ ligands, the affinity for the 5-HT₂ receptor as shown in the ³H-ketanserin binding test being very high as compared to the affinity for the dopamine D-2 receptor as measured in the ³H-spiroperidol binding test. As compared to the known standard 5-HT₂ antagonists ritanserin and ICI 169369 the compounds of the invention are in general found to be more selective.

Additionally the compounds of the invention were tested in the following well known and reliable *in vivo* tests :

QUIPAZINE INHIBITION

Quipazine is a 5-HT₂ agonist, which induces head twitches in rats. The test is a test for 5-HT₂-antagonistic effect testing the ability to inhibit head twitches. The method and test results for some reference substances are published by Arnt et al. (*Drug Development Research*, **16**, 59-70, 1989).

ANTAGONISM OF PERGOLIDE-INDUCED CIRCLING BEHAVIOUR IN RATS WITH UNILATERAL 6-OHDA LESIONS

Dopamine D-2 agonists induce contralateral circling behaviour in rats with 6-OHDA lesions. Pergolide-induced circling is antagonized by dopamine D-2 antagonists. (Arnt, J. and J. Hyttel, *Eur. J. Pharmacol.* **102**, 349-354, 1984; Arnt, J. and J. Hyttel, *J. Neural. Transm.* **67**, 225-240, 1986). The test is an extremely sensitive test for dopamine D-2 antagonism *in vivo*.

These *in vivo* tests showed that the compounds of the invention are strong and selective 5-HT₂ antagonists with long duration of action *in vivo* (Quipazine test) and that they are substantially without

dopamine D-2 antagonistic activity *in vivo* as shown in the test for antagonism of pergolide induced circling.

Accordingly, the compounds of the present invention are selective 5-HT₂ antagonist *in vivo* and *in vitro* thus being useful in the treatment of anxiety, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, and Parkinson's Disease without neurological side effects as known from the classical neuroleptics.

FORMULATION EXAMPLES

The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.

For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.

Typical examples of recipes for the formulation of the invention are as follows:

1) Tablets containing 5 milligrams of Compound 4c calculated as the free base:

| | |
|--------------------|--------|
| Comp. 4c | 5 mg |
| Lactose | 18 mg |
| Potato starch | 27 mg |
| Sucrose | 58 mg |
| Sorbitol | 3 mg |
| Talcum | 5 mg |
| Gelatine | 2 mg |
| Povidone | 1 mg |
| Magnesium stearate | 0.5 mg |

2) Tablets containing 50 milligrams of Compound 4b calculated as the free base:

| | |
|--------------------|--------|
| Comp. 4b | 50 mg |
| Lactose | 16 mg |
| Potato starch | 45 mg |
| Sucrose | 106 mg |
| Sorbitol | 6 mg |
| Talcum | 9 mg |
| Gelatine | 4 mg |
| Povidone | 3 mg |
| Magnesium stearate | 0.6 mg |

3) Syrup containing per milliliter:

5

10

| | |
|----------------|----------|
| Comp. 4h | 10 mg |
| Sorbitol | 500 mg |
| Tragacanth | 7 mg |
| Glycerol | 50 mg |
| Methyl-paraben | 1 mg |
| Propyl-paraben | 0.1 mg |
| Ethanol | 0.005 ml |
| Water | ad 1 ml |

15 4) Solution for injection containing per milliliter:

20

| | |
|---------------|---------|
| Comp. 4c | 50 mg |
| Acetic acid | 17.9 mg |
| Sterile water | ad 1 ml |

25 5) Solution for injection containing per milliliter:

25

30

| | |
|------------------|---------|
| Comp. 4h | 10 mg |
| Sorbitol | 42.9 mg |
| Acetic acid | 0.63 mg |
| Sodium hydroxide | 22 mg |
| Sterile water | ad 1 ml |

35 Claims


Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. An 3-arylindole or 3-arylindazole derivative having formula :

40

45

50



55 wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, hydroxy, trifluoromethyl, and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R¹-R⁴ are independently selected from hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulphonyl, cyano, trifluoromethyl, or trifluoromethylthio;


the dotted line emanating from X in the ring system designates an optional bond; when said dotted line indicates a bond, X is nitrogen or a group CR⁶ wherein R⁶ is hydrogen, halogen, trifluoromethyl or C₁-C₄ alkyl;

when the dotted line indicates no bond, X is CH₂ ;

the dotted line, emanating from the Y, indicates an optional bond;


when it does not indicate a bond Y is N or CH; and when it indicates a bond Y is C; R⁵ is hydrogen or C₁-C₄ alkyl, optionally substituted with one or two hydroxy groups, or R⁵ is a group taken from structures 1a and 1b :

10



15

or



1b.

wherein n is an integer from 2 - 6;

W is oxygen, or sulphur;

U is nitrogen or CH;

Z is -(CH₂)_m, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH₂- or -CSCH₂-;

V is oxygen, CH₂, or NR⁷, wherein R⁷ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups;

U¹ is a group NR⁸, wherein R⁸ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups; and


V¹ is NR⁹R¹⁰, where each of R⁹ and R¹⁰ may be independently selected among the R⁸-substituents; provided that R⁵ may not be methyl when R¹-R⁴ each are hydrogen, X and Y are CH, and Ar is phenyl; and pharmaceutically acceptable acid addition salts and prodrugs thereof.

30


2. A derivative according to claim 1, **characterized in** that Ar is phenyl optionally substituted with halogen, preferably 4-fluorophenyl.

3. A derivative according to any of claims 1 or 2 **characterized in** that R⁵ is a group of the formula

40



or



45

where R⁷, R⁸, R⁹ and R¹⁰ independently are selected from hydrogen, C₁-C₄ alkyl and C₂-C₄ alkenyl.

4. A derivative according to any of the previous claims, **characterized in** that X is CR⁶.


5. A derivative according to claim 4, **characterized in** that R² and/or R⁶ are other than hydrogen.

6. A derivative according to any of the previous claims, **characterized in** that R² is selected from halogen, -CH₃, and -CF₃ and/or R³ is selected from hydrogen, halogen, -CH₃, and -CF₃.


7. A derivative according to claim 1, **characterized in** that it is: 5-Chloro-3-(4-fluorophenyl)-1-[1-[2-(3-methylimidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole, 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole, 3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole,

2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-1*H*-indole,
 2,5-Dimethyl-3-(4-fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1*H*-indole,
 2,5-Dimethyl-3-(4-fluorophenyl)-1-(1-methyl-4-piperidyl)-1*H*-indole, or 1-[1-[2-(1,3-Dimethyl-1-ureido)-ethyl]-4-piperidyl]-3-(4-fluorophenyl)-5-methyl-1*H*-indole.


8. A pharmaceutical preparation **characterized in** that it comprises a compound of any of the claims 1 - 7 or a pharmaceutically acceptable salt or a prodrug thereof as an active ingredient together with a pharmaceutically acceptable carrier or diluent.
9. Use of a derivative of any of claims 1 - 7 or a pharmaceutically acceptable salt or a prodrug thereof for the manufacture of a medicament for the therapeutical treatment of anxiety, aggression, negative symptoms of schizophrenia, depression, migraine, sleep disturbances, drug-induced Parkinsonism or Parkinsons disease.
10. A method for the preparation of a derivative of claim 1 comprising
 - a) reacting a compound of the following formula:



wherein R¹, R², R³, R⁴, X, Y, Ar and the dotted lines are as defined above, with a C₁-C₄ alkyl halide, alkyl mesylate or tosylate, with an epoxide of the formula




wherein R' is hydrogen, methyl or ethyl or with a halide of the general formula




wherein n, W, U, V, Z, V' and U' are as defined above;

b) reacting a compound of following formula:




wherein R¹, R², R³, R⁴, R⁶, Ar and the dotted line are as defined above, with a compound of the general formula




in which R⁵ is as defined above and hal is halogen;

c) reducing the indole ring of a compound of the general formula



35


wherein R¹-R⁵, Ar, Y and the dotted line are as defined above, to a dihydroindole ring;
d) reducing the double bond in the tetrahydropyridyl ring in a compound of the formula:



wherein R¹ - R⁵, X, Ar and the dotted line are as defined above;

55


e) reducing the pyridinium ring in a compound of following formula:



15 wherein R¹ - R⁵, X, Ar and the dotted line are as defined above except that R⁵ may not be hydrogen, and hal is halogen, to a tetrahydropyridine ring;

f) reducing the pyridinium ring in a compound of the above Formula VIII or the pyridyl ring of a compound of formula XIV to a piperidine ring;


g) reducing the carbonyl group of a compound of the following formula :



35


40 wherein R¹ - R⁴, X, Y, Ar and the dotted lines are as previously defined and R¹⁶ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkoxy;

h) acylating an aminoalkyl derivative of the following formula :




wherein $R^1 - R^4$, X, Y, Ar, R^8 , n and the dotted lines are as defined above, with an acylating agent such as a carboxylic acid halogenide, anhydride or mixed anhydride, or a carbamyl or thiocarbamyl chloride, an isocyanate, isothiocyanate, or a substituted chloroformate;

i) ringclosure reaction of an intermediate ethylene or propylene diamine derivative of the following formula :



wherein $R^1 - R^4$, R^8 , n, X, Y, Ar and the dotted lines are as defined above and m is 2 or 3, with phosgene, thiophosgene or carbondisulphide to form a substituent of the structure **1a** ; or
j) reducing a carboxylic acid or carboxylic acid derivative of the following formula :



wherein $R^1 - R^4$, X, Y, Ar and the dotted lines are as previously defined, R^{17} is hydrogen or lower alkyl and p is 1, 2 or 3 ;

and then, if desired:


acylating a compound prepared in one of the methods (a) to (j) having the formula I in which R^5 is a structure **1a** or **1b** wherein V is NH, or V^1 is NHR^{10} or U^1 is NH with an acylating agent, or esterifying an available hydroxy group in a compound of formula I in order to obtain a prodrug;

converting a compound prepared in one of methods (a) to (j) in a pharmaceutically acceptable acid addition salt thereof; or

resolving an optically active compound of formula I prepared in one of methods (a) to (j) in optically active isomers thereof.

Claim for the following Contracting States : ES, GR

1. A method for the preparation of an 3-arylindole or 3-arylindazole derivative having formula :



wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, hydroxy, trifluoromethyl, and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;


R¹-R⁴ are independently selected from hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulphonyl, cyano, trifluoromethyl, or trifluoromethylthio;

the dotted line emanating from X in the ring system designates an optional bond; when said dotted line indicates a bond, X is nitrogen or a group CR⁶ wherein R⁶ is hydrogen, halogen, trifluoromethyl or C₁-C₄ alkyl;


when the dotted line indicates no bond, X is CH₂ ;

the dotted line, emanating from the Y, indicates an optional bond;

when it does not indicate a bond Y is N or CH; and when it indicates a bond Y is C; R⁵ is hydrogen or C₁-C₄ alkyl, optionally substituted with one or two hydroxy groups, or R⁵ is a group taken from structures 1a and 1b :



1a.



1b.

wherein n is an integer from 2 - 6;

W is oxygen, or sulphur;

U is nitrogen or CH ;


Z is -(CH₂)_m-, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH₂- or -CSCH₂-;

V is oxygen, CH₂, or NR⁷, wherein R⁷ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups;


U¹ is a group NR⁸, wherein R⁸ is hydrogen or C₁-C₄ alkyl or C₂-C₄ alkenyl, C₃-C₈ cycloalkyl or C₃-C₈ cycloalkyl(C₁-C₄)alkyl optionally substituted with one or two hydroxy groups; and

V¹ is NR⁹R¹⁰, where each of R⁹ and R¹⁰ may be independently selected among the R⁸-substituents; provided that R⁵ may not be methyl when R¹-R⁴ each are hydrogen, X and Y are CH, and Ar is phenyl; or a pharmaceutically acceptable acid addition salt or prodrug thereof comprising


a) reacting a compound of the following formula:




wherein R¹, R², R³, R⁴, X, Y, Ar and the dotted lines are as defined above, with a C₁-C₄ alkyl halide, alkyl mesylate or tosylate, with an epoxide of the formula



wherein R' is hydrogen, methyl or ethyl or with a halide of the general formula




or




wherein n, W, U, V, Z, V¹ and U¹ are as defined above;

b) reacting a compound of following formula:




wherein R¹, R², R³, R⁴, R⁵, Ar and the dotted line are as defined above, with a compound of the general formula




in which R⁵ is as defined above and hal is halogen;


c) reducing the indole ring of a compound of the general formula



wherein R¹-R⁵, Ar, Y and the dotted line are as defined above, to a dihydroindole ring;
d) reducing the double bond in the tetrahydropyridyl ring in a compound of the formula:




wherein R¹ - R⁵, X, Ar and the dotted line are as defined above;
e) reducing the pyridinium ring in a compound of following formula:




wherein R¹ - R⁵, X, Ar and the dotted line are as defined above except that R⁵ may not be hydrogen, and hal is halogen, to a tetrahydropyridine ring;
f) reducing the pyridinium ring in a compound of the above Formula VIII or the pyridyl ring of a compound of formula XIV to a piperidine ring;

g) reducing the carbonyl group of a compound of the following formula :



20 wherein R¹ - R⁴, X, Y, Ar and the dotted lines are as previously defined and R¹⁶ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkoxy;

h) acylating an aminoalkyl derivative of the following formula :




40 wherein R¹ - R⁴, X, Y, Ar, R⁸, n and the dotted lines are as defined above, with an acylating agent such as a carboxylic acid halogenide, anhydride or mixed anhydride, or a carbamyl or thiocarbamyl chloride, an isocyanate, isothiocyanate, or a substituted chloroformate;

i) ringclosure reaction of an intermediate ethylene or propylene diamine derivative of the following formula :

45


50

55



wherein $R^1 - R^4$, R^8 , n , X , Y , Ar and the dotted lines are as defined above and m is 2 or 3, with phosgene, thiophosgene or carbondisulphide to form a substituent of the structure **1a**; or
 j) reducing a carboxylic acid or carboxylic acid derivative of the following formula :

20



wherein $R^1 - R^4$, X , Y , Ar and the dotted lines are as previously defined, R^{17} is hydrogen or C_1-C_4 alkyl and p is 1, 2 or 3 ;
 and then, if desired:

40

acylating a compound prepared in one of the methods (a) to (j) having the formula I in which R^5 is a structure **1a** or **1b** wherein V is NH , or V^1 is NHR^{10} or U^1 is NH with an acylating agent, or esterifying an available hydroxy group in a compound of formula I in order to obtain a prodrug;
 converting a compound prepared in one of methods (a) to (j) in a pharmaceutically acceptable acid addition salt thereof; or
 resolving an optically active compound of formula I prepared in one of methods (a) to (j) in optically active isomers thereof.

45


50

55

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Ein Arylindol oder 3-Arylindazolderivat mit folgender Formel:




worin Ar eine Phenylgruppe ist, gegebenenfalls substituiert mit einem oder mehreren Substituenten ausgewählt aus Halogen, Hydroxy, Trifluormethyl und Cyan, oder Ar ist 2-Thienyl, 3-Thienyl, 2-Furyl, 3-Furyl, 2-Pyridyl, 3-Pyridyl, oder 4-Pyridyl.

R¹-R⁴ sind unabhängig ausgewählt aus Wasserstoff, Halogen, C₁-C₄ Alkyl, C₁-C₄ Alkoxy, C₁-C₄ Alkylthio, C₁-C₄ Alkylsulphonyl, Cyan, Trifluormethyl, oder Trifluormethylthio;


die von X ausgehende gestrichelte Linie im Ringsystem deutet gegebenenfalls eine Bindung an; wenn die besagte gestrichelte Linie eine Bindung bezeichnet, dann ist X Stickstoff oder eine Gruppe CR⁶, worin R⁶ Wasserstoff, Halogen, Trifluormethyl oder C₁-C₄ Alkyl ist; wenn die gestrichelte Linie keine Bindung ist, dann ist X gleich CH₂;

die von Y ausgehende gestrichelte Linie, bedeutet gegebenenfalls eine Bindung; wenn sie keine Bindung anzeigt ist Y gleich N oder CH; wenn sie eine Bindung anzeigt, ist Y gleich C;

R⁵ ist Wasserstoff oder C₁-C₄ Alkyl, gegebenenfalls substituiert mit einer oder zwei Hydroxygruppen, oder R⁵ wird aus den Strukturen 1a und 1b genommen.



oder



1a.

1b.

worin n eine ganze Zahl von 2-6 ist;

W ist Sauerstoff, oder Schwefel;

U ist Stickstoff oder CH;

Z ist -(CH₂)_m-, wobei m 2 oder 3 ist, oder Z ist ein 1,2-Phenylen wahlweise substituiert mit Halogen oder Trifluormethyl, oder Z ist -CH=CH-, -COCH₂- oder -CSCH₂-;

V ist Sauerstoff, CH₂, oder NR⁷, worin R⁷ Wasserstoff ist oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert;

U¹ ist eine Gruppe NR⁸, worin R⁸ ein Wasserstoff ist, oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert; und


V¹ ist NR⁹R¹⁰, wo jede der R⁹ und R¹⁰ Gruppen unabhängig voneinander aus den R⁸-Substituenten ausgewählt werden können;

vorrausgesetzt daß, wenn R¹-R⁴ jeweils Wasserstoff sind, X und Y gleich CH sind, und Ar eine


Phenylgruppe ist, R⁵ nicht Methyl sein kann;

und pharmazeutisch annehmbare Säureadditionssalze und Medikamentenvorstufen derselben.

2. Derivat gemäß Anspruch 1, dadurch gekennzeichnet, daß Ar Phenyl ist, gegebenenfalls mit Halogen substituiert, vorzugsweise 4-Fluorphenyl.
3. Derivat gemäß irgendeiner der Ansprüche 1 oder 2 dadurch gekennzeichnet, daß R⁵ eine Gruppe der folgenden Formel ist



oder



worin R⁷, R⁸, R⁹ und R¹⁰ unabhängig aus Wasserstoff, C₁-C₄ Alkyl oder C₂-C₄ Alkenyl ausgewählt sind.

4. Derivat gemäß irgendeinem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß X gleich CR⁶ ist.

5. Derivat gemäß Anspruch 4, dadurch gekennzeichnet, daß R² und/oder R⁶ etwas anderes als Wasserstoff sind.

6. Derivat gemäß einem beliebigen der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß R² aus Halogen, -CH₃, und -CF₃ ausgewählt ist und/oder R³ ist ausgewählt aus Halogen, -CH₃, und -CF₃.


7. Derivat gemäß Anspruch 1, dadurch gekennzeichnet, daß dieses ist:
- 5-Chlor-3-(4-fluorphenyl)-1-[1-[2-(3-methyl-imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1H-indol,
 3-(4-Fluorphenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1H-indol,
 3-(4-Fluorphenyl)-5-methyl-1-[1-[2-(3-(2-propyl)imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1H-indol,
 2,5-Dimethyl-3-(4-fluorphenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4yl]-1H-indol,
 2,5-Dimethyl-3-(4-fluorphenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-1H-indol,
 2,5-Dimethyl-3-(4-fluorphenyl)-1-(1-methyl-4-piperidyl)-1H-indol, oder
 1[1-[2-(1,3-Dimethyl-1-ureid)ethyl]-4-piperidyl]-3-(4-fluorphenyl)-5-methyl-1H-indol.

8. Pharmazeutische Zubereitung dadurch gekennzeichnet, daß sie eine Verbindung gemäß irgendeiner der Ansprüche 1-7, oder ein pharmazeutisch annehmbares Salz oder eine Medikamentenvorstufe derselben als aktiver Bestandteil umfasst, zusammen mit einem pharmazeutisch annehmbaren Träger oder Verdünnungsmittel.

9. Verwendung eines Derivates gemäß irgendeinem der Ansprüche 1-7 oder eines pharmazeutisch annehmbaren Salzes oder eine Medikamentenvorstufe derselben, zur Herstellung eines Medikaments für die therapeutische Behandlung von Angstzuständen, Aggressivität, negativen Symptomen von Schizophrenie, Depression, Migräne, Schlafstörungen, Pharmainduzierter Parkinsonismus oder Parkinsonscher Krankheit.

10. Verfahren zur Herstellung eines Derivates gemäß Anspruch 1, umfassend


a) zur Reaktion bringen einer Verbindung folgender Formel:




20 worin R¹, R², R³, R⁴, X, Y, Ar und die gestrichelten Linien wie oben definiert sind, mit einem C₁-C₄ Alkylhalogenid, Alkylmesylat oder Tosylat, mit einem Epoxid der Formel




30 worin R' Wasserstoff, Methyl oder Ethyl oder ein Halogenid der allgemeinen Formel



40 ist, worin n, W, U, V, Z, V¹, und U¹ wie oben definiert sind;
b) zur Reaktion bringen einer Verbindung folgender Formel:




55 worin R¹, R², R³, R⁴, R⁶, Ar und die gestrichelten Linien wie oben definiert sind, mit einer Verbindung der allgemeinen Formel




in der R⁵ wie oben definiert ist und hal ist Halogen;

c) Reduzieren des Indolrings einer Verbindung der allgemeinen Formel




worin R¹-R⁵, Ar, Y und die gestrichelten Linien wie oben definiert sind, zu einem Dihydroindolring;

d) Reduzieren der Doppelbindung im Tetrahydropyridylring in einer Verbindung der Formel:



worin R¹-R⁵, X, Ar und die gestrichelten Linien wie oben definiert sind,


e) Reduzieren des Pyridiniumrings in einer Verbindung der folgenden Formel:



worin R¹-R⁵, X, Ar und die gestrichelten Linien wie oben definiert sind, mit Ausnahme daß R⁵ nicht Wasserstoff sein kann, und hal ist Halogen, zum Tetrahydropyridinring;


f) Reduzieren des Pyridiniumrings in einer Verbindung der obigen Formel VIII oder der Pyridylring einer Verbindung der Formel XIV zu einem Piperidinring;

g) Reduzieren der Carbonylgruppe einer Verbindung der folgenden Formel:



20 worin R¹-R⁴, X, Y, Ar und die gestrichelten Linien wie vorher definiert sind und R¹⁶ ist Wasserstoff, C₁-C₄ Alkyl oder C₁-C₄ Alkoxy;

h) Acylieren eines Aminoalkylderivates der folgenden Formel:




40 worin R¹-R⁴, X, Y, Ar, R⁸, n und die gestrichelten Linien wie oben definiert sind, mit einem Acylierungsreagenz wie einem Carbonsäurehalogenid, Anhydrid oder einen gemischten Anhydrid, oder einem Harnstoff- oder Thioharnstoffchlorid, einem Isocyanat, Isothiocyanat, oder einem substituierten Chlorkohlensäureester.

45 i) Ringschlußreaktion eines intermediären Ethylen- oder Propylendiaminderivates der folgenden Formel:


50

55



worin R^1 - R^4 , R^8 , n , X , Y , Ar und die gestrichelten Linien wie oben definiert sind und m 2 oder 3 ist, mit Phosgen, Thiophosgen oder Kohlenstoffdisulfid zur Bildung eines Substituenten der Struktur **1a**; oder

j) Reduzieren einer Carbonsäure oder eines Carbonsäurederivates der folgenden Formel:



worin R^1 - R^4 , X , Y , Ar und die gestrichelten Linien wie oben definiert sind, R^{17} ist Wasserstoff oder ein niedriger Alkylrest und p ist 1, 2, oder 3;

und dann, wenn gewünscht:


Acylieren einer gemäß, einem der Verfahren (a) bis (j) hergestellten Verbindung der Formel I, in der R^5 einer Struktur **1a** oder **1b** entspricht, worin V gleich NH , oder V^1 gleich NHR^{10} ist, oder U^1 gleich NH ist, mit einem Acylierungsreagenz, oder Veresterung einer verfügbaren Hydroxygruppe in einer Verbindung der Formel I um eine Medikamentenvorstufe zu erhalten;

Umwandlung einer, nach Methoden (a) bis (j) hergestellten Verbindung, in ein pharmazeutisch annehmbares Säureadditionssalze derselben; oder

Auflösung einer optisch aktiven Verbindung der Formel I, hergestellt nach einer der Verfahren (a) bis (j) in optisch aktive Isomere derselben.

Patentanspruch für folgende Vertragsstaaten: ES, GR

1. Ein Verfahren zur Herstellung eines Arylindol- oder 3-Arylindazolderivates mit folgender Formel:




worin Ar eine Phenylgruppe ist, gegebenenfalls substituiert mit einem oder mehreren Substituenten ausgewählt aus Halogen, Hydroxy, Trifluormethyl und Cyan, oder Ar ist 2-Thienyl, 3-Thienyl, 2-Furyl, 3-Furyl, 2-Pyridyl, 3-Pyridyl, oder 4-Pyridyl.

R¹-R⁴ sind unabhängig ausgewählt aus Wasserstoff, Halogen, C₁-C₄ Alkyl, C₁-C₄ Alkoxy, C₁-C₄ Alkylthio, C₁-C₄ Alkylsulphonyl, Cyan, Trifluormethyl, oder Trifluormethylthio;


die von X ausgehende gestrichelte Linie im Ringsystem deutet gegebenenfalls eine Bindung an; wenn die besagte gestrichelte Linie eine Bindung bezeichnet, dann ist X Stickstoff oder eine Gruppe CR⁶, worin R⁶ Wasserstoff, Halogen, Trifluormethyl oder C₁-C₄ Alkyl ist; wenn die gestrichelte Linie keine Bindung ist, dann ist X gleich CH₂;

die von Y ausgehende gestrichelte Linie, bedeutet gegebenenfalls eine Bindung; wenn sie keine Bindung anzeigt ist Y gleich N oder CH; wenn sie eine Bindung anzeigt, ist Y gleich C;

R⁵ ist Wasserstoff oder C₁-C₄ Alkyl, gegebenenfalls substituiert mit einer oder zwei Hydroxygruppen, oder R⁵ wird aus den Strukturen 1a und 1b genommen.



1a.



1b.

worin n eine ganze Zahl von 2-6 ist;

W ist Sauerstoff, oder Schwefel;

U ist Stickstoff oder CH;

Z ist $-(CH_2)_m$, wobei m 2 oder 3 ist, oder Z ist ein 1,2-Phenylen wahlweise substituiert mit Halogen oder Trifluormethyl, oder Z ist $-CH=CH-$, $-COCH_2-$ oder $-CSCH_2-$;

V ist Sauerstoff, CH₂, oder NR⁷, worin R⁷ Wasserstoff ist oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert;

U¹ ist eine Gruppe NR⁸, worin R⁸ ein Wasserstoff ist, oder C₁-C₄ Alkyl oder C₂-C₄ Alkenyl, C₃-C₈ Cycloalkyl oder C₃-C₈ Cycloalkyl(C₁-C₄) Alkyl gegebenenfalls mit einer oder zwei Hydroxygruppen substituiert; und


V¹ ist NR⁹R¹⁰, wo jede der R⁹ und R¹⁰ Gruppen unabhängig voneinander aus den R⁸-Substituenten ausgewählt werden können;

vorausgesetzt daß, wenn R¹-R⁴ jeweils Wasserstoff sind, X und Y gleich CH sind, und Ar eine Phenylgruppe ist, R⁵ nicht Methyl sein kann;


oder ein pharmazeutisch annehmbares Säureadditionssalz oder Medikamentenvorstufe derselben,

umfassend:



a) zur Reaktion bringen einer Verbindung folgender Formel:




20 worin R¹, R², R³, R⁴, X, Y, Ar und die gestrichelten Linien wie oben definiert sind, mit einem C₁-C₄ Alkylhalogenid, Alkylmesylat oder Tosylat, mit einem Epoxid der Formel




worin R' Wasserstoff, Methyl oder Ethyl oder ein Halogenid der allgemeinen Formel



40 ist, worin n, W, U, V, Z, V¹, und U¹ wie oben definiert sind;
b) zur Reaktion bringen einer Verbindung folgender Formel:




50 worin R¹, R², R³, R⁴, R⁶, Ar und die gestrichelten Linien wie oben definiert sind, mit einer Verbindung der allgemeinen Formel




in der R⁵ wie oben definiert ist und hal ist Halogen;

c) Reduzieren des Indolrings einer Verbindung der allgemeinen Formel




worin R¹-R⁵, Ar, Y und die gestrichelten Linien wie oben definiert sind, zu einem Dihydroindolring;

d) Reduzieren der Doppelbindung im Tetrahydropyridylring in einer Verbindung der Formel:



worin R¹-R⁵, X, Ar und die gestrichelten Linien wie oben definiert sind;


e) Reduzieren des Pyridiniumrings in einer Verbindung der folgenden Formel:



worin R¹-R⁵, X, Ar und die gestrichelten Linien wie oben definiert sind, mit Ausnahme daß R⁵ nicht Wasserstoff sein kann, und hal ist Halogen, zum Tetrahydropyridinring;

f) Reduzieren des Pyridiniumrings in einer Verbindung der obigen Formel VIII oder der Pyridylring einer Verbindung der Formel XIV zu einem Piperidinring;


g) Reduzieren der Carbonylgruppe einer Verbindung der folgenden Formel:



20

worin R^1 - R^4 , X, Y, Ar und die gestrichelten Linien wie vorher definiert sind und R^{16} ist Wasserstoff, C_1 - C_4 Alkyl oder C_1 - C_4 Alkoxy;


h) Acylieren eines Aminoalkylderivates der folgenden Formel:



45


worin R^1 - R^4 , X, Y, Ar, R^8 , n und die gestrichelten Linien wie oben definiert sind, mit einem Acylierungsreagenz wie einem Carbonsäurehalogenid, Anhydrid oder einem gemischten Anhydrid, oder einem Harnstoff- oder Thioharnstoffchlorid, einem Isocyanat, Isothiocyanat, oder einem substituierten Chlorkohlensäureester.

i) Ringschlußreaktion eines intermediären Ethylen- oder Propylendiaminderivates der folgenden Formel:



worin R^1 - R^4 , R^5 , n , X , Y , Ar und die gestrichelten Linien wie oben definiert sind und m 2 oder 3 ist, mit Phosgen, Thiophosgen oder Kohlenstoffdisulfid zur Bildung eines Substituenten der Struktur **1a**; oder

j) Reduzieren einer Carbonsäure oder eines Carbonsäurederivates der folgenden Formel:



worin R^1 - R^4 , X , Y , Ar und die gestrichelten Linien wie oben definiert sind, R^{17} ist Wasserstoff oder ein niedriger Alkylrest und p ist 1, 2, oder 3;

und dann, wenn gewünscht:

Acylieren einer gemäß einem der Verfahren (a) bis (j) hergestellten Verbindung der Formel I, in der R^5 einer Struktur **1a** oder **1b** entspricht, worin V gleich NH , oder V^1 gleich NHR^{10} ist, oder U^1 gleich NH ist, mit einem Acylierungsreagenz, oder Veresterung einer verfügbaren Hydroxygruppe in einer Verbindung der Formel I um eine Medikamentenvorstufe zu erhalten;


Umwandlung einer, nach Methoden (a) bis (j) hergestellten Verbindung, in ein pharmazeutisch annehmbares Säureadditionssalze derselben; oder

Auflösung einer optisch aktiven Verbindung der Formel I, hergestellt nach einer der Verfahren (a) bis (j) in optisch aktive Isomere derselben.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Un dérivé de 3-arylindole ou de 3-arylindazole de formule :



dans laquelle Ar est un phényle facultativement substitué avec un ou plusieurs substituants choisis parmi un halogène, un hydroxy, un trifluorométhyle et un cyano, ou Ar est un 2-thiényle, un 3-thiényle, un 2-furyle, un 3-furyle, un 2-pyridyle, un 3-pyridyle ou un 4-pyridyle ;

R¹ à R⁴ sont indépendamment choisis parmi un hydrogène, un halogène, un alkyle en C₁-C₄, un alcoxy en C₁-C₄, un alkylthio en C₁-C₄, un alkylsulfonyl en C₁-C₄, un cyano, un trifluorométhyle ou un trifluorométhylthio ;


le pointillé partant de X dans le système cyclique indique une liaison facultative ; lorsque ledit pointillé indique une liaison, X est un azote ou un groupe CR⁶ dans lequel R⁶ est un hydrogène, un halogène, un trifluorométhyle ou un alkyle en C₁-C₄ ;

lorsque le pointillé n'indique pas de liaison, X est CH₂ ;


le pointillé partant de Y indique une liaison facultative ;

lorsqu'il n'indique pas une liaison, Y est N ou CH ; et lorsqu'il indique une liaison, Y est C ;

R⁵ est un hydrogène ou un alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ou R⁵ est un groupe choisi parmi les structures 1a et 1b :



1a.



1b.

où n est un entier de 2 à 6 ;

W est un oxygène ou un soufre ;

U est un azote ou CH ;

Z est -(CH₂)_m, m étant 2 ou 3, ou Z est un 1,2-phénylène facultativement substitué avec un halogène ou un trifluorométhyle, ou Z est -CH=CH-, -COCH₂- ou -CSCCH₂- ;

V est un oxygène, CH₂ ou NR⁷, où R⁷ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ;

U¹ est un groupe NR⁸ dans lequel R⁸ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ; et


V¹ est NR⁹R¹⁰ où chacun de R⁹ et de R¹⁰ peut être indépendamment choisi parmi les substituants R⁸ ; sous réserve que R⁵ ne puisse pas être un méthyle lorsque R¹ à R⁴ sont chacun un hydrogène, X et Y sont CH et Ar est un phényle ;

et les sels d'addition d'acides pharmaceutiquement acceptables et les précurseurs de médicament

correspondants.

2. Un dérivé selon la revendication 1, caractérisé en ce que Ar est un phényle facultativement substitué avec un halogène, de préférence un 4-fluorophényle.

3. Un dérivé selon l'une quelconque des revendications 1 ou 2, caractérisé en ce que R⁵ est un groupe de formule :



où R⁷, R⁸, R⁹ et R¹⁰ sont choisis indépendamment parmi un hydrogène, un alkyle en C₁-C₄ et un alcényle en C₂-C₄.

4. Un dérivé selon l'une quelconque des revendications précédentes, caractérisé en ce que X est CR⁶.

5. Un dérivé selon la revendication 4, caractérisé en ce que R² et/ou R⁶ sont autres qu'un hydrogène.

6. Un dérivé selon l'une quelconque des revendications précédentes, caractérisé en ce que R² est choisi parmi un halogène, -CH₃ et -CF₃ et/ou R³ est choisi parmi un hydrogène, un halogène, -CH₃ et -CF₃.

7. Un dérivé selon la revendication 1, caractérisé en ce qu'il est :

le 5-chloro-3-(4-fluorophényl)-1-[1-[2-(3-méthylimidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-1H-indole,

le 3-(4-fluorophényl)-1-[1-[2-(imidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-5-méthyl-1H-indole,

le 3-(4-fluorophényl)-5-méthyl-1-[1-[2-(3-(2-propyl)imidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-1H-indole,

le 2,5-diméthyl-3-(4-fluorophényl)-1-[1-[2-(imidazolidine-2-one-1-yl)éthyl]-1,2,3,6-tétrahydropyridine-4-yl]-1H-indole,

le 2,5-diméthyl-3-(4-fluorophényl)-1-[1-[2-(imidazolidine-2-one-1-yl)éthyl]-4-pipéridyl]-1H-indole,

le 2,5-diméthyl-3-(4-fluorophényl)-1-(1-méthyl-4-pipéridyl)-1H-indole ou


le 1-[1-[2-(1,3-diméthyl-1-uréido)éthyl]-4-pipéridyl]-3-(4-fluorophényl)-5-méthyl-1H-indole.

8. Une préparation pharmaceutique, caractérisée en ce qu'elle comprend un composé de l'une quelconque des revendications 1 à 7 ou un sel pharmaceutiquement acceptable ou un précurseur de médicament correspondants, en tant qu'ingrédient actif avec un véhicule ou diluant pharmaceutiquement acceptables.


9. Utilisation d'un dérivé de l'une quelconque des revendications 1 à 7 ou d'un sel pharmaceutiquement acceptable ou d'un précurseur de médicament correspondants pour la préparation d'un médicament pour le traitement thérapeutique de l'anxiété, de l'agression, des symptômes négatifs de la schizophrénie, de la dépression, de la migraine, des troubles du sommeil, du syndrome parkinsonien médicamenteux ou de la maladie de Parkinson.

10. Un procédé pour la préparation d'un dérivé de la revendication 1 comprenant :



a) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, X, Y, Ar et les pointillés sont tels que définis ci-dessus, avec un halogénure d'alkyle en C₁-C₄, un mésylate d'alkyle ou un tosylate, avec un époxyde de formule




dans laquelle R' est un hydrogène, un méthyle ou un éthyle, ou avec un halogénure de formule générale



où n, W, U, V, Z, V¹ et U¹ sont tels que définis ci-dessus ;
b) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, R⁶, Ar et le pointillé sont tels que définis ci-dessus, avec un composé de formule générale




dans laquelle R⁵ est t l que défini ci-dessus et hal est un halogène ;

c) la réduction du cycle indole d'un composé de formule générale




dans laquelle R¹ à R⁵, Ar, Y et le pointillé sont tels que définis ci-dessus, en un cycle dihydro-indole ;

d) la réduction de la double liaison du cycle tétrahydropyridyle d'un composé de formule :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus ;


e) la réduction du cycle pyridinium d'un composé de formule suivante :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus, si ce n'est que R⁵ ne peut pas être un hydrogène, et hal est un halogène, en cycle tétrahydropyridine ;

f) la réduction du cycle pyridinium d'un composé de formule VIII ci-dessus ou du cycle pyridyle d'un composé de formule XIV en un cycle pipéridine ;


g) la réduction du groupe carbonyle d'un composé de formule suivante :



20

dans laquelle R^1 à R^4 , X, Y, Ar et les pointillés sont tels que précédemment définis et R^{16} est un hydrogène, un alkyle en C_1 - C_4 ou un alcoxy en C_1 - C_4 ;

h) l'acylation d'un dérivé d'aminalkyle de formule suivante :



40


dans laquelle R^1 à R^4 , X, Y, Ar, R^8 , n et les pointillés sont tels que définis ci-dessus, avec un agent d'acylation tel qu'un halogénure, un anhydride ou un anhydride mixte d'acide carboxylique, ou un chlorure de carbamyle ou de thiocarbamyle, un isocyanate, un isothiocyanate ou un chloroformiate substitué ;

45

i) la réaction de cyclisation d'un dérivé intermédiaire d'éthylène-ou de propylène-diamine de formule suivante :


50

55



20 dans laquelle R¹ à R⁴, R⁸, n, X, Y, Ar et les pointillés sont tels que définis ci-dessus et m est 2 ou 3, avec le phosgène, le thiophosgène ou le disulfure de carbone, pour former un substituant de structure 1a ; ou

j) la réduction d'un acide carboxylique ou d'un dérivé d'acide carboxylique de formule suivante :




40 dans laquelle R¹ à R⁴, X, Y, Ar et les pointillés sont tels que précédemment définis, R¹⁷ est un hydrogène ou un alkyle inférieur et p est 1, 2 ou 3 ;

puis, si on le désire :

45 l'acylation d'un composé préparé dans l'un des procédés (a) à (j) répondant à la formule I dans laquelle R⁵ est une structure 1a ou 1b lorsque V est NH, ou V¹ est NHR¹⁰, ou U¹ est NH, avec un agent d'acylation, ou l'estérification d'un groupe hydroxy disponible dans un composé de formule I pour obtenir un précurseur de médicament ; la conversion d'un composé préparé selon l'un des procédés (a) à (j) en un sel d'addition d'acide pharmaceutiquement acceptable correspondant ; ou le dédoublement d'un composé optiquement actif de formule I, préparé selon l'un des procédés (a) à (j), en ses isomères optiquement actifs.

Revendication pour les Etats contractants suivants : ES, GR

1. Un procédé pour la préparation d'un dérivé de 3-arylindole ou de 3-arylindazole de formule :



dans laquelle Ar est un phényle facultativement substitué avec un ou plusieurs substituants choisis parmi un halogène, un hydroxy, un trifluorométhyle et un cyano, ou Ar est un 2-thiényle, un 3-thiényle, un 2-furyle, un 3-furyle, un 2-pyridyle, un 3-pyridyle ou un 4-pyridyle ;

R¹ à R⁴ sont indépendamment choisis parmi un hydrogène, un halogène, un alkyle en C₁-C₄, un alcoxy en C₁-C₄, un alkylthio en C₁-C₄, un alkylsulfonyl en C₁-C₄, un cyano, un trifluorométhyle ou un trifluorométhylthio ;


le pointillé partant de X dans le système cyclique indique une liaison facultative ; lorsque ledit pointillé indique une liaison, X est un azote ou un groupe CR⁶ dans lequel R⁶ est un hydrogène, un halogène, un trifluorométhyle ou un alkyle en C₁-C₄ ;

lorsque le pointillé n'indique pas de liaison, X est CH₂ ;

le pointillé partant de Y indique une liaison facultative ;


lorsqu'il n'indique pas une liaison, Y est N ou CH ; et lorsqu'il indique une liaison, Y est C ;

R⁵ est un hydrogène ou un alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ou R⁵ est un groupe choisi parmi les structures 1a et 1b :



1a.

ou



1b.

où n est un entier de 2 à 6 ;

W est un oxygène ou un soufre ;

U est un azote ou CH ;

Z est -(CH₂)_m, m étant 2 ou 3, ou Z est un 1,2-phénylène

facultativement substitué avec un halogène ou un trifluorométhyle, ou Z est -CH=CH-, -COCH₂- ou -CSCH₂- ;


V est un oxygène, CH₂ ou NR⁷, où R⁷ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ;

U¹ est un groupe NR⁸ dans lequel R⁸ est un hydrogène ou un alkyle en C₁-C₄ ou un alcényle en C₂-C₄, un cycloalkyle en C₃-C₈ ou un (cycloalkyl en C₃-C₈)alkyle en C₁-C₄ facultativement substitué avec un ou deux groupes hydroxy ; et

V¹ est NR⁹R¹⁰ où chacun de R⁹ et de R¹⁰ peut être indépendamment choisi parmi les substituants R⁸ ; sous réserve que R⁵ ne puisse pas être un méthyle lorsque R¹ à R⁴ sont chacun un hydrogène, X et Y sont CH et Ar est un phényle ;

ou d'un sel d'addition d'acide pharmaceutiquement acceptable ou d'un précurseur de médicament correspondants, comprenant


a) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, X, Y, Ar et les pointillés sont tels que définis ci-dessus, avec un halogénure d'alkyle en C₁-C₄, un mésylate d'alkyle ou un tosylate, avec un époxyde de formule



dans laquelle R' est un hydrogène, un méthyle ou un éthyle, ou avec un halogénure de formule générale



35 où n, W, U, V, Z, V¹ et U¹ sont tels que définis ci-dessus ;
b) la réaction d'un composé de formule suivante :




dans laquelle R¹, R², R³, R⁴, R⁶, Ar et le pointillé sont tels que définis ci-dessus, avec un composé de formule générale




dans laquelle R⁵ est tel que défini ci-dessus et hal est un halogène ;

c) la réduction du cycle indole d'un composé de formule générale




dans laquelle R¹ à R⁵, Ar, Y et le pointillé sont tels que définis ci-dessus, en un cycle dihydro-indole ;

d) la réduction de la double liaison du cycle tétrahydropyridyle d'un composé de formule :



dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus ;


e) la réduction du cycle pyridinium d'un composé de formule suivante :




dans laquelle R¹ à R⁵, X, Ar et le pointillé sont tels que définis ci-dessus, si ce n'est que R⁵ ne peut pas être un hydrogène, et hal est un halogène, en cycle tétrahydropyridine ;

f) la réduction du cycle pyridinium d'un composé de formule VIII ci-dessus ou du cycle pyridyle d'un composé de formule XIV n un cycle pipéridine ;

g) la réduction du groupe carbonyle d'un composé de formule suivante :



20 dans laquelle R^1 à R^4 , X, Y, Ar et les pointillés sont tels que précédemment définis et R^{16} est un hydrogène, un alkyle en C_1 - C_4 ou un alcoxy en C_1 - C_4 ;
h) l'acylation d'un dérivé d'aminoalkyle de formule suivante :




40 dans laquelle R^1 à R^4 , X, Y, Ar, R^8 , n et les pointillés sont tels que définis ci-dessus, avec un agent d'acylation tel qu'un halogénure, un anhydride ou un anhydride mixte d'acide carboxylique, ou un chlorure de carbamyle ou de thiocarbamyle, un isocyanate, un isothiocyanate ou un chloroformiate substitué ;

45 i) la réaction de cyclisation d'un dérivé intermédiaire d'éthylène-ou de propylène-diamine de formule suivante :


50

55



15 dans laquelle R¹ à R⁴, R⁸, n, X, Y, Ar et les pointillés sont tels que définis ci-dessus et m est 2 ou 3, avec le phosgène, le thiophosgène ou le disulfure de carbone, pour former un substituant de structure 1a ; ou

20 j) la réduction d'un acide carboxylique ou d'un dérivé d'acide carboxylique de formule suivante :



35 dans laquelle R¹ à R⁴, X, Y, Ar et les pointillés sont tels que précédemment définis, R¹⁷ est un hydrogène ou un alkyle en C₁-C₄ et p est 1, 2 ou 3 ; puis, si on le désire :

40 l'acylation d'un composé préparé dans l'un des procédés (a) à (j) répondant à la formule I dans laquelle R⁵ est une structure 1a ou 1b lorsque V est NH, ou V' est NHR¹⁰, ou U' est NH, avec un agent d'acylation, ou l'estérification d'un groupe hydroxy disponible dans un composé de formule I pour obtenir un précurseur de médicament ; la conversion d'un composé préparé selon l'un des procédés (a) à (j) en un sel d'addition d'acide pharmaceutiquement acceptable correspondant ; ou

45 le dédoublement d'un composé optiquement actif de formule I, préparé selon l'un des procédés (a) à (j), en ses isomères optiquement actifs.